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Type 1 diabetes (T1D) is a chronic autoimmune condition hallmarked by a decline in the mass 
of insulin-secreting beta cells and resultant hyperglycaemia when approximately 70-80% of beta cells 
have been destroyed. The condition can be accurately predicted by the presence of multiple islet 
autoantibodies, but these are not directly related to the rate of beta cell destruction and have not 
proved useful as a measure of therapeutic benefit in clinical trials. Methods measuring the level of 
cell-free (cf) DNA containing fragments of the beta cell-specific insulin gene, released from dying beta 
cells into the circulation have been reported as a potential method for detecting real-time beta cell 
death and may represent an effective strategy for monitoring beta cell destruction in individuals at 
risk of future T1D, those with T1D and recipients of islet transplants. 
  Assays targeting the insulin gene have been reported but have proven difficult to replicate. 
The aim of this study, therefore, was to identify additional differentially methylated loci specific for 
the beta cell genome which could be multiplexed to an assay targeting exon 2 of the Insulin gene 
previously developed in the Bristol laboratory for high throughput analysis by droplet digital PCR. 
Initial approaches involved targeting PDX-1, but ultimately a genome-wide approach was used to 
obtain DNA methylation signatures in islets compared with peripheral blood mononuclear cells 
(PBMC) using the Illumina Infinium Human Methylation EPIC BeadChip. Through bioinformatic 
analyses, 3866 CpG loci were differentially hypomethylated, and 4990 CpG loci were differentially 
hypermethylated in islets when compared to the PBMC methylome. Combining the EPIC analysis with 
methylation signatures from other tissues conducted by the Roadmap and ENCODE studies resulted 
in 425 hypomethylated and 228 hypermethylated CpG targets that are differentially methylated in 
islets, but not in liver, lung, thymus, pancreas, spleen and peripheral blood mononuclear cells. 
Subsequently, the multiplex methylation sensitive assay was developed based on a combination of 
beta cell-specific differentially methylated regions (DMRs) of the combined promoter for MIR-
200c/MIR-141 and exon 2 of the insulin gene. This multiplex biomarker discriminated circulating beta 
cell DNA fragments in the circulation of recently diagnosed paediatric T1D patients, individuals at 
increased risk of developing T1D and in the circulation of T1D patients post islet transplantation 
therapy. Multiplexing several beta cell-specific targets increased the ability of the assay to discriminate 
between cases and controls. 
The data presented in this thesis demonstrates that DMR based biomarkers could provide 
highly specific real-time detection of dying beta cells in the early stages of T1D pathology and 
potentially measure responses to clinical therapy. The newly developed assay will be further validated 
in the future by testing larger cohorts of patients and “at-risk individuals”, with longitudinal sampling 
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1. General Introduction  
1.1.  Type 1 Diabetes 
Type 1 Diabetes (T1D) is a chronic autoimmune disease that results from specific immune-
mediated destruction of the insulin-producing beta cells in the Langerhans islets of the pancreas. 
Uncontrolled hyperglycemia characterises this autoimmune disorder, due to insufficient insulin 
production. Although not the most common form of diabetes (accounting for 7-12% of all diabetes), 
T1D is the most common type of diabetes among children and adolescents under the age of 20 (IDF 
2017). According to the last report of the International Diabetes Federation (IDF) in 2017, the 
incidence rate of T1D is increasing by 3% annually; approximately 132,600 new cases are registered 
each year. There are about 1,106,200 child and adolescents under the age of 20 years living with this 
condition globally, half of whom live in Europe (28.4%) and North American/Caribbean regions (both 
account for 21.5%). The report has also informed that Finland, Kuwait and Sweden were the countries 
with the highest incidence of T1D in children under the age of 15 (Figure 1.1) (IDF 2017).  Moreover, 
data collected from two major international T1D registries (DIAMOND1 & EURODIAB2) showed that 
there is a wide variation in T1D incidence between different geographic populations. They reported 
that the incidence rate was highest in Finland and Sardinia and was lowest in other populations such 
as China and Venezuela (Soltesz et al. 2007). Predictions based on EURODIAB registered children 
suggested that the incidence of T1D would double in European children under the age of 5 years 
between the years 2005-2020, and T1D prevalence will increase up to 70% in children under age 15 
years (Patterson et al. 2007). Additionally, an analysis of time trends by the Nationwide Diabetes 
                                                          
1 Multinational Project for Childhood Diabetes (Diabetes Mondiale) DIAMOND: The DIAMOND project was initiated by the World Health Organization in 1990 to address 
the public health implications of T1D with a main objective to describe the incidence of T1D in children. 
2 EURODIAB collaborative group established in 1988 prospective geographically-defined registers of new cases diagnosed under 15 years of age, the aim of this study 





Incidence Study in Sweden (DISS)3 showed that the incidence of T1D onset in individuals aged 0-34 
years from 1983 to 2007 shifted to younger ages (<14 years) (Dahlquist et al. 2011). 
T1D is often diagnosed when vague symptoms appear such as fatigue and lack of energy, night 
sweating, sudden weight loss, frequent thirst and urination, blurred vision and constant hunger (IDF 
2017). These symptoms start to appear when almost 70-80% of the individual’s beta cells are already 
destroyed (Cnop et al. 2005, Notkins and Lernmark 2001). At this point, the only option is lifelong 
insulin replacement and blood glucose monitoring. Insulin replacement treatment does not work 
equally for all recipients. Exogenous insulin is not as exquisite as the endogenous insulin in controlling 
blood sugar levels, leaving the patient at risk of life-threatening hypoglycemic episodes, kidney failure, 
stroke and death. The time window between the onset of seroconversion, as indicated by the 
appearance of islet autoantibodies, and the appearance of the first clinical symptom of T1D can be 
rapid; for instance, in the case of children diagnosed at six months of age but may take decades 
(Bingley et al. 2006, Ziegler et al. 2012). Meanwhile, persistent destruction of beta cells occurs silently 
and undetected until hyperglycaemia is diagnosed. The progress to overt T1D is described as occurred 
through three stages (Figure 1.2): the first stage (the seroconversion stage) is characterised by the 
appearance of the islet autoantibodies in the circulation with the absence of any other clinical 
symptoms. The second stage is also asymptomatic, but dysglycaemia can be detected, and the third 
and final stage is when the clinical symptoms described above appear (Insel et al. 2015). The diagnosis 
of T1D is confirmed by measurement of beta cell function with tests identifying the glycated 
haemoglobin A1C (HbA1C), blood C- peptide levels, fasting plasma glucose, oral glucose tolerance 
testing (OGTT) and proinsulin level (Figure 1.2) (Lebastchi and Herold 2012). According to the World 
Health Organization (WHO), diabetes is diagnosed when the level of fasting plasma glucose exceeds 7 
mmol/L (126 mg/dL), the level of plasma glucose is ≥ 11mmol/L (200 mg/dL) two hours following a 
                                                          
3 DISS is a nation-wide study based on the six major health regions of Sweden that follows the incidence of diabetes and its complications among young adults (15-34 




75g oral glucose intake, the level of random glucose exceeds 11 mmol/L (200 mg/dL) or the HbA1c is 
≥ 48 mmol/mol (equivalent to 6.5%) (WHO 2006).
 
Figure 1.1: The incidence T1D in children (0-14) years.  
 
The estimated number of new cases of T1D in children (0-14) years per 100,000 per year. The map is 




























• Multiple autoantibodies 
•Dysglycaemia: IFG and/or IGT 
• FPG 100-125 mg/dL (5.6-6.9 
mmol/L) 
• 2h PG 140–199 mg/dL (7.8-11.0 
mmol/L) 
• HbA1c 5.7-6.4% (39-47 







• No IGT or IFG 
 
• Appearance of 
clinical symptoms 




Clinically, type 1 diabetes can be categorised into three stages: stage 1 is asymptomatic and is characterized by the appearance of islet autoantibodies with normal blood glucose levels; 
stage 2 is also asymptomatic and is characterized by the presence of autoantibodies combined with hyperglycaemia, Stage 3 is when the clinical diabetes symptoms appear. 





1.2. Pancreatic Beta Cells 
The beta cell is a hormone-secreting cell that forms a significant component (about 60-80 %) 
of the islets of Langerhans in the pancreas. The pancreas is an organ of mixed cell types including 
exocrine, endocrine and endothelial cells as well as neurons. In addition to the beta cells, the islets 
consist of at least another four types of endocrine hormone-producing cells: 30% alpha-cells (secreting 
glucagon), <10% delta-cells (secreting somatostatin), <5% gamma-cells (secreting pancreatic 
polypeptide) and epsilon cells (ghrelin secreting) (Cabrera et al. 2006, Orci et al. 1976). The islets of 
Langerhans represent the endocrine section of the pancreas and account for only 1-2 % of the total 
mass of the human pancreas (Ionescu-Tirgoviste et al. 2015). An anatomical and three-dimensional 
(3D) virtualisation study showed that the endocrine pancreas is uniquely heterogeneous with respect 
to islet number and size. Most of the islets are ellipsoid or spherical. However, some, under the effect 
of the pressure of the adjacent structure, are irregular in shape (Ionescu-Tirgoviste et al. 2015). The 
total number of islets were approximately between 3.6-14.8 million, and their size varied from 0.5 to 
1.3 cm3 (Hellman 1959a, b, Ionescu-Tirgoviste et al. 2015, Saito et al. 1978). Although islets are more 
densely localised in the head of the pancreas, the body and the tail have a higher number of islets 
(Ionescu-Tirgoviste et al. 2015).  
The beta cell is highly specialised with the ability to sense alterations in the level of circulating 
blood glucose and in response, it synthesises, stores and secretes insulin. The mature insulin is a 51-
amino acid molecule that is processed from its precursors, the pre-proinsulin (in the endoplasmic 
reticulum) and the proinsulin (in the Golgi apparatus) in a multistep process. The biogenesis of insulin 
starts when an inactive precursor single chain pre-proinsulin is translated from insulin mRNA. The pre-
proinsulin is converted to proinsulin when pre-proinsulin enters the lumen of the rough endoplasmic 
reticulum, and its N-terminal signal peptide is removed via signal peptidases. Next, proinsulin is 
transported to the Golgi apparatus where it is arranged into an immature secretory granule. Finally, 
the mature insulin protein is generated by cleaving proinsulin into insulin and C-peptide by the effect 




peptide along with islet amyloid polypeptide and other less abundant beta cell secretory products are 
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1.3. T1D Etiology 
The etiology of T1D is complex; caused by a combination of the environmental trigger(s) and 
genomic susceptibility that leads to activation of autoimmune responses selectively against the 
pancreatic beta cells (van Belle et al. 2011) (Figure 1.4). Multiple genes have been shown to contribute 
to T1D susceptibility (Pociot et al. 2010, Pociot and McDermott 2002). Environmental factors have 
long been suggested to influence T1D progression as well as potentiate beta cell destruction 
(Akerblom et al. 2002, Knip et al. 2005, Lernmark 2016, Peng and Hagopian 2006). Therefore, the next 
section will briefly discuss the genetic susceptibility factors and some of the environmental triggers 
that are widely believed to accelerate the appearance of T1D pathology.  
 
  
When an individual with one or more genetic susceptibility variants is exposed to one or more environmental risk factors, 
the activation of chronic islet autoimmunity occurs. There is a preclinical gap between the initiation of autoimmunity 
toward beta cells and the appearance of the first symptoms of T1D which can vary from months to decades. The 
autoreactive response results in depletion of beta cell mass and eventually the appearance of clinical symptoms due to 
lack of insulin production. 




- High risk HLA alleles.
- Non-HLA Variants 
(Table 1.1).
Putative Enviromental Triggers
- Disequilibrium in intestinal 
bacterial flora.
-Viral infection. 
- Early life hygiene. 
- Early feeding regimen.
-Early life vitamin D 
deficiency.
immunocytes mediated insulitis 
- Imbalance between 
regulatory T cells and 
cytotoxic T cells. 
- Activating APCs leads to 
recruitment of cytotoxic
CD8 T cells in the pancreatic 
islet and the release of 
cytotokines and 
chemokines. 
- Various cytokines lead to 











Selective destruction of up to 
70% of insulin producing 
beta cells.




1.3.1. Genetic Susceptibility of T1D 
Much evidence underlies the robust association between genetic elements and T1D susceptibility. 
This was shown in genetically identical monozygotic (MZ) siblings who have a higher risk rate for 
developing T1D (Redondo et al. 1999, Redondo et al. 2001) and in families of individuals with T1D 
where there is a high sibling concordance rate (Clayton 2009). Genome-wide association studies 
(GWAS) have linked more than 50 genetic variants to T1D (Barrett et al. 2009, Barrett et al. 2011). 
Among studied loci, the human leukocyte antigen (HLA) chromosomal region is confirmed as the most 
important genetic susceptibility factor for T1D (Table 1.1). It has been well acknowledged that about 
50% of the T1D genetic susceptible factors are accounted for the highly polymorphic HLA class II 
regions (mainly HLA-DRB1, -DQA1 and -DQB1 genes) (Cudworth and Woodrow 1974, Nerup et al. 
1974, Noble et al. 1996, Pociot et al. 2010, Singal and Blajchman 1973). Other significant non-HLA 
susceptibility gene loci include those for insulin (INS) (Barratt et al. 2004, Bell et al. 1984, Bennett et 
al. 1995, Vafiadis et al. 1997), cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (Anjos et al. 2004, 
Kristiansen et al. 2000, Nistico et al. 1996, Ueda et al. 2003), protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) (Bottini et al. 2004, Smyth et al. 2004), interleukin 2 receptor alpha 
(IL2RA) (Lowe et al. 2007, Qu et al. 2007, Vella et al. 2005) and the ubiquitin-associated and SH3 






The figure was adapted from (Pociot et al. 2010) 











Full Name References 
6p21.3 HLA-DQB1 HLA Chr6: 32659464..32666689 6.8 Human Leukocyte Antigen 
GWAS database, (Cudworth and Woodrow 1975, 
1976, Nerup et al. 1979, Nerup et al. 1974)  
11p15.5 INS rs7928968 A>T chr11:2047640..2072504 1.25 Insulin Gene (Bell et al. 1984, Bradfield et al. 2011)  
1p13.2 PTPN22 
rs2476601 C>T chr1:113839149..114551845 2.05 
Protein Tyrosine Phosphatase, Non-Receptor Type 22 
(Lymphoid) 
(Smyth et al. 2008) 
rs2476601 G>A chr1:113839149..114551845  (Barrett et al. 2009) 
rs2476601 G>A chr1:113839149..114551845 1.96 (Bradfield et al. 2011) 
4p15.2  rs10517086 G>A chr4:26027797..26132152 1.09  (Barrett et al. 2009) 
4q27 IL2 rs4505848 A>G chr4:122938634..123565302  Interleukin 2 (Barrett et al. 2009) 
6q15 BACH2 rs11755527 C>G chr6:90806835-91030155 1.13 
BTB and CNC Homology 1, Basic Leucine Zipper 
Transcription Factor 2 
(Barrett et al. 2009, Cooper et al. 2008, Smyth et 
al. 2008) 
6q22.32  rs9388489 A>G chr6:126457495..127419697 1.17  (Barrett et al. 2009) 
9p24.2 GLIS3 
rs7020673 G>C chr9:4238265..4315101 1.14 
GLIS Family Zinc Finger 3 
(Barrett et al. 2009) 
rs10758593 G>A chr9:4238265..4315442 1.15 (Bradfield et al. 2011) 
12p13.31 CD69 rs4763879 G>A chr12:9583216..9972763 1.09 CD69 Molecule (Barrett et al. 2009) 
12q13.2 ERBB3 rs705704 G>A chr12:56351937..56791230 1.35 
v-erb-b2 Avian Erythroblastic Leukemia Viral Oncogene 
Homolog 3 
(Bradfield et al. 2011) 
12q24.12 SH2B3 rs3184504 G>A chr12:111716376..113030487 1.28 SH2B Adaptor Protein 3 (Smyth et al. 2008) 
13q32.3 GPR183 rs9585056 T>C chr13:99892888..100186578 1.15 G Protein-Coupled Receptor 183 (Heinig et al. 2010) 
14q32.2  rs4900384 A>G chr14:98363512..98604701 1.09  (Barrett et al. 2009) 
16p11.2 IL-27 rs9924471 G>A chr16:28295306..29025978 1.24 Interleukin 27 (Barrett et al. 2009) 





(Barrett et al. 2009) 
rs8056814 G>A 1.25 (Bradfield et al. 2011) 
18p11.21 PTPN2 rs1893217 A>G chr18:12738413..12925253 1.20 Protein Tyrosine Phosphatase, Non-Receptor Type 2 (Bradfield et al. 2011) 
18q22.2 CD226 rs763361 G>A chr18:67498673..67570160 1.16 CD226 Molecule (Smyth et al. 2008) 
21q22.3 UBASH3A rs11203203 G>A chr21:43809418..43878660 1.14 Ubiquitin Associated and SH3 Domain Containing A (Bradfield et al. 2011) 
22q12.2  rs5753037 C>T chr22:30073905..30669187 1.10  (Barrett et al. 2009) 
22q12.3  rs229541 C>T chr22:37568670..37660255 1.11  (Cooper et al. 2008, Smyth et al. 2008) 




1.3.1.1. The Human Leukocyte Antigen (HLA) 
The HLA region represents a cluster of genes that are located on chromosome 6p21 
(previously known as the IDDM1 locus). The composition of the HLA system is complex, consisting of 
large numbers of highly polymorphic genes, inherited as co-dominant haplotypes. The HLA gene family 
is arranged in 3 subgroups, class I, class II and class III. The class II loci are located at the centromeric 
end of the q arm, while class I is at the telomeric end, and both are flanking the Class III loci (Figure 
1.6). Among the three classes of HLA, class II genes showed the most significant association with T1D 
as their alleles were found to be ranging from protective to strongly associated (Howson et al. 2009, 
Lambert et al. 2004). The HLA is stated to account for about 40-50% of the familial aggregation of T1D 
(Lambert et al. 2004). The HLA complex was first linked to T1D when serological typing showed an 
association between several HLA class I antigens such as HLA-B8, HLA-B18 and HLA-B15 in affected 
sibling pairs (Cudworth and Woodrow 1975, 1976, Nerup et al. 1979). Later, with the development of 
advanced analysis methods, a stronger association was discovered between the HLA class II genes 
(DQ, DR and DP) and T1D (Noble and Valdes 2011). Nonetheless, more loci within or near the HLA 
complex were found to be associated with the risk of T1D which add more complexity for analysing 
the contribution of HLA genes to the T1D genetic susceptibility for T1D. 
1.3.1.1.1. HLA Class I 
The HLA class I region is 1.8 Mb with 128 loci: 42 protein genes, 12 gene candidates, 10 non-
coding genes and 64 pseudogenes, which all clustered in three separate duplication blocks: α, β and κ 
blocks (Shiina et al. 2009). The HLA molecule is a heterodimeric glycoprotein consisting of HLA- 
encoded 44 KD heavy α chains of and HLA-independent 12 KD light β chain (β2-microglobulin) 
(encoded in chromosome 15) (Mehra and Kaur 2016, Strominger 1987). Within the coding genes, six 
genes are sub-grouped into classical HLA genes (A, B and C) and three non-classical genes (E, F and G). 
The classical HLA class I antigens are expressed on most nucleated cells and platelets while non-
classical HLA class I antigen expression is limited and appeared to have defined functions in 




a predisposing allele and HLA-B*57:01 as a protective allele (Noble et al. 2010). Other reported T1D 
susceptible haplotypes include HLA-A*24:02, HLA-A*02:01, HLA-B*18:01 and protective alleles HLA-
C*05:01, HLA-A*11:01, HLA-A*32:01, HLA-A*66:01, HLA-B*07:02, HLA-B*44:03, HLA-B*35:02, HLA-
C*16:01, and HLA-C*04:01 (Noble et al. 2010). HLA-A*02 is also reported to be directly associated with 
T cell autoreactivity to insulin (Nejentsev et al. 2007, Pinkse et al. 2005, Valdes et al. 2005). 
1.3.1.1.2. HLA class II 
The class II HLA region is 700 Kb with 27 defined genes region, 17 protein-coding genes, 7 
pseudogenes and 3 non-coding genes. The HLA class II region D, consists of three classical loci R, Q 
and P, and three non-classical loci M, N and O. Being classical or non-classical is based on several 
criteria such as the degree of gene polymorphism (high polymorphisms in classical genes) and the 
expression on tissues (Table 1.2). Class II antigens are expressed on some immunocytes such as B-
cells, macrophages, dendritic cells and activated T cells (Cresswell 1994, Holling et al. 2002). B cells 
and dendritic cells have a role in activating CD4+ T cells by presenting HLA class II antigens thereby 
initiating the immune response (Kambayashi and Laufer 2014). T1D is strongly linked to several HLA 
class II genes, the haplotypes DR-DQ: DRB1*03:01-DQA1*05:01-DQB1*02:01 (DR3) 
and DRB1*04:01/02/04/05/08-DQA1*03:01-DQB1*03:02/04 (DR4) were shown to confer the highest 
risk for T1D (Noble and Valdes 2011) while DRB1*15:01-DQA1*01:02-DQB1*06:02 (DR2) protects 
from the disease (Graham et al. 1999, Noble and Valdes 2011, Pugliese et al. 1995). HLA class II genetic 
susceptibility differs from one ethnic group to another; for example, in Caucasians, the DRB1*03-
DQB1*0201 and/or DRB1*04-DQB1*0302 haplotypes are predominant in T1D individuals, but they 
are rare in Japanese populations (Ikegami et al. 2006). The DRB1*0405-DQB1*0401 and DRB1*0901-
DQB1*0303 HLA class II haplotypes are more frequently associated with T1D in Japanese populations 










































































Class II Class III Class I
The HLA is the most polymorphic genomic region, which spans 3,807,696 nucleotides. The gene is divided into 3 main groups, 
Class I, Class II and Class III. Each of the classes is subdivided into specific genetic loci. Adapted from (Undlien et al. 2001). 
 




   
Locus Gene Type Alleles Notes/ Function 
Classical HLA Class I 
HLA-A coding gene 4,200 
• Presenting peptides to T cells. 
• Inhibit the activity of NK cells. 
HLA-B coding gene 5,091 
HLA-C coding gene 3,854 
Non-Classical HLA Class I 
HLA-E coding gene 27 
Indirect “detector” of HLA class Ia 
molecules allowing NK cells to monitor 
many HLA allelic variants with a single 
receptor. 
HLA-F coding gene 30 
Mainly expressed in tonsil, spleen and 
thymus. 
HLA-G coding gene 60 
• Predominantly expressed on 
placental trophoblast. 
•  Might have a role in protecting 
the foetus from maternal NK cell 
attack. 
Classical HLA Class II 
HLA-DR 
HLA-DRA coding gene 7 
Comprise 1 α gene (DRA) and up to 9 β 
genes (DRB). HLA-DRB 
DRB 1,3,4,5 (Coding genes) 
DRB 2,6,7,8,9 (Pseudogenes)  
2,464 
HLA-DQ 
HLA DQA1 coding gene 94 Constituted by 1 expressed α gene 
(DQA) and 1 β gene (DQB). HLA-DQB1 coding gene 1,196 
HLA-DP 
HLA-DPA1 coding gene 65   
HLA-DPB1 coding gene 975 
Non-Classical HLA Class II 
HLA-DM 
HLA-DMA coding gene 7 Help in constructing the antigenic 
peptides for class II HLA molecules. HLA-DMB coding gene 13 
HLA-DO 
HLA-DOA coding gene 12 Regulation of class II HLA antigen 
processing. HLA-DOB coding gene 13 
Table 1.2: The classical and non-classical loci of the Class I and Class II HLA region. 




1.3.1.2. The Insulin Gene (INS) 
INS is located on the short (p) arm of chromosome 11q15.5 and is associated with about 10% 
of genetic susceptibility to T1D (Steck and Rewers 2011). The promoter of INS is characterised by the 
presence of “the variable number of tandem repeat” (VNTR), which is a linear arrangement of multiple 
copies of short repeated DNA sequence “ACAGGGGTGTGGGG” and is known to be highly polymorphic 
amongst the same species. The sequence is repeated 28-44 times in the class I VNTR allele, and 138-
159 times in the class III VNTR allele. The Class II VNTR allele has intermediately sized repeats and is 
rare (Stead et al. 2000). The INS-VNTR is located 0.5 kb upstream the transcription initiation site and 
has been shown to affect transcription rates. The association of INS with T1D was reported for the 
first time in the mid of 1980s when the length of the VNTR was linked to T1D progression in 
Caucasoids, showing that T1D is susceptible to the class I VNTR (Bell et al. 1984). Conversely, the 
inheritance of at least one copy of the class III VNTR allele reduced the probability of developing T1D 
3-5-fold compared to the common I/I homozygous VNTR genotype (Bennett et al. 1995). Furthermore, 
expression of the class III allele was found to be associated with a higher (15-20 %) insulin mRNA 
secretion in adults and foetal human pancreatic cells when compared to those who express class I 
VNTR (Vafiadis et al. 1996). Higher expression of proinsulin mRNA in the thymus in early life is thought 
to induce central immune tolerance and eliminate T cell autoreactivity (Pugliese et al. 1997, Vafiadis 
et al. 1997). 
1.3.1.3. The cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
CTLA-4, also known as CD152, is another confirmed T1D risk gene located on chromosome 
2q33. CTLA-4 consists of four exons and three introns that encode an immunoglobulin receptor that 
is expressed on the surface of active T helper cells (Dariavach et al. 1988, Harper et al. 1991). The 
CTLR-4 receptor has a critical role in T cell homeostasis, acting as an "off" switch for the signals 
mediated by CD80 or CD86 on the surface of active antigen-presenting cells. CD80 is a protein found 
on the surface of the dendritic cells, activated B cells and monocytes and provides a co-stimulatory 




through the inhibition of T cell activation, IL-2 production, and cell cycle progression (Eagar et al. 2002, 
Linsley et al. 1991). The link between CTLA-4 and T1D was demonstrated in a Non-Obese Diabetic 
(NOD) model as CTLA-4 knockout mice develop severe lymphoproliferative disorders (Waterhouse et 
al. 1995). There are at least three known polymorphisms in the CTLA-4 which are associated with 
immune diseases: the promoter C-328T SNP (Deichmann et al. 1996), the A49G SNP in exon 1 (Nistico 
et al. 1996), and the (AT)n dinucleotide repeat polymorphism in the 3’ untranslated region of exon 4 
(Harper et al. 1991, Polymeropoulos et al. 1991). The A49G polymorphism has shown a strong 
association with T1D (Nistico et al. 1996), which causes changes in the primary amino acid sequence 
of CTLA-4 signal peptide resulting in a reduction in T helper cell immunoglobulin surface expression,  
and therefore, is likely to play a role in the central immune tolerance (Anjos et al. 2002). Further, the 
long (AT)n dinucleotide repeat has been shown to be associated with increased genetic risk for islet 
autoimmunity (de Jong et al. 2016). 
1.3.1.4. Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) 
 The PTPN22 gene is located on chromosome 1q13 and encodes the lymphoid protein tyrosine 
phosphatase (LYP) which functions as a negative regulator of spontaneous T cell activation. LYP 
controls T cell activation through dephosphorylation of T cell trapping substrates such as Lck, Zap70, 
TCR/CD3ε complex, Vav and valosin-containing proteins (Wu et al. 2006). A substitution of the 
nucleotide C1858T within PTPN22, which changes codon 620 from arginine (CGG) into tryptophan 
(TGG), has been reported to be associated with T1D. This SNP disrupts the formation of the LYP-Csk 
complex, which usually shuts down the hyper-reactivity of T cells, making individuals who are 
heterozygous or homozygous for the tryptophan variant more predisposed to developing T1D (Bottini 
et al. 2004, Steck et al. 2006, Zoledziewska et al. 2008). Trp620 is also linked to a gain-of-function 




1.3.1.5. The Ubiquitin-associated and SH3 domain-containing protein A (UBASH3A) 
 UBASH3A is a protein encoded by the gene UBASH3A that is located on chromosome 21q22.3 
(Wattenhofer et al. 2001) and is expressed mainly on T cells (Carpino et al. 2004). UBASH3A is one of 
two family protein members belonging to the T cell ubiquitin ligand family that are known to 
negatively regulate T cell signalling (Collingwood et al. 2007). UBASH3A induces apoptosis in T cells by 
a growth factor withdrawal mechanism through its SH3 domain interaction with c-CBL through binding 
to ubiquitinated and ubiquitylated proteins via its UBA domain (Feshchenko et al. 2004, Tsygankov 
2008). UBASH3A is considered to be T1D risk candidate loci (Barrett et al. 2009, Concannon et al. 2008, 
Grant et al. 2009, Johnson et al. 2012, Onengut-Gumuscu et al. 2015, Plagnol et al. 2011). The SNP 
rs876498, located in the 6th intron of UBASH3A, was shown to be associated with developing T1D. This 
has been shown through studying SNP genotyping data from a linkage study of T1D sibling pairs in 
about 2,500 multiplex families (Concannon et al. 2008). Follow-up of a 1715 SNPs study from the 
Wellcome Trust Cases Control Consortium genome-wide association study in T1D families confirmed 
UBASH3A as a genetic risk factor for T1D (Cooper et al. 2009). UBASH3A AA genotype could be useful 
for T1D risk prediction as it was shown to be an independent predictor of persistent islet autoimmunity 
and T1D in children who do not have a family history for T1D but carry the high-risk HLA genotype 
HLA-DR3/4, DQB1*0302 (Johnson et al. 2012). 
1.3.1.6. IL-2 receptor complex (IL-2Rα “CD25”) 
The IL-2 gene is located on chromosome 10p15.1, and its protein IL-2 has been shown to have 
broad effects on T cells including survival, proliferation, activation-induced cell death (AICD), T cell 
differentiation, cytokine production and immune tolerance (Malek and Bayer 2004, Malek and Castro 
2010). Low concentrations of IL-2 induce effector or memory T cell differentiation, while high 
concentrations of this cytokine induce the apoptosis of conventional T cells through AICD sensitisation 
(Bachmann and Oxenius 2007). The interleukin-2 receptor alpha subunit (IL-2Rα “CD25”) is expressed 




two SNPs located at the 5′ end of intron 1 (rs706778 and rs3118470) (Qu et al. 2007). Further, 
downregulation of soluble IL-2Rα levels in the circulation is associated with susceptibility genotypes 
in T1D patients (Maier et al. 2009). Incongruously, none of the polymorphic variants of the IL2Rα gene 
has been shown to have a functional effect. Further, Belot and colleagues showed that there is a 
significant association between some differentially methylated CpG islands in the proximal promoter 
of IL-2Rα (CpGs -373 and -456) and the IL2Rα SNPs associated with T1D. They also showed an 
association between DNA methylation level at CpG -373 with SNPs within the promoter and intron 1 
of IL-2Rα gene with T1D (Belot et al. 2013).  
1.3.1.7. The Interferon Induced with Helicase C Domain 1 Gene (IFIH1) 
 IFIH1 is located on chromosome 2q24.2 and encodes the protein melanoma differentiation 
associated protein 5 (MDA5). As MDA5 plays an important role in recognising viral dsRNA during viral 
infection, IFIH1 could potentially link environmental triggers and genetic susceptibility for T1D (Lincez 
et al. 2015). It was hypothesised that viral infections in patients with elevated MDA5 levels are mainly 
activated the MDA5 pathway, which leads to escalating antiviral responses and the secretion of 
interleukins and interferons (Lincez et al. 2015, van Belle et al. 2011). Remarkably, MDA5 signalling 
downregulation prompts regulatory T cell levels at the site of autoimmunity suggesting a potential 
protective mechanism (Downes et al. 2010, Lincez et al. 2015, Nejentsev et al. 2009). Furthermore, 
the minor allele of rs1990760 polymorphism in the IFIH1 gene was shown to be strongly associated 
with T1D (Smyth et al. 2006, Todd et al. 2007). In the Chinese Han population, the allele rs3747517 





1.3.2. Environmental Risk Factors 
As discussed previously, the genes involved in T1D susceptibility explain why some individuals 
are more likely to develop T1D. However, it does not answer a question as to why one monozygotic 
twin develops T1D while the other sibling develops the condition later in life or, in some cases, does 
not? Defining the environmental trigger is not a straightforward task. The long gap between initiation 
and diagnosis of T1D (decades in slow progressors) have made it challenging to define environmental 
factors that can trigger autoimmunity. During this time window, a genetically susceptible individual 
may be exposed to multiple environmental factors. Different combinations of triggers may be required 
to develop autoimmunity toward the pancreatic beta cell. Therefore, in the next section, the 
important environmental factors that have been implicated in the pathogenesis of T1D will be 
summarised briefly.  
1.3.2.1. Migration Studies 
T1D epidemiology migration studies focused on migrants who moved from countries that 
have a low incidence of T1D such as Asian countries to high incidence areas such as Scandinavian 
countries. The main finding of these studies revealed that the migrants from low-incidence countries 
to high-incidence countries adopt the local risk rate of the country they migrated to (Oilinki et al. 
2012). A study in Bradford, UK focused on Asian population children aged 0-16 years showed that the 
incidence of T1D had increased from 3.1: 100,000/ year in the period 1978-1981 to 11.7: 100000/ year 
in the period 1988-1990 among this Asian cohort. This incidence rate was higher than T1D rates of the 
native population children which were 10.5: 100,000/ year (Bodansky et al. 1992). Another migration 
study reached the same conclusion showing that Sweden born children who originated from low 
incidence countries had a higher risk of developing T1D (Hjern et al. 2012, Soderstrom et al. 2012). 
Additional evidence of the effect of early exposure to environmental factors on T1D incidence rates 
was from a study comparing the age of T1D onset in the Swedish population to those with non-
Swedish born parents (Hussen et al. 2013). The study included individuals aged 0-30 years and showed 




environmental exposure to influence T1D initiation. On the other hand, some other studies failed to 
reach the same conclusion. A study done on Japanese children living in Hawaii who were diagnosed 
with T1D showed them to have the same incidence rates to their native Japanese (Patrick et al. 1997). 
Nonetheless, comparing T1D incidence in different ethnic groups in the Hawaiian population showed 
a variance. Japanese children had the lowest incidence rate (2.85-3.08: 100,000) while the half 
Hawaiian/half Japanese children had the highest incidence rates (15.34-16.58: 100,000). Caucasian 
children were the next highest with incidence rates (6.21-6.71: 100,000), followed by the Filipino 
children (3.66-3.96: 100,000) and finally the Japanese. The authors indicated that the variation in 
incidence rates might suggest that genetics play a more significant role in T1D development than 
environmental effectors (Patrick et al. 1997). 
1.3.2.2. The Virus Hypothesis 
The role of viruses in susceptibility to T1D is the subject of ongoing debate. The most extensive 
study to date, “The Environmental Determinants of Diabetes in the Young (TEDDY)”4 failed to find a 
link between viral infections and T1D in young children (Lee et al. 2013). Meanwhile, other major 
studies reported the opposite conclusion. The Diabetes and Autoimmunity Study in the Young (DAISY)5 
found that enterovirus infections “accelerate” progression from the preclinical to the clinical stage in 
children (Stene et al. 2010). A nationwide study of children up to age 18 years in the period 2000-2008 
in Taiwan compared the incidence rate of T1D among children who were diagnosed with enterovirus 
infections and reported a positive association between enterovirus infection and developing T1D (Lin 
et al. 2015). In parallel, a meta-analysis study had also confirmed a strong association between 
enterovirus infection and T1D. The study demonstrated that the risk of detecting enterovirus infection 
in children at the onset of T1D is almost ten-fold higher. They also found that T1D incidence is almost 
four-fold higher in pre-clinical T1D children when compared to control subjects (Yeung et al. 2011). 
The Diabetes Virus Detection study (DiViD) study also reported the presence of enterovirus in all 
                                                          
4 TEDDY is a longitudinal study was established in 2002 and are examining the environmental causes of T1D. The study follows children at high genetic risk for T1D from 
birth to 15 years of age. 




examined pancreatic islets samples (n=6) of T1D patients but in very few (2 of 9) in control islet 
samples (Krogvold et al. 2015). More recent data had shown that T1D children had been infected with 
enteroviruses three times more than control children samples (Honkanen et al. 2017) 
The influence of viral infection on the progression of T1D is widely studied. The viral infection is 
believed to occur several years before the onset of T1D (Lonnrot et al. 2000). Rubella and 
enteroviruses are viruses that have been most closely linked to T1D development (Hyoty and Taylor 
2002, Yeung et al. 2011). Enterovirus has been detected in the serum (Nairn et al. 1999), pancreas 
(Dotta et al. 2007) and small intestine (Oikarinen et al. 2008, Oikarinen et al. 2012) of the prediabetic 
paediatric T1D patients. Further, enterovirus was detected in sera of 64% of children who were 
diagnosed with T1D before the age of six (Clements et al. 1995). Among enteroviruses, Coxsackievirus 
B4 (CVB4) has been actively associated with T1D (Andreoletti et al. 1998, Hyoty and Taylor 2002). 
Coxsackievirus antibodies have been shown to induce apoptosis of pancreatic beta cells (Bason et al. 
2013). The CVB4 infection has also been detected in islets of pancreatic samples from 3 of 6 T1D 
patients but not in the 26 tested control pancreatic tissue samples (Dotta et al. 2007). Furthermore, 
the enteroviral capsid protein vp1 (vp1) has been reported to be present at approximately 61% (44 of 
72) in multiple islets of recently diagnosed T1D paediatric patients but in very few (3 out of 50 islets) 
age-matched controls (Richardson et al. 2009). Moreover, the presence of immunoreactive vp1 in beta 
cells of T1D patients has been shown to change the cellular phenotype in a way consistent with the 
activation of pathways of antiviral response and apoptosis (Richardson et al. 2013). Recently, data had 
shown that detecting enterovirus in young children stool samples is associated with the appearance 
of seroconversion within approximately 1 year post the infection (Honkanen et al. 2017). Interestingly, 
children carrying the high-risk haplotype HLA-DR3/DR4 were shown to have a higher CVB4 antibody 
titre when compared with children who are carrying the protective HLA-DR2 haplotype (Sadeharju et 
al. 2003). Overall, these finding support the hypothesis suggesting that enterovirus infections may play 





1.3.2.3. Gut Microbiome and the Hygiene Hypothesis  
The role of the intestinal flora in causing and preventing diseases is acknowledged. The 
development and maturation of the mucosal immune system is essential for the maintenance of 
immune homeostasis (Knip and Honkanen 2017). With regard to T1D, it has been shown that the 
normal mucosal immune system is capable of producing regulatory T cells which are known to have a 
critical role in preventing the development of T1D (Locke et al. 2006). Additionally, the composition 
of intestinal microflora of children at risk of T1D was found to be different from healthy controls. 
Intestinal microflora of children at high risk for T1D was found to be composed of non-butyrate-
producing lactate-utilising bacteria that are known to prevent optimal mucin synthesis and as a 
consequence, form a “leaky gut” phenotype which is a commonly seen in T1D patients. In contrast, 
the gut microflora of healthy controls was composed of lactate and butyrate-producing bacteria that 
induce a sufficient amount of mucin that maintains gut integrity (Brown et al. 2011). Another 
interesting observation is that intestinal microbial antibodies are reported to be present in the 
circulation of Russian Karelian children at a higher concentration than in a matched population in 
Finland (Seiskari et al. 2007). Finland and Russian Karelia are two neighbouring countries whose 
populations share genetic background, yet the incidence of T1D in Finland is six times higher than in 
Russian Karelia (41.1/100000 VS 7.4/100000 child under 15 years) (Kondrashova et al. 2005). An 
investigation of school children in both countries showed that Karelian children who are living in a 
poorer hygiene environment developed a higher titre of microbial antibodies (antibodies against 
Coxsackievirus B4, Helicobacter pylori, Toxoplasma gondii and Hepatitis A virus) in their system 
(Seiskari et al. 2007). This observation suggests that children who were exposed to microbes in their 
early childhood developed better gut immunity and may be protected from autoimmune disorders. 
Again, this is supported by two observations 1) infants born by Caesarean section are at increased risk 
of T1D and 2) it has been shown that NOD mice housed under pathogen-free condition developed T1D 




environment (King and Sarvetnick 2011). Collectively, these findings suggest an important role of the 
microbiome as well as living in conventional environment in T1D prevention and/or development. 
1.3.2.4. Vitamin D Hypothesis 
Vitamin D refers to a group of fat-soluble secosteroids that function mainly as mineral 
absorption enhancers in the intestine. In humans, vitamin D3 (cholecalciferol) is the most abundant 
subtype (Bikle 2014). The activation of cholecalciferol occurs in two steps. The first step occurs in the 
liver in which the enzyme 25-hydroxylase, (CYP2R1) converts the cholecalciferol into 25-
hydroxyvitamin D3-25-OHD3. Another hydroxylation takes place in the kidneys, where the enzyme 1-
α hydroxylase (CYB27B1) converts 25-hydroxyvitamin D3-25-OHD3 into the active secosteroid 
hormone, 1α,25-dihydroxy vitamin D3 (1α,25(OH)2D3; vitamin D). Vitamin D exerts its action via 
binding to the nuclear vitamin D receptor (VDR). The VDR gene is located on chromosome 12q13.11 
and is located very near to the vitamin D hormone hydrolysing gene CYB27B1 (located 10 Mb 
centromeric of the VDR gene at 12q13.1-13.3) (Bikle 2014). 
 Vitamin D is considered a possible environmental susceptibility factor that can influence the 
immune attack in T1D patients. An association between T1D and vitamin D was first proposed when 
a significant relationship between vitamin D deficiency and pancreatic beta cell malfunction was 
reported (Norman et al. 1980). This observation has been confirmed in rodents by inducing mutations 
in VDR, which leads to insulin secretion reduction (Zeitz et al. 2003). Moreover, it has been shown that 
rendering NOD mice vitamin D deficient in early life induced impaired glucose tolerance within the 
first 100 days of life and a doubling of the prevalence of T1D in the following 100 days (Giulietti et al. 
2004). This effect of vitamin D appears to be strain specific, as knocking VDR out in a different mouse 
strain (Zeitz) did not affect the function of beta cells (Mathieu et al. 2001). Conflicting conclusions of 
the effect of vitamin D on the progression of T1D has been reported by leading diabetes research 
groups around the world. The DAISY study group failed to find an association between vitamin D intake 




population (Simpson et al. 2011). Another study in Denmark also failed to find evidence as exposing 
mothers during gestation and the child at first year of life to low dose of vitamin D can affect the risk 
of developing T1D before the age of 15 years (Jacobsen et al. 2015). On the other hand, the DISS study 
showed that patients at the onset of T1D have lower levels of plasma 25(OH)D when compared with 
a matched control group. Vitamin D was also shown to function as a protective factor from T1D in 
infants from seven European countries (EURODIAB Substudy 2 Study Group) (Group 1999). This 
protective role of vitamin D was confirmed by a meta-analysis of five retrospective studies (Zipitis and 
Akobeng 2008). A Finnish birth-cohort study concluded that the intake of dietary vitamin D in the first 
year of life decreases T1D risk in their birth-cohort study (Hypponen et al. 2001). Another interesting 
observation is the combined effect of two environmental factors in boosting the incidence of T1D; 
enterovirus infection has been reported to be more frequent in recent-onset T1D patients with co-





1.3.3. The Effect of Environmental Interaction with Genetic Traits in T1D Development (Twin 
Studies)  
Twins studies are valuable in medical research as they helped in understanding the effect of 
the environment on different human disease. Monozygotic (MZ) and dizygotic (DZ) twin studies 
provide an assessment of the effect and/or the contribution of genetic or environmental factors on 
the etiology of the disease. Despite sharing identical genetic polymorphisms in MZ twins (as they were 
developed from a single fertilised oocyte), they show significant phenotypic differences implicating 
the significant involvement of epigenetic and environmental factors (Fraga et al. 2005). A DZ twin is 
developed from two fertilised oocytes, and are shown to share 50% of genes, as non-twin siblings do 
(Boomsma et al. 2002).  
Classic MZ twin and population-based registry studies showed that the concordance rate of 
T1D developing within identical twins is 50% and this percentage decreases in DZ twins down to 10 % 
(Hyttinen et al. 2003, Kaprio et al. 1992, Kyvik et al. 1995, Redondo et al. 2001). The study also revealed 
that there is a variation in the timing of seroconversion and development of overt T1D among MZ 
siblings who were followed-up for an extended period. In some cases, the seroconversion occurred in 
the second twin, three decades after T1D development in the first sibling, suggesting a considerable 
impact of the environmental factors in developing T1D. In another study, siblings of 53 MZ and 30 DZ 
twin pairs who had T1D were tested for the presence of autoantibodies (Redondo et al. 1999). The 
data showed the rate of having multiple autoantibodies in MZ twins is higher in comparison to DZ twin 
siblings. These data also revealed that having multiple autoantibodies in MZ twins is linked to the 






1.4. Autoimmunity in T1D 
1.4.1. Beta Cell Death in T1D (Insulitis) 
The infiltration of the immune and inflammatory cells into and around the beta cells in the 
pancreatic islets “insulitis” is a hallmark phenomenon in autoimmune beta cell-specific destruction 
(Gepts 1965, Itoh et al. 1993). According to the consensus guidelines for the diagnosis of insulitis in 
humans (2013), insulitis is defined as follows: 1) “the presence of a predominantly lymphocytic 
infiltration specifically targeting the islets of Langerhans”. 2) “The lesion should be established in a 
minimum of three islets, with a threshold level of ≥ 15 CD45+ cells/islet”. 3) “The infiltrating cells may 
be found in the islet periphery (peri-insulitis) or diffuse and present throughout the islet parenchyma 
(intra-insulitis)” 4) “The presence of pseudoatrophic islets (insulin-negative)” (Campbell-Thompson et 
al. 2013, Campbell-Thompson et al. 2017, In't Veld 2014). Up to date, our most extensive knowledge 
about beta cell inflammation is derived from studying the histopathology of pancreatic samples 
obtained from patients near the time of diagnosis (Foulis et al. 1986, Imagawa et al. 2001, Krogvold et 
al. 2014, Willcox et al. 2009). 
Insulitis was described for the first time over a century ago when a characteristic inflammatory 
infiltration was documented in the islets of Langerhans of a child that died from diabetic ketoacidosis 
(Schmidt 1902). This immunological cell infiltration was referred to as “insulitis” (Von Meyenburg 
1940). In a landmark paper published in 1965, Willy Gepts had described the insulitis as infiltration of 
lymphatic cells to the pancreatic islet. He documented the presence of insulitis in 68% (15 out of 22) 
of at onset T1D individuals while it was absent in long-duration T1D patients (Gepts 1965). Two 
decades later, Bottazzo and his group had observed that the CD8+ T cell infiltration in and around the 
islets is associated with a dramatic upregulation in the expression of MHC class I on the pancreatic 
beta cell surface (Bottazzo et al. 1985). Later, in 1986, a landmark study done by Foulis and his group 
who used samples obtained from 119 young patients who died before the age of 20 in the UK, had 
shown that insulitis was present in 78% (47 out of 60) among recent onset of T1D young patients (<1 




in only 1% of insulin-deficient islets. This latter observation had suggested that insulitis represents an 
immune-mediated process that results in pancreatic beta cell destruction (Foulis et al. 1986).  
Foulis and his colleagues, in a separate study, confirmed the hyperexpression of MHC class I 
on the surface of beta cells and showed that interferon γ (INFγ) levels were elevated as well (Foulis et 
al. 1991). The hyper-expression of HLA class I antigen on islet cells is associated with STAT1 expression 
upregulation, which uniquely occurs in T1D patients and thereby contributing to their selective 
susceptibility to autoimmune-mediated destruction (Richardson et al. 2016). The characterisation of 
the immune cells infiltrating indicated that cytotoxic CD8+ T cells are the most abundant cell type, 
followed by CD20+ B cells, macrophages (CD68+) and finally CD4+ T cells. The CD138+ plasma cells, Treg 
cells and natural killer (NK) cells were rarely detected (Willcox et al. 2009). Collectively, the data 
confirm the involvement of both innate and adaptive immune systems in the insulitis process.   
The presence of insulitis seems to be dependent on both the onset age and the duration of the 
disease. For instance, the average onset age among those who were insulitis positive in Gepts’ study 
was 7.9 years while the average age of the cases without insulitis was 17.1 years (Gepts 1965), 
suggesting that insulitis is present in patients in whom T1D onset occurred at a young age. A meta-
analysis of 213 T1D cases had shown that insulitis was present in 73% of young (≤ 14 years) T1D 
patients who had short disease duration (≤ 1 month); in 60% of young patients with a disease duration 
of 1 month to 1 year, and only in 4% of young patients with long T1D duration (>1 year) (In't Veld 
2014). Our limited understanding of human insulitis and beta cell death has come from the 
histopathological analysis of pancreatic autopsy specimens collected from T1D patients near the time 
of diagnosis, e.g. Foulis Study 1986. Fresh biopsy samples from new onset T1D patients taken recently 
in the Diabetes Virus Detection Study from Norway and in earlier studies from Japan provided 
additional information, but they stopped recruiting patients following unexpectedly high complication 
rates (Imagawa et al. 2001, Krogvold et al. 2014). During the last ten years, the Juvenile Diabetes 
Research Foundation (JDRF) has supported the initiation of an organised effort to study T1D patients 




research resource for T1D by obtaining samples (such as the pancreas, pancreatic lymph nodes, 
spleen, thymus and blood) from organ donors with diagnosed and pre-clinical T1D patients. These 
samples are distributed to worldwide nPOD-approved investigators, to allow the broad and diverse 
study of human insulitis as well as the causes and the mechanisms of beta cell death and T1D. The 
Initiative also endorsed collaboration between different T1D research groups via sharing tissue and 
data, and through initiating and managing cooperative projects. Collectively, nPOD efforts should 
facilitate a comprehensive understanding of human T1D (Campbell-Thompson et al. 2012, Pugliese et 
al. 2014).  
1.4.1.1. T Cells in T1D 
In humans, the development of self-recognition of T cells occurs in the thymus. During early 
life, T cells are negatively and positively selected in the thymic medulla and cortex, respectively  
(Kappler et al. 1987, Takaba and Takayanagi 2017). The mechanism of self-recognition is essential to 
minimise autoreactivity of T cells in the periphery later in life. Mature T cells express unique T cell 
receptors (TCR) and are divided into two distinct populations upon their surface expression: the co-
receptor molecules CD4+ and CD8+. Each population binds to antigens presented by different classes 
of MHC molecules and once activated, each subtype differentiates into functionally distinct effector 
cells. CD8+ T cells have a cytotoxic role, while CD4+ T cells “help” other immune cells during adaptive 
immunity. The cluster of differentiation (CD) receptors have a more important role than just being a 
phenotypic marker; they stabilise the interactions between the peptide-MHC complexes on the 
surface of antigen presenting cells (APC) and the TCR during immune responses (Chaplin 2010, Parkin 
and Cohen 2001). Evidence shows that T cells play an important role in T1D pathogenesis, for instance, 
treatment with immunosuppressive drugs that target T cells, e.g. cyclosporine A, although it did not 
affect the level of circulating autoantibodies but it delayed the progression to clinical diabetes 
(Bougneres et al. 1988, Mandrup-Poulsen et al. 1990). Further, treating recently diagnosed T1D 
patients with anti-T cell monoclonal antibodies improved the insulin production in these patients 




healthy pancreas that was transplanted in a T1D patient from his non-diabetic identical twin strongly 
suggests the involvement of immunological memory in islet-specific T cells (Sibley et al. 1985). 
1.4.1.1.1. CD4+ T Cell 
The CD4+ helper (Th) cells have been shown to be present at low levels during all phases of 
insulitis (Richardson et al. 2011). Previously, Th cells have been subdivided into two lineages, Th1 and 
Th2, based on the expression of molecules on their surface, the cytokines they release and their 
transcription factors (Mosmann et al. 1986, 2005). Now, there are at least five identified Th 
subpopulations including Th1, Th2, Th17, inducible T regulatory cells (iTregs) and follicular T helper 
cells (Tfh) (Walker and von Herrath 2016). Th1 cells have been shown to be involved in the 
pathogenesis of T1D in mice, as T cells from neonatal NOD mice express a diabetogenic TCR when the 
T cell is differentiated into a Th1, but not a Th2 phenotype (Katz et al. 1995). Th2 cells were also 
reported to be involved in T1D progression (Almawi et al. 1999, Poulin and Haskins 2000). Although 
still not fully understood, it has been recently suggested that Th17, as well as Tfh subpopulations 
contribute to T1D development (Heuts et al. 2017, Kenefeck et al. 2015, Walker and von Herrath 
2016). 
1.4.1.1.2. CD8+ T Cell 
Cytotoxic (CD8+) T cells are believed to have an essential role in insulitis initiation and beta cell 
destruction (Coppieters et al. 2012, Roep 2003, Roep and Peakman 2011, van der Torren et al. 2016) 
as they are the most abundant cell type found in the insulitis lesion (Willcox et al. 2009), and they are 
found in the circulation of T1D patients at onset (Roep et al. 1990). The exact mechanisms by which 
CD8+ T cell-mediated beta cell destruction are still not fully clear. Nevertheless, the process is 
suggested to involve: 1) direct induction of cell death though releasing perforin and granzymes and 
the binding of Fas Ligand to the Fas receptor. 2) Indirect cytotoxicity by secretion of inflammatory 
cytokines such as TNF and INFγ, with the generation of free radicals that induce endoplasmic reticulum 
















1.4.1.2. B Cells in T1D 
Although the specific pathogenic role of B cells in beta cell mediated destruction is not 
apparent, the presence of activated B cells in sections of islets near to T1D diagnosis suggest their role 
in the pathogenesis of T1D (Boldison and Wong 2016; Richardson et al. 2011; Willcox et al. 2009; Wong 
and Wen 2012). It has been documented that CD20+ B cells were present in only small numbers in 
early insulitis (Willcox et al. 2009). However, in cross-sectional studies, their infiltration was found to 
peak during the late-stage of insulitis in parallel with the time when beta cell mass declines 
(Richardson et al. 2011; Willcox et al. 2009). Additionally, variable infiltrations of CD20+ B cells 
phenotypes (CD20Hi and CD20Lo) were reported to be related to the age of T1D diagnosis. Leete and 
colleagues reported that CD20Hi B cells predominate within B cell infiltration of the islets of children 
who were diagnosed before the age of 7 years, while the CD20Lo B cell phenotype was predominant 
The TCR of CD8+ T cell identifies beta cells via its expression of MHC class I. Mechanisms of beta cell destruction include: 
production of perforin and granzymes, Fas/FasL interaction that activates the Bcl-2-regulated or mitochondrial apoptosis 
pathway. Other mechanisms include releasing of cytokines that induce free radical production leading to endoplasmic 
reticulum stress and cell apoptosis. 
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in those diagnosed after the age 13 years. They also showed that The CD20Hi phenotype was 
associated with more aggressive and rapid T1D onset (Leete et al. 2016). 
The role of B cells in the process of beta cell destruction involves producing pro-inflammatory 
cytokines and presenting the beta cell-specific antigens to CD4+ T cells (Boldison and Wong 2016; 
Silveira and Grey 2006). The elimination of B cells via anti-CD20 monoclonal treatment (Rituximab) 
partially reverses diabetes in recent-onset T1D human patients as well as attenuating beta cell loss 
(Pescovitz et al. 2009; Pescovitz et al. 2014). Treating transgenic NOD mice (expressing human CD20+) 
with a single cycle of anti-human CD20+ monoclonal antibodies (temporarily eliminating B cells) 
significantly delayed the onset of diabetes in mice and was shown to reverse diabetes in approximately 
one-third of diabetic NOD mice (Hu et al. 2007). Furthermore, the study showed that treatment with 
anti-CD20+ monoclonal antibodies partially enhanced the diabetes outcome by influencing Treg clones 
during the period of B cell reconstitution in NOD mice (Hu et al. 2007; Xiu et al. 2008). Similar results 
were observed when B cells were eliminated via anti-CD22 monoclonal treatment in the NOD model 
(Fiorina et al. 2008). Depleting B cells by inactivating the μ immunoglobulin gene in the NOD mice also 
showed to protect from insulitis and T1D (Serreze et al. 1996). Additionally, the increase in CD19 
expression on the surface of B cells enhanced the presentation of islet-specific glucose-6-phosphatase 
catalytic subunit-related protein (IGRP), leading to proliferation of reactive T cells specific for beta cells 
antigens (Ziegler et al. 2013a). The report also demonstrated that downregulation of CD19 had 
significantly inhibited the proliferation of CD8+ T cells, suggesting that altering the CD19 signalling 
pathway may have a role in preventing islet-specific autoreactive T cell proliferation (Ziegler et al. 
2013b). Together, these strands of evidence suggest the critical role of B cells in the pathogenesis of 
T1D. More evidence is required to confirm these data. It would be interesting to study the effect of B 
cell elimination in individuals “at risk” for T1D who carry high genetic risk alleles and/or are positive 




1.4.2. Autoimmune Destruction of Beta Cells in T1D 
  During the early stages of insulitis, activated local APCs migrate to the pancreatic lymph node, 
recruit, and activate CD4+ helper T cells by presenting beta cells antigens, leading to the release of 
chemokines and cytokines. CD4+ helper T cells then stimulate APC to secrete more cytokines and nitric 
oxide. The released cytokines induce the secretion of chemokines by surrounding endothelial cells, 
which enhance the recruitment of more immune cells into the islets and, together with cytokines, 
activate cytotoxic CD8+ T cells. Binding of the cytokine IL-1β to its receptor on the surface of beta cells 
activates the Nuclear Factor κB (NF-κB), Protein Kinase C (PKC), p38, and c-Jun N-terminal kinase (JNK). 
IL-1β binding also prompts the construction of a multiple-protein complex: IL-1R accessory protein (IL-
1R AcP), Toll-interacting protein (Tollip), Myeloid differentiation primary response gene 88 (MyD88) 
and the IL-1 receptor-associated kinases (IRAKs): IRAK-1 and IRAK-4. The cytokine TNF α activates 
caspase-8, NF-κB and the mitogen-activated protein kinase (MAPK) p38 and JNK, whereas the cytokine 
IFNγ activates Stat-1 and the extracellular signal-regulated kinase (ERK). Collectively these activation 
pathways induce beta cell apoptosis (Pirot et al. 2008, Pugliese 2016). 
1.4.3. Mechanism of Beta Cell Death in T1D, Necrotic or Apoptotic Pathway? 
Necrotic cell death is considered to be a possible mechanism of beta cell damage in T1D by 
which cytolytic CD8+ T cells mediate the cell death (Figure 1.7). As mentioned earlier, predominance 
of CD8+ T and macrophage cell infiltration might mediate necrosis (Eizirik and Darville 2001, Kurrer et 
al. 1997). Necrotic cell death can result as a consequence of releasing granules that contain granzymes 
and perforin by the T cells. Perforin acts on the membrane of the beta cell forming a pore in 
Ca2+ dependent mechanisms. The pore allows the access of the serine protease granzyme into the cell 
which results in cleavage and activation of several targets, such as effector caspase-3 and the BH3 
protein Bid (Eizirik and Mandrup-Poulsen 2001). Other necrotic cell death mediators are involved 
including Ca2+ and reactive oxygen species which lead to mitochondrial injury and affect both cell 
membrane integrity and ion balance (Jorns et al. 2014, Zhao et al. 2015). Another factor that may 




protein 1 (RIP1) which is prompted by ligand-receptor interactions and ATP depletion (Thomas and 
Kay 2011). Necrotic beta cells release their cellular contents including high mobility group box 1 
proteins, heat shock proteins, uric acid and pro-inflammatory cytokines, which trigger phagocytosis 
and immunological activity. Genetic pathway studies have suggested the involvement of apoptotic 
beta cell death pathways (Marroqui et al. 2015). Beta cell apoptotic pathways are possibly activated 
by TNF Fas/FasL pathway (Figure 1.7). Fas (CD95), which is a member of the TNF family, is activated 
through its binding to Fas L (CD 178) at the surface of beta cells. Upon activation, Fas recruits the Fas-
associated death domain which initiates recruitment and activation of pro-caspase-8, cleaving the 
effector caspase-3 or activating the BH3 interacting domain death agonist which leads eventually to 
beta cell apoptosis (Pirot et al. 2008). Caspase induced apoptosis results in the emergence of the 
apoptotic cell features such as chromatin condensation and nuclear fragmentation (Elmore 2007). In 
T1D, beta cell death is most probably induced through the activation of both necrotic and apoptotic 
pathways, as both have been documented in cytokine-mediated islet cell death and post-death 
receptors FasL and TNFR activation (Stephens et al. 1999, Walter et al. 2000). 
1.4.4. Autoantibodies to Islet Antigens 
Islet autoantibodies are detected in the circulation of preclinical T1D individuals (Bingley et al. 
2001, Pihoker et al. 2005). Although islet antigen-specific autoantibodies are not believed to be 
involved directly in beta cell destruction, they reflect the presence of beta cell damage, and therefore, 
are considered to be diagnostic rather than causative factors in T1D (De Filippo et al. 1997, Wong et 
al. 2004). By analogy to the TCR of T cells, B cells express receptors known as B cell receptor (BCR). 
The BCR components that are responsible for the recognition of antigens are known as 
immunoglobulins. When an antigen binds to the BCR, the B cells differentiate into an antibody-
producing CD138+ plasma cell. Consequently, plasma cells produce antibodies with a specificity 
equivalent to the immunoglobulin that recognised the antigen. The discovery of the first islet antigen 
autoantibody, the islet cell cytoplasmic antibody (ICA) (Bottazzo et al. 1974), contributed greatly to 




disadvantage of ICA screening, at the time, was the difficulty in standardising the detection assay 
(Lernmark et al. 1991). Currently, there are four main autoantibodies assays that predict T1D with a 
high specificity; insulinoma-associated antigen 2 autoantibodies (IA-2A, ICA512) (Bonifacio et al. 1995, 
Rabin et al. 1992), insulin autoantibodies (IAA) (Palmer et al. 1983, Williams et al. 1997), glutamic acid 
decarboxylase 65 autoantibodies (GAD65A) (Baekkeskov et al. 1990) and the zinc transporter 8 
autoantibodies (ZnT8A) (Long et al. 2012, Wenzlau et al. 2007). More recently, a fifth autoantibody 
which recognises a 38 kDa pancreatic islet glycosylated membrane-associated protein has been 
detected in >30 % of T1D patients: the tetraspanin protein family member (TSPAN7) known as glima38 
(McLaughlin et al. 2016). The IA-2, ZnT8, and glima38 antigens exist on the membrane of secretory 
granules of the beta cell, insulin is contained within the granules, while the GAD65 is found in the 
cytoplasm of synaptic-like microvesicles (SLMV) (Lampasona and Liberati 2016). Although 
autoantibodies are considered to be diagnostic, several reports had suggested that autoantibodies 
specific to islet antigens can induce T1D by inducing reactive CD4+ T cell (Silva et al. 2011) and CD8+ T 





1.5.  The Progression of T1D 
The chronic progressive autoimmune disease model of T1D was suggested by Johnny 
Ludvigsson at a Nordic Symposium and later, by George Eisenbarth in 1986 (Eisenbarth 1986). 
Although this model has been subjected to several modifications over the years as our understanding 
of the etiology of T1D enhanced, it remained the reference model of describing the natural history of 
T1D (Figure 1.8). 
1.5.1. The Linear Beta Cell Declines Hypothesis 
 The linear model was suggested by Eisenbarth in 1986 (Eisenbarth 1986). The hypothesis 
implies that at some point, the genetically susceptible individuals are exposed to the environmental 
agent(s) that trigger islet autoimmune reaction initiation, which will result in the development of islet-
specific autoantibodies, a linear decay in beta cell mass, a complete loss of C-peptide and the 
appearance of hyperglycaemia as the endpoint. Although the suggested linear model explains the 
sequence of events that occur during T1D pathogenesis, it failed to explain the variable prediabetic 
time window seen in T1D patients.  This led to the conclusion that the process of progression to clinical 
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1.5.2. The Non-Linear Relapsing-Remitting Model 
The relapsing-remitting model, proposed by Van Belle in 2011, is a very informative version of 
the nonlinear model (Bonifacio et al. 1999, van Belle et al. 2011, von Herrath et al. 2007). This model 
suggests that the selective autoimmune destruction of pancreatic beta cells in T1D results from failure 
of central and/or peripheral immune tolerance (Figure 1.9). Generally speaking, central tolerance 
originates from sites of lymphocyte development such as the thymus (for T cells) and bone marrow 
(for B cell) while peripheral tolerance is related to sites of antigen recognition and/or processing. The 
elimination of T cell auto-reactivity takes place in the thymus early in life, failure to correctly complete 
this process results in the release of autoreactive T cells to the circulation that recognise self-antigens 
as foreign molecules. In the case of T1D, failure of adverse selection of insulin-responsive T cells in the 
thymus results in a breakdown in central immune tolerance and consequently, T cells attack self-islet 
antigens (Klein et al. 2014, Kronenberg and Rudensky 2005). Analysis of islet infiltration in pre-diabetic 
NOD mice revealed the domination of CD4+ and CD8+ T cell subtypes (Wegmann et al. 1994). Later, 
studies showed that among all T cell subtypes, CD8+ T cells have the most exclusive specificity towards 
islet autoantigens in both humans and the NOD mouse (Coppieters et al. 2012). Remarkably, these 
autoreactive effector T cells are not exclusively found in the periphery of T1D patients, but they are 
detectable in the circulation of healthy individuals as well (Arif et al. 2004, Peterson et al. 1999, Roep 
et al. 1999a). So, why are they pathogenic in T1D and not in healthy individuals? Healthy individuals 
are protected from pathogenicity of effector T cells by the action of other populations of specialised 
T lymphocytes called regulatory T cells (Treg) (Figure 1.9).  Treg cells are a minor subpopulation of T 
cells that develop in the thymus and migrate to the periphery, where they maintain tolerance to self-
antigens by suppressing self-reactive T cells that escape adverse selection in the thymus (Groux et al. 
1997, Roncarolo and Levings 2000). IL-2/IL-2R signalling is vital for Treg development in the thymus, 
as well as their function and maintenance in the periphery (Chinen et al. 2016, Jenkinson et al. 1987, 
Raulet 1985, Tentori et al. 1988). This observation links three elements seen in T1D patients: low IL-2 




peripheral immune tolerance and the dominance of effector T cells. Studies on NOD mice have 
supported this conclusion. In NOD mice, it has been observed that Treg cell apoptosis peaks at the 









1.5.3. Fertile Field Model: 
Von Herrath suggested the fertile field model of T1D progression in 2003. This model describes 
factors that lead to T1D autoimmunity during the time window post multiple viral insults. The 
hypothesis proposed that post each viral infection; T cell autoreactivity is induced by molecular 
mimicry or bystander activation, resulting in initiation of the autoimmune reaction and progression to 
clinical T1D (von Herrath et al. 2003).  
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Healthy Population T1D Patients 
Treg cells have impaired function in patients with T1D, thereby failing to suppress autoreactive effector T cells. 
Alternatively, immune regulation might not suffice if effector T cells are resistant to immune regulation, as reported in 
patients with T1D. The information in the figure is based on (Roep and Tree 2014).   





1.6.1. General Introduction 
The human body contains approximately 3.7X1013 cells (Bianconi et al. 2013), each of which 
contains about two meters of DNA (Alberts et al. 2002). In a typical eukaryotic cell, the DNA and its 
associated protein (histone) are packaged inside the nucleus. The DNA is wrapped around the histone 
composing of repetitive units called nucleosomes. Each nucleosome consists of duplicates of the core 
histone octamers H2A, H2B, H3, and H4, which are wrapped 1.67 times in left-handed turns by 147 bp 
of DNA. The wrapper DNA enters and leaves the nucleosomes at points close to each other, a point 
where a fifth core histone H1 (the linker core histone) attaches to the DNA between two neighbouring 
histones (Kouzarides 2007) (Figure 1.10). The nucleosomes are the building unit of chromatin, the 
compact form of DNA inside the nucleus. The DNA sequences of all human body cells are similar, yet, 
each specialised cell (e.g. hepatocyte, keratinocytes, neurons, etc.) have different structures and 
functions. The diversity in the structure and the function of different cells results from the diversity of 
genes expression in different cell types. In the human genome, The DNA and its associated histones 
can be tagged by chemical molecules that have been shown to control the destiny of gene expression 
in the cell (Bird and Wolffe 1999, Dong and Weng 2013), these modifications are called Epigenetics. 
The Greek words (Epi) means “above” the genome; epigenetics are defined as modifications that 
change the function of the molecule (phenotype) without altering its primary structure (genotype) 
(Dupont et al. 2009). Several epigenetic modifications are known to control gene expressions such as 
the covalent modifications of DNA and histones, chromatin remodelling and the non-coding RNAs 
(Collins et al. 2017, Portela and Esteller 2010). The epigenetic modifications are also fundamental in 
controlling many other cell regulatory functions such as DNA-protein interactions, suppression of 
transposable element mobility, cellular differentiation, X-chromosome inactivation and genomic 
imprinting (Handy et al. 2011). Dysregulation of the epigenetic factors was shown to be associated 




2015), learning difficulties (Franklin and Mansuy 2011) and autoimmune disorders (Farh et al. 2015, 










1.6.1.1. microRNA (miRNA) 
MicroRNAs (miRNAs) are short non-coding RNA molecules (20-22 nucleotides) which are 
known to have a post-transcriptional gene regulating function. To date, there are 38589 identified 
miRNAs in 271 species (Entry number 22, March 2018, www.mirbase.org). The main regulating 
mechanism of miRNA is to “silence genes”, a function that is reported to be initiated partially through 
binding to the 3’-untranslated end of a gene transcript (mRNA) to prevent its translation (Bartel 2004). 
Other regulating functions of miRNAs are activating the translation process of some genes (Vasudevan 
2012) and heterochromatin formation (Kim et al. 2009). These regulating functions of miRNAs are 
described to be ‘multiple’ and ‘cooperative’, which means that one miRNA can target multiple mRNAs, 
meanwhile, one mRNA can be targeted by several miRNAs (Peter 2010). The majority of miRNAs are 
transcribed by the enzyme RNA polymerase II (Pol II), others, especially those which are lined within 
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et al. 2004). The translation of miRNAs undergoes several steps. First, the enzyme RNA Pol II 
transcribes the stem looped pri-miRNA. Then Drosha (ribonuclease III enzyme) cleaves pri-miRNA into 
hairpin structured pre-miRNA. Next, the pre-miRNA is transported into the cytoplasm by exportin-5 
where a second cleavage occurs. The endoribonuclease Dicer cleaves the pre-miRNA into imperfect 
duplex strands of about 22 nucleotides, the mature miRNA and the passenger miRNA (Zamore et al. 
2000). Finally, the mature strand either exerts its function inside the cells by fusing with Argonaute 
proteins (mainly Aro1 and Aro2) and integrating with the RNA-induced silencing complex (RISC) 
(Chendrimada et al. 2005) or is secreted into the circulation as ‘circulating miRNAs’. Circulating 
miRNAs are either secreted as a vesicle-free form coupled with RNA binding proteins such as 
lipoproteins and Aro2 or encapsulated in vesicles as exosomes, microvesicles or apoptotic bodies 
(Kosaka et al. 2010). 
miRNAs play important roles in many diseases including cancer (Jansson and Lund 2012), 
cardiovascular (Small and Olson 2011) and autoimmune diseases (Qu et al. 2014, Singh et al. 2013). 
miRNAs are also  central regulators of beta cell biology as they are functionally associated with 
multiple mechanisms including the immune system (O'Connell et al. 2010), beta cell differentiation, 
function and survival (in particular MIR-375) (Lahmy et al. 2014). Furthermore, miRNAs function in 
response to viral infections (Ho et al. 2016), particularly in response to enterovirus infection. 
Enterovirus infection significantly dysregulates the miRNAs in human pancreatic islets (Nair et al. 
2013) implicating that miRNA dysregulation could be a key mechanism of enterovirus-induced beta 
cell damage. Indeed, dysfunction to specific miRNAs has been linked to T1D development (Assmann 
et al. 2017). 
1.6.1.2. The Epigenetic Covalent Modifications 
The epigenetic covalent modifications occur when a chemical group is added directly to the 
DNA (commonly the methylation of cytosine nucleotides) or the histone tail (lysine acetylation, lysine 




sumoylation) (Bannister and Kouzarides 2011). Histones are essential key elements in epigenetics as 
they have important roles in transcriptional regulation (Karlic et al. 2010), DNA repair (Huertas et al. 
2009) alternative splicing (Luco et al. 2010, Zhou et al. 2014) and chromosome condensation 
(Kouzarides 2007). The covalent modifications of the histone tail regulate gene expression, for 
instance, the acylation of H3K9, H3K27 and H3K18 in the promoter region is correlated with 
transcription activation (Kurdistani et al. 2004) while trimethylation of the histone H3K9, H3K27 and 
H3K79 is associated with transcription repression (Vakoc et al. 2006). The second epigenetic covalent 
modification (DNA methylation) will be discussed in more detail in the next section.   
1.6.2. DNA Methylation Modification  
In addition to its well-acknowledged role in gene expression, DNA methylation has an 
important role in inducing cell apoptosis. Through each DNA replication, the cell accumulates errors 
in DNA methylation resulting in inactivation of several important genes which eventually induces 
apoptosis (Mazin 1994, 2009). Further, DNA methylation is thought to have an evolutionary function; 
it has been reported that the mammalian genome has lost about 3% of 5-methylCytosines (5mC) and 
6% of GC pairs in comparison to our ancestors (Mazin 1994). Consequently, cytosine mutation induces 
spontaneous changes in genome structure and function which influence the genetic and biological 
diversity among species (Cooper and Gerber-Huber 1985). Moreover, DNA methylation has been 
shown to have multiple roles in mammals’ health and disease such as:  
➢ X-chromosome inactivation: 
o The human male germ cell has only one X chromosome and one Y chromosome, 
meanwhile, the female germ cell has two X chromosomes. DNA methylation randomly 
inactivates one of the female X chromosomes, so that, individuals of both genders will 
have the same amount of X-related gene products. The X-chromosome inactivation 
process is considered to be a dosage compensation mechanism that starts in early 




➢ Genomic imprinting: 
o Genomic imprinting is an epigenetic phenomenon that results in expressing the 
genes in a paternal-/maternal-origin-specific manner. Normally, only one allele of a 
gene, either paternal or maternal origin, is expressed. For instance, the gene 
encoding insulin-like growth factor 2 is only expressed from the allele inherited from 
the father (Court et al. 2014). Genomic imprinting is controlled by imprinted control 
regions (ICRs). The ICRs have clustered organisation allowing cis-regulation of 
expressing parental-specific DNA methylation and/or histone modifications resulting 
in monoallelic expression. A CpG rich ICR which is differentially methylated on one 
allele (hypermethylated in one allele and hypomethylated in the other) is associated 
with silencing of the gene of that allele (Li et al. 1993).  
➢ Suppression of transposable element (TE): 
o TEs are DNA sequences that can mobile from one position to another in the genome. 
About 45% of the human genome consists of transposable elements (Lander et al. 
2001). Due to their dynamic transport nature, TE integration could lead to gene 
inactivation, control gene expression or induce illegitimate recombination (Rebollo et 
al. 2012). Furthermore, foreign TEs, such as parasitic and retroviral TEs, can integrate 
into the host genome of other species. Suppression of the expression of the TEs by 
DNA hypermethylation is shown to be a defensive mechanism (Barlow 1993, Yoder et 
al. 1997). 
➢ Development and cell/tissue differentiation: 
o DNA methylation (along with histone modifications) define the fate of the cell 
differentiation at early stages of embryogenesis. DNA Re-methylation (at the 
blastocyst stage) occurs in a tissue-specific manner allowing the expression of genes 
vital for the cell type, creating differentially methylated regions (DMR) among 




1.6.2.1. DNA Methyltransferase 
The process of DNA methylation is established in early life by a family of DNA 
methyltransferase enzymes, including Dnmt1, Dnmt2, and Dnmt3 (Figure 1.12). Dnmt2 is the most 
conserved and the less understood enzyme among the methyltransferase enzymes. Dnmt2 is now 
known as tRNA aspartic acid methyltransferase 1, which catalyses the methylation of position 38 in 
tRNA to yield 5-methylcytosine (Goll et al. 2006). Knocking-out Dnmt2 results in no phenotype in mice 
(Okano et al. 1998). The Dnmt1 enzyme is mainly involved in methylation of hemimethylated DNA 
strands during cell division, while Dnmt3 are more involved in the de novo DNA methylation during 
embryogenesis. The process of DNA methylation involves the adding of a methyl group to the fifth 
carbon atom in the cytosine nucleotide which is donated from a methyl donor molecule (S-
adenosylmethionine; SAM) under the effect of DNA methyltransferase enzyme (Figure 1.13).  
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The reaction is catalysed by DNA methyltransferase (Dnmt) that transfers a methyl group from the donor S-adenosyl-
methionine (SAM) to the 5’ carbon of an unmethylated Cytosine nucleotide.  




1.6.2.2. Methylation Reprogramming 
1.6.2.2.1. DNA Demethylation 
DNA demethylation occurs by either a passive or an active mechanism. Passive demethylation 
occurs in cases when the Dnmt1 enzyme fails to methylate the daughter DNA strand during cell 
division (Hashimoto et al. 2012). Active demethylation has been described during embryogenesis. The 
Ten-eleven translocation protein (TET) family, including TET1, TET2 and TET3, function as an eraser of 
cytosine methylation by catalysing the 5mC into intermediate oxidative products such as 5hmC, 5-
formylcytosine (5fC), and 5-carboxylcytosine (5caC) (He et al. 2011, Ito et al. 2011, Tahiliani et al. 
2009), which eventually are converted to unmodified cytosines as part of the active DNA 
demethylation pathway (Rasmussen and Helin 2016).  
The maternal oocyte and the paternal sperm each have a different genome methylation 
pattern. Once fertilisation occurs, both genomes are contained in one cell (zygote; Figure 1.14). Most 
recently, it has been shown that the DNA contained in the zygote undergoes three waves of 
demethylation in a stepwise manner (Zhu et al. 2018). Within twelve hours post fertilisation, the 
zygote genome undergoes the first wave of demethylation targeting CpGs located in enhancers and 
gene bodies. This wave affects the oocyte-derived and sperm-derived pronucleus differently; the 
oocyte-derived DNA loses about 4% of its genomic methylation (decreased from 54.5% to 50.7%) while 
the sperm-derived genome loses approximately 29% (decreased from 82.0% to 52.9%). Both the 
second and the third global demethylation waves target intron regions and short interspersed nuclear 
elements (SINEs), such as the evolutionarily younger subfamily of Alu elements. The second wave of 
global demethylation occurs in the stage between the late zygote and the 4-cell stage embryo, 
decreasing the global genomic methylation levels by approximately 10% (from 49.9% to 40.4%), while 
the third wave of demethylation occurs between the stage of 8-cell embryo and morula stage, 
lowering the global methylation levels by about 11% (from 47.0% to 35.1%). At the end of the morula 
stage, the global genomic methylation level reached the minimum (Zhu et al. 2018). The mechanism 




primarily involved. TET3 protein actively demethylates the DNA by oxidising the 5mC into 5hmC, 5fC 
or 5caC (Gu et al. 2011, Inoue et al. 2011, Inoue and Zhang 2011, Ito et al. 2011). Finally, the 
intermediate oxidative products are replaced by unmodified cytosines via the base excision repair 
pathway (He et al. 2011, Zhang et al. 2012). Previously, the maternal genome was thought to undergo 
global demethylation differently to the paternal genome demethylation. The Maternal genome was 
thought to be globally demethylated through gradual passive demethylation; however, recent studies 
have shown both maternal and paternal demethylation undergo similar mechanism of embryogenesis 
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1.6.2.2.2. De novo DNA Methylation and the Maintenance of DNA Methylation  
During human embryogenesis, two waves of de novo methylation occur, a major and minor wave. 
Both methylation waves target the major families of repeat elements, such as SINEs, long interspersed 
nuclear elements (LINEs), and long terminal repeats (LTRs). Methylation waves also target 
evolutionarily younger subfamilies, such as Alu and LINE-1 (L1) retroelements. The first de novo 
methylation wave is minor but significant, occurs in the spermatozoa genome between the early to 
the mid-pronuclei stage of the zygote. The second de novo methylation wave is major and occurs in 
the 4-cell to 8-cell stage of the embryo (Zhu et al. 2018) (Figure 1.14). Interestingly, a similar de novo 
DNA methylation wave has been reported to occur in the 2-cell to 8-cell embryo progression in 
monkeys (Gao et al. 2017).  
The cycles of demethylation and de novo methylation that occur in the embryogenesis 
demonstrate the nature of DNA methylation reprogramming. It shows that the methylation process 
is dynamic and transient, as the strong genome-wide demethylation is balanced by targeted DNA 
methylation (Figure 1.14). The DNA demethylation and methylation cycles also demonstrate that the 
process may occur as the gene regulation requires (Gao et al. 2017, Zhu et al. 2018). The process of 
de novo DNA methylation is accomplished by the effect of Dnmt3a and Dnmt3b enzymes; both 
enzymes have been shown to be the most highly expressed enzymes in undifferentiated human 
embryonic stem cells (Liao et al. 2015). It has also been shown that Dnmt3a methylate the cytosine 
nucleotides at a faster rate in comparison to Dnmt3b, but slightly slower than Dnmt1. Dnmt3a 
establishes differential DNA methylation at the ICRs in gametes (Kaneda et al. 2004, Kato et al. 2007, 
Nishikawa et al. 2015). Combined or individual deletion of human Dnmt3b or Dnmt3a were shown to 
cause embryonic lethality (Liao et al. 2015, Okano et al. 1999). 
Dnmt1 enzyme carries out the process of DNA methylation maintenance during the cell division 
and DNA replication. The process occurs passively or actively in a symmetrical manner where 




the synthesis phase of the DNA replication, the SET and RING-associated (SRA) domain of the protein 
ubiquitin-like containing PHD and RING finger domains 1 (UHRF1), identifies and binds to newly 
synthesised hemimethylated DNA strand (Jones and Liang 2009). SRA-DNA interaction induces Dnmt1 
recruitment, which copies the DNA methylation pattern of the parental DNA strand to the daughter 
strand (Frauer et al. 2011, Jones and Liang 2009). Furthermore, the Dnmt3a and Dnmt3b (responsible 
for de novo DNA methyltransferases) have also shown to be associated with the DNA methylation 
maintenance (Chen et al. 2003, Hashimoto et al. 2012, Ji et al. 2014, Jones and Liang 2009). 
The Dnmt3-like enzyme, known as Dnmt3l, is mainly expressed during the development 
(Aapola et al. 2000). Although Dnmt3l has been shown to have no catalytic activity itself, its expression 
is crucial for gene imprinting. The genetic deletion of Dnmt3l results in the death of the foetus and the 
co-expression of paternal genes in mice (Bourc'his and Bestor 2004, Bourc'his et al. 2001). Dnmt3l also 
functions as a cofactor for Dnmt3a and Dnmt3B to bind to their catalytic domain and thereby 
accelerating their ability to attach to SAM and therefore stimulating their ability to methylate DNA in 
the methylation de novo pathway (Chedin et al. 2002, Gowher et al. 2005, Jia et al. 2007). Another 
Dnmt3 isoform (Dnmt3c) was shown to be responsible for the methylation of evolutionarily young 
retrotransposon promoters in the male germ line which is required for mouse fertility (Barau et al. 
2016).  
1.6.3. The DNA Methylome of the Pancreatic Beta Cell 
The methylation pattern of pancreatic beta cell specific genes e.g. insulin offers a classic 
example of the role of a gene promoter methylome in determining cell identity. This was reported for 
the first time in a study by Gilbert and colleagues in 1983 on the rat genome (Cate et al. 1983). They 
demonstrated that the promoters of the rat insulin-I and insulin-II genes in insulin expressing cell lines 
are differentially hypomethylated when compared with non-insulin expressing cells. Later, insertion 
of a methylated and mock-methylated reporter in the promoter of INS gene constructs in the insulin-
producing cell line (NIT-1) results in insulin gene suppression (Kuroda et al. 2009). A similar conclusion 




180, -102 and +63) correlates negatively with an expression in the INS gene in human pancreatic islets 
(Yang et al. 2011). Collectively, these observations suggest that differential hypomethylation of the 
INS gene promoter is a unique feature of beta cell identity.  








1.7. Biomarkers of Predicting T1D 
1.7.1. General Introduction 
A biomarker is an indicator that objectively measures a normal or pathological body state as well 
as evaluating biological responses to a therapeutic intervention (Biomarkers Definitions Working 
Group 2001). Ideally, a biomarker should have some specific criteria to be of clinical value; it should 
be highly selective and specific to a target, have a detectable threshold in the circulation and be 
reproducible. Above all, a biomarker should be non-invasive, acceptable to the patient and easily 
interpreted by the clinician (LaBaer 2005). Biomarkers could be powerful tools for monitoring 
health/disease states and predicting future changes in health due to treatments or environmental 
alteration. Different biomarkers have different functions, and accordingly, they are classified into 
different categories according to their proposed application. Thus, the adoption of unified biomarker 
classification will provide a more natural way to describe a biomarker and define its function. Many 
attempts had been made to categorise the biomarkers into different subgroups mainly according to 
their clinical application or according to their physiological type (genomic, proteomic, or their 
physiological products). Categorising the biomarker based on its clinical function is the most common 
way for subgrouping it (Table 1.3). Nevertheless, this approach to subgrouping has a primary 
disadvantage because a biomarker could belong to more than one subgroup, e.g. diagnostic and 
staging biomarkers. Hence, adopting a more generalised classification such as the one suggested by 
Mayeux would be more convenient (Mayeux 2004). He divided biomarkers into two major types: 
biomarkers of exposure (predicting the risk of development of a disease and assessment of a drug 
effect) and biomarkers of disease (utilised to screen, diagnose and monitor disease progression).  
1.7.2. Discovering a Novel Biomarker 
The first step in the process of developing a novel biomarker is defining its clinical purpose (Table 
1.3). Then, a biomarker should ensure to meet the clinical qualities (Table 1.4). An acceptable 
biomarker should be sensitive and specific for the targeted disease/tissue, applicable to different 




stage of the disease. Extra factors should be considered for diagnostic and therapeutic biomarkers: 
the expense, the difficulty of sample collection and patient disturbance during sample collection. For 
example, a biomarker destined to be used in routine screening tests should have the advantage of 
both easy access and minimum cost per sample. On the other hand, diagnostic and research 
biomarkers should be highly specific for the targeted specimen such as a tissue biopsy. In that case, 
the number of the processed samples will be limited, but the specificity and the sensitivity will be at 







In a disease state, where there is a high rate of specific cell type death, the contents of the 
dying cells are released into the body’s circulation. The contents of these cells, which include proteins, 
lipids, nucleic acids or gene products, can provide important biomarker readouts specific to those 
cells. Therefore, various assay techniques are required to detect the changes in these biological 
parameters. Genomic and epigenomic biomarkers are an advanced approach that has been widely 
used in cancer research recently (Boutros 2015, Leygo et al. 2017, Voyias et al. 2016). The advantage 
of the epigenomic biomarkers over conventional techniques is their ability to predict diseases in 
preclinical stages as well as accurate identification of drug target and treatment response (Heyn and 
Esteller 2012, Simon 2011). 
Type of Biomarker The Purpose 
Antecedent Identifying the risk of developing an illness 
Screening Screening for the presence of suspected subclinical disease 
Monitoring Monitoring functions of organs/tissue states 
Diagnostic Confirm the presence of an illness 
Staging Tracking disease severity 
Endpoint Analysis Monitoring the efficacy of a therapeutic agent 




1.7.3. Prediction and Diagnostic Biomarkers for Overt Diabetes  
In T1D, the ideal biomarker should have the capability to detect early insulitis, predict diabetes 
development in “at risk” individuals, predict therapy outcomes by measuring beta cell death and mass 
(Tooley and Herold 2014). Our current capability for direct quantification of insulin secretion, beta cell 
mass or death is limited due to the difficult anatomical position of the islet in the pancreas as well as 
their low abundance (only 1-2% of the whole pancreas mass) (Ionescu-Tirgoviste et al. 2015). It is not 
considered ethical to acquire a biopsy sample and applying imaging techniques to study them in vivo 
directly.  
1.7.3.1. Autoantibodies to Islet Antigens as Predictive Biomarkers for T1D Development:  
Islet autoantibodies are highly stable biomarkers, and they can be measured in the serum, 
plasma or saliva. In the last twenty years, a considerable effort was made by the Diabetes 
Autoantibody Standardization Program (DASP) to identify the most sensitive and specific assays, 
determine the ideal antigens and reference standards, and underline the weakness of different 
methods (Bingley et al. 2003; Lampasona et al. 2011). These efforts have contributed to standardising 
islet autoantibody measurement, prediction and diagnostic assays (Table 1.5). By the time of disease 
Table 1.4: Features and characterization of the ideal biomarker. 
Characterization Comments 
Specific 
Have the ability to differentiate pathological from normal state 
Specific to the affected cells or tissue 
Sensitive Rapid and significant release upon disease development 
Anticipative 
Long half-life in biological sample 
Its release is proportional to the degree of disease severity 
Robust 
Rapid, simple, accurate and inexpensive detection 
Not changed by environmental factors and other diseases 
Non-invasive 
Present in easily accessible biological fluid samples 







onset, 60-80% of T1D patients are positive for GADA, 40-50% are positive for IA-2A, 75%–85% are 
positive for ICA. It is also reported that 70-80% of the patients who were diagnosed before the age of 
5 years with T1D are positive for IAA, but the percentage drops up to <40% when the diabetes is 
diagnosed after the age of 12 years (Sacks et al. 2011, Ziegler et al. 1999). It was shown that 60-80% 
of the newly diagnosed with T1D patients were positive for ZnT8A (Wenzlau et al. 2007). Although, 
IAA are more commonly detected (>70%) in the sera of young children in comparison to adult samples, 
screening for IAA becomes invalid once exogenous insulin treatment is started. This is because 
exogenous insulin might induce antibody secretion against it, making differentiating newly developed 
antibodies from pre-existing IAA difficult (Winter and Schatz 2011). IAA is usually the first 
autoantibody to be detected, followed by GADA, while both IA-2A and ZnT8A, are considered as “late” 
autoantibodies that are rarely detected at the time of initial seroconversion. The peak of islet antigen-
specific autoantibody seroconversion has been reported to occur between the age of 9 months and 
two years (Giannopoulou et al. 2015, Ziegler et al. 1999). Islet antibody seroconversion can be 
detected in sera as early as six months of age, and it is rare to occur before that age (Krischer et al. 
2015, Parikka et al. 2012, Ziegler et al. 2012). The detection of autoantibodies is useful as a predictive 
biomarker for T1D progression as seroconversion to multi antibodies increases the lifetime risk of 
developing stage 3 T1D to 100% in children (Ziegler et al. 2013a). The presence of one or more islet 
autoantibodies in the circulation has been shown to be a very accurate predictor for T1D. Although 
different studies have given different risk results, screening for GAD, IA-2 and/or insulin antibodies 
using sensitive radio-binding assays can identify 85% of cases of newly diagnosed or future T1D with 
98% specificity (Bingley et al. 2001). The presence of multiple islet autoantibodies in the sera of high-
risk children increases the risk for developing T1D by 43.5%, 69.7% and 84.2% in 5, 10 and 15 years of 
follow-up, respectively (Steck et al. 2015, Ziegler et al. 2013a). Remarkably, the number of detected 
autoantibodies is associated with T1D risk. In high-risk infants, the detection of one, two or three 
autoantibodies increases the risk of development to stage 3 T1D to 12.7%, 61.6% and 79.1%, 




developing symptomatic T1D is elevated by 11%, 36% 47% in individuals who have one, two and three 
autoantibodies, respectively, by the age of 5 years (Steck et al. 2015). Seroconversion at a young age 
is another risk factor for stage 3 T1D progression. Development of multiple autoantibodies at the age 
1-2 years increases the rate of progression to symptomatic T1D by 75% within six years of life (Steck 
et al. 2015; Ziegler et al. 2013). Further, children who had seroconversion before the age of 3 years 
had a risk of progression to symptomatic T1D of 74.9%, while those who had seroconversion after the 
age of 3 years had a risk of 60.9% for progression to symptomatic T1D by the age of 10 years (Ziegler 
et al. 2013). It has been well acknowledged that there is an association between specific HLA alleles 
and the development of islet autoantibodies. For example, GADA is strongly associated with the HLA 
DR3-DQ2 allele, while IAA and IA-2A are more related to the HLA DR4-DQ8 allele and INS VNTR 
(Giannopoulou et al. 2015, Graham et al. 2002). Islet autoantibody development is also controlled by 
other polymorphisms in the PTPN22, ERBB3, SH2B3, and INS genes according to the TEDDY study 





Table 1.5: The sensitivity and the specificity of the primary antibodies and targets used as a predicting biomarker of T1D. 
Assay Age of Onset 
% of Newly 
Diagnosed 
Genetic Association Sensitivity Specificity κ (95% CI) of the Assay Comment 




0.7 (0.58-0.82) 8 
 74%7 85%7 
83%8 92%8 




 52%7 97%7 
68%8 98%8 
IAA Children < 5years >70%–80%9 
HLA DR4–DQA1*0301–
DQB1*0302 & INS VNTR4 
  
occurs in <40% of individuals who develop diabetes after the age 
of 12 years 
ICA  75%–85%9  85%8 99%8 Difficult to Standardize 
ZnT8A  60-80%    






The presence of three or more autoantibodies increases the risk. 48%7 97%7 
83%8 92%8 
T cell proliferation 
58%7 91%7 





0.63 (0.41-0.86) 8 Require fresh cells, large volumes, and multiple antigens. 
74%8 88%8 
                                                          
6 (Torn et al. 2015) 
7 (Seyfert-Margolis et al. 2006) 
8 (Herold et al. 2009) 




1.7.3.2. Islet Autoantibodies and C-Peptide in the Assessment of T1D Clinical Therapies 
Pancreatic islet transplantation is a conventional T1D therapy used to reinstate insulin 
secretion and production in individuals with ongoing issues with controlling blood glucose level. Islet 
transplantation is usually rejected due to autoimmunity relapses even after the administration of 
immunosuppressive drugs. In combination with the indices of glucose homeostasis and C-peptide 
levels, islet autoantibodies are used to predict pancreatic allograph rejection. They were found to 
reappear, or their titres increase when the grafted islets are rejected (Bosi et al. 2001, Braghi et al. 
2000, Roep et al. 1999b).  Although GADA were the first autoantibodies to reappear, screening for IA-
2A and ZnT8A are found to be the more robust islet transplant failure predictors (Piemonti et al. 2013).  
Several reports had shown the shortcomings of using islet autoantibodies as a biomarker for 
predicting and assessing the T1D Therapies. First of all, anti-islet autoantibodies are not the primary 
effectors of insulitis and beta cell destruction; instead, they are an indirect reflection of the process. 
Therefore, autoantibody titres post immunotherapy are probably not an indication of immune efficacy 
(Rekers et al. 2015). Secondly, as explained earlier, T1D is a T cell-mediated disorder so naturally, most 
therapeutic strategies target T cells. Meanwhile, autoantibodies can be secreted independently by 
long-lived plasma cells that are not affected by immunosuppressive therapies, and from new plasma 
cells that can be further differentiated from memory B cells under the stimulation of persistent or 
recurrent T cells. Furthermore, T cells have a faster dynamic response to external modifications than 
changes in autoantibody titres. This has been shown in new-onset T1D patients followed up for both 
autoantibodies and T cell responses from diagnosis for a median of 11 months. It has been 
demonstrated that administration of pre-proinsulin and GAD epitopes decreased the number of 
reactive T cell responses (from 60 to 20% for pre-proinsulin and 67 to 20% for GAD) meanwhile, the 
titre of GAD and IA-2 autoantibodies remained unchanged in 75% of cases (Martinuzzi et al. 2008). 
Furthermore, anti-CD3 immunotherapy (which targets reactive T cells and partially depletes B cells) in 
new onset T1D patients demonstrated better preservation of residual insulin secretion but did not 




Madaschi et al. 2010). Unchanged autoantibody levels can be solely because anti-CD3 immunotherapy 
targets T cells but not B cells. Another example is the immunotherapy trial on IAA positive T1D patients 
with anti-CD20 rituximab, which targets B cells resulting in the elimination of IAA in only 40% of 
treated group patients in comparison to the placebo-treated group (Pescovitz et al. 2014, Pescovitz et 
al. 2009, Yu et al. 2011). Finally, islet autoantibody measurements are not valid in a non-autoimmune 
condition that may need beta cell grafting such as type 2 diabetes.  
C-peptide is another robust biomarker that reflects beta cell function. C-peptide is the part of 
proinsulin which is cleaved and co-secreted with insulin from the secretory granules of the beta cell 
(Figure 1.3). Following proinsulin cleavage, insulin (51-amino-acid peptide) and the C-peptide (31-
amino-acid peptide) are produced in a 1:1 ratio (Marques et al. 2004, Steiner et al. 1967). The 
measurement of C-peptide levels is a useful indicator to distinguish between the different types of 
diabetes, e.g. type 1 diabetes from type 2 diabetes or Maturity onset diabetes of the young (MODY) 
as a very low C-peptide confirms type 1 diabetes (Jones and Hattersley 2013). Measuring the secretion 
levels of C-peptide in type 1 diabetes can assist in estimating the secretion of endogenous insulin 
especially when the patient receives insulin therapy and when measuring endogenous insulin levels 
becomes difficult (Clark 1999, Shapiro et al. 1988). Like islet autoantibodies, C-peptide measurement 
showed several limitations as an indicator for the outcomes of clinical trails. Although it is not affected 
by exogenous insulin, C-peptide is usually influenced by factors that have an impact on insulin 
secretion, such as insulin resistance (Saisho 2016). Further, the level of C-peptide essentially reflects 
the remaining beta cell function rather than measuring the dying beta cells. Further, C-peptide often 
fails to reflect the presence of beta cell destruction during the pre-diabetic stage, particularly at the 
very early period of T1D development and in latent autoimmune diabetes in adults (LADA) when the 
beta cell injury is slow. Moreover, C-peptide metabolic clearance rate may fluctuate from one 
individual to another, and due to the long half-life of C-peptide, false positive results could be caused 
by short time intervals of the tests (Polonsky et al. 1986a, Polonsky et al. 1986b, Polonsky and 




preventative and interventional therapeutic approaches still poses an immense challenge. Recently, 
evidence has accumulated showing that epigenomic biomarkers such as DNA methylation of key beta 
cell genes have the potential to be powerful tools to detect beta cell injury in the early preclinical stage 
of T1D.   
1.7.3.3. Differentially Methylated Circulating DNA as an Indicator of Beta Cell Death 
During the pathogenesis of a disease, injured cells release their DNA into the circulation. 
Isolating and quantifying such cell-free DNA (cfDNA) has been used recently to study the rate of cell 
turnover and/or cell apoptosis/necrosis (Schwarzenbach et al. 2011). cfDNA is fragmented gDNA 
which originates from multiple possible sources such as normal cell turnover, the breakdown of blood 
cells, leukocyte surface DNA, newly synthesised DNA or from released DNA/RNA-lipoprotein 
complexes from healthy cells. When the size of the cell-free nucleic acids was measured with gel 
electrophoresis, the result was a ladder-like pattern where the nucleic acid fragments were mainly 
around 180-1000 bp in size. Massively parallel sequencing is a more advanced technology with higher 
resolution that was used recently to confirm the size of those cell-free nucleic acids. It showed that 
the majority of cfDNA fragments are around 166 bp which suggests that apoptosis is the major source 
of cfDNA in the circulation (Jiang and Lo 2016). In healthy individuals, the mean quantity of plasma 
cfDNA is from 10 ng/μL - 1.5 μg/ μL (Elshimali et al. 2013, Fleischhacker and Schmidt 2007). This low 
concentration of cfDNA is due to the efficient removal of dead cells by circulating phagocytes. It has 
been shown that in the case of diseases such as cancer and developing autoimmunity, the level of 
cfDNA is dramatically increased due to the rapid destruction of cells (Jiang and Lo 2016). One of the 
approaches to identify such circulating cfDNA is through detecting differentially methylated sites 
specific to the injured cell. This approach is particularly promising in biomarker development research, 
and it has been applied successfully in cancer research (Han et al. 2017, Wang et al. 2017). 
Beta cells have uniquely hypomethylated CpG sites within the promoter of the INS gene which is 




Lehmann-Werman et al. 2016). Targeting differentially hypomethylated CpG sites within INS seems to 
be a promising strategy for monitoring beta cell death. Multiple groups have made an effort to develop 
a unique DMR-based biomarker for monitoring beta cell injury when required. Ferreri and colleagues 
reported that specific CpG sites within the insulin gene promoter are uniquely hypomethylated in both 
human (INS) and mouse (Ins2) beta cells (Husseiny et al. 2012, Kuroda et al. 2009). They reported that 
CpG sites (−357, −345, −234, −206, −180, −135, −102, −69 and −19 relative to the transcription start 
site, TSS) were uniquely hypomethylated in the human beta cell INS promoter but not in other tested 
control tissues, such as liver and kidney. Further analysis had shown that only CpG -19, -69, -135, -206 
and -357 from TSS were significantly hypomethylated in beta cells but not elsewhere (Husseiny et al. 
2014). They further showed that hypermethylation induction in specific CpG sites resulted in 
significantly decreasing insulin gene expression in the NOD mouse model. They were also able to 
reprogram mouse embryonic stem cells to differentiate into insulin-producing cells by demethylating 
specific CpG sites in the Ins2 gene promoter in vitro (Kuroda et al. 2009). A differentially methylated 
assay whose design was based on the CpG sites -206 and-135 was able to successfully detect 
hypomethylated INS beta cell-derived DNA in the circulation of human islet transplant recipients 
(Husseiny et al. 2014). Another differentially methylated assay designed by another group based on 
the CpG -69 was successful in differentiating beta cell-derived DNA in the circulation of recently 
diagnosed T1D patients as well as in the circulation of a NOD mouse model which underwent xeno-
islet transplantation rejection (Fisher et al. 2015).  
Another group, Herold and colleagues (Akirav et al. 2011) were also able to confirm the presence 
of two differentially hypomethylated CpG sites located outside the promoter region of human INS 
gene (CpG +273 and +399 relatives to TSS). Herold and his group suggested that CpG +273 and +399 
are potentially better targets for discriminating beta cell-derived DNA from non-beta cell DNA. Based 
on which, a beta cell discriminating assay was designed and used to monitor beta cell death in recent 
onset and at risk T1D individuals (Akirav et al. 2011, Herold et al. 2015a, Usmani-Brown et al. 2014), 




2017). Despite the success of the assay in detecting beta cell-derived DNA, a considerable background 
level of hypomethylated INS DNA was detected in control samples (Bellin et al. 2017, Herold et al. 
2015a). The authors referred to the source of hypomethylated INS background levels as of non-beta 
cell origin, since the same CpG site was previously reported to be hypomethylated in non-beta cells 
(Husseiny et al. 2014). The sensitivity and specificity of the detection assay were shown to be increased 
when multiple adjacent CpGs were multiplexed together (Lehmann-Werman et al. 2016). High-
throughput methylation sequencing of six individual CpG sites within the promoter of the INS gene in 
multiple tissues revealed that these CpG sites are 90-95% hypomethylated in beta cell genome and 5-
15% in other studied tissues. The specificity of these CpG sites to discriminate beta cell from non-beta 
cell DNA was increased by combining the six sites (multiplexing), decreasing the detection of 
hypomethylated CpG sites in the non-beta cell genome to 0.01% (Lehmann-Werman et al. 2016). The 
power of multiplexing was also manifested in an experiment which showed that the analysis of the 
concentration of individual hypomethylated CpG sites of the INS promoter in DNA fragments failed to 
differentiate between T1D and control serum samples. However, when the result was multiplexed, a 
clear signal discriminating T1D from controls was observed (beta cell-derived cfDNA level was 1.9-
5.5% in T1D patients and 0-0.1% in control)(Lehmann-Werman et al. 2016).   
The pancreatic beta cell is also known to expresses multiple genes almost exclusively, which hence 
could be regulated by a unique methylome. Therefore, other beta cell-specific genes might be used to 
design methylation sensitive assays. For instance, specific differentially hypomethylated CpG sites 
within the islet-specific gene amyloid polypeptide (amylin) had shown the ability to discriminate beta 
cell-derived cfDNA in the circulation of both humans and a mouse model (Olsen et al. 2016). The study 
demonstrated that a methylation sensitive assay design based on CpG +5414 and +5419 successfully 
discriminated beta cell-derived DNA in the circulation of recently onset T1D individuals (Olsen et al. 
2016). Another example is the use of differentially methylated CpG sites in exon 1 of the gene 
glucokinase (GCK), which was shown to be predominantly hypomethylated in the islet genome but 




specific biomarkers based on the CpGs +13, +17 and +19 of exon 1 of the gene GCK and the biomarker 
based on the CpG -69 of INS promoter designed by (Fisher et al. 2015). Although both assays were not 
statistically significant in differentiating between recently diagnosed T1D patients or those who are at 
risk of developing T1D from non-diabetic matched controls (Sklenarova et al. 2017), GCK and amylin 
based biomarkers were a step forward toward employing beta cell-specific genes, apart from INS, for 
designing differentially methylated biomarkers that detect beta cell death in the circulation.  
1.7.3.4. DNA Methylation in Assessing the Outcomes of Clinical Practice  
A differentially methylated based biomarker has been used for assessing beta cell survival 
following innovative therapies. It has proved to be of benefit in the evaluation of beta cell responses 
to the anti-CD3 immune therapy (teplizumab) in recent-onset T1D patients (Lebastchi et al. 2013).  
Differentially hypomethylated INS based assays were also shown to be of benefit in assessing the 
outcomes of allogeneic islet transplantation in humans. Following up islet transplant patients (n=6) 
showed that hypomethylated INS levels significantly increased a day after transplantation, the 
elevated level persisted for at least fourteen days (Husseiny et al. 2014). The hypomethylated INS 
promoter CpG was also used to interpret the outcomes of cadaveric allogeneic islet transplantation in 
longstanding T1D patients (n=10) (Lehmann-Werman et al. 2016). Hypomethylated INS promoter 
cfDNA was detected in the plasma of islet recipients 1-2 hours post the transplantation; the level 
declined sharply in the following hours and days in a manner that was in parallel with the result of 
imaging studies done on islet transplantation recipients (Eich et al. 2007). Increased levels of 
hypomethylated INS promoter fragments were re-detected in the circulation of the recipients 7-days 
to 1-month post the transplantation, indicating ongoing cell injury (Lehmann-Werman et al. 2016). 
More recently, it was possible to correlate between beta cell-specific cfDNA post clinical islet allograft 
and recipient outcomes (Gala-Lopez et al. 2018). Another example of the visibility of using 
differentially hypomethylated circulating INS DNA fragments to assess the outcomes of a clinical trial 
was a study of the INS cfDNA level in patients undergoing pancreatectomy with islet 




demethylation INS ratio (demethylated INS counts / demethylated INS counts + methylated INS counts 
(U/[M+U])) was significantly raised in the first three hours post islet infusion in TPIAT patients. Variable 
late elevation (between the day 3 and 30 post islet infusion) in the methylated INS cfDNA ratio was 
noticed, suggesting inconsistency in graft loss among recipients (Bellin et al. 2017). Collectively, these 
findings suggest that differentially methylated circulating DNA is a potentially powerful and highly 
specific biomarker for monitoring beta cell death during and after islet graft. Despite the number of 
described assays that can discriminate T1D from controls, none are used clinically and workshops have 





1.8. DNA Methylation Profiling Technologies and Studies 
1.8.1. DNA Methylome Profiling  
Next-generation methylation sequencing (NGMS) technologies are non-Sanger-based, 
massively parallel high-throughput DNA sequencing technologies. Genome-wide methylation testing 
permits the analysis of global epigenetic changes and therefore the opportunity to assess the whole 
genome to identify more gene-specific DMRs (Beck and Rakyan 2008, Bock et al. 2010). There are 
several different experimental technologies for profiling genome-wide DNA methylation, summarised 
in Table 1.6. Microarrays are one of the widely used techniques that allow studying genome-wide 
epigenetic modifications at a molecular-level among healthy and disease samples. Infinium Human 
Methylation 450 BeadChip and the more recently Illumina MethylationEPIC BeadChip are a method 
of choice for epigenome-wide association studies (Rakyan et al. 2011b). The EPIC microarray provides 
an assessment for more than 850,000 CpG loci, covering key features of the human genome including 
enhancers, CpG islands, shores, promoters, gene bodies, intergenic, and imprinted regions (Moran et 
al. 2016).  
Large volumes of data have been generated from microarrays, the first genome-wide, single-
base resolution sequencing of the mammalian genome was published in 2009 (Lister et al. 2009). Large 
international initiatives are contributing to the mapping of the human epigenome as the International 
Human Epigenome Consortium (IHEC) (Bujold et al. 2016; Stunnenberg et al. 2016). IHEC coordinates 
the contribution from seven international consortia; ENCODE (Consortium 2012), NIH Roadmap 
(Bernstein et al. 2010, Kundaje et al. 2015), CEEHRC, BLUEPRINT (Adams et al. 2012), DEEP, AMED-
CREST, and KNIH; that aims to sequence and decipher 1000 human epigenomes of various cell types. 
The Roadmap Epigenomics consortium recently published a landmark paper of post-translational 
modification profiles for 111 reference human epigenomes such as histone modification, DNA 
accessibility, DNA methylation and RNA expression by using high-throughput sequencing techniques 
(Kundaje et al. 2015). Other key studies include, the DNA methylation profiling of 17 human somatic 




30 diverse human cell and tissue types (Ziller et al. 2013), analysis of the methylation signature of 1628 
human samples (Fernandez et al. 2012) and profiling methylation of 82 human cell lines (Varley et al. 
2013). 
1.8.2. DNA Methylation-Sensitive Assay Design 
The first designed generation of methylation-sensitive assays used SYBR Green (Akirav et al. 
2011, Husseiny et al. 2012). The SYBR Green-based technology had some limitations, firstly, SYBR 
green technology has the potential for high background signals, off-target annealing of the 
methylation-sensitive primers which could decrease the assay sensitivity and the inability to multiplex 
multiple targets in one reaction. In 2013, Mirmira and colleagues introduced a dual-labelled probe-
based methodology (TaqMan) in a semi-quantitative manner, which allowed multiplexing the 
methylated and unmethylated CpG -182 (relative to TSS) of the Ins2 DNA probe in one reaction (Fisher 
et al. 2013). The proposed method obviated the need for the nested PCR step and significantly 
decreased the background signal. The dual-labelled probe-based methodology was the basis of the 
development of the second generation of absolute quantitative assays using the droplet digital PCR 
(ddPCR). ddPCR is a technique that involves a water-oil emulsion droplet (microfluidics) technology 
that partitions the sample into 20,000 droplets. The fractionated samples are then amplified by 
thermal cycling, and then Poisson statistics are used to calculate the absolute copy numbers of DNA 
fragments (Bio-Rad droplet digital application guide). Utilising ddPCR has led to the development of 
two insulin based methylation-sensitive assays to monitor beta cell death (Fisher et al. 2015, Usmani-
Brown et al. 2014).  
1.8.3. The Effect of Diabetes on the Methylome of Beta Cell-Specific Genes 
T1D-specific methylation has been reported to be present at variable positions in the DNA of 
monocytes isolated from MZ and discordant healthy controls. T1D MZ and pre-T1D individuals who 
were positive for the diabetes-associated autoantibodies (GAD65, IA-2 and Islet Cell Antibodies), had 
healthy blood glucose levels and were not receiving insulin treatment showed a higher level of DNA 




progression and is not due to post-disease associated factors such as hyperglycaemia (Rakyan et al. 
2011a). Furthermore, islets isolated from subjects with type 2 diabetes displayed higher methylation 
levels in the INS gene in comparison to islets isolated from control subjects (Yang et al. 2011). 
Additionally, the CpG hypermethylation at defined positions in the INS proximal promoter (-69, -102, 
-108, -206) were strongly correlated with the INS cis-genotype at the rs689 polymorphism, which is 
known to be strongly associated with T1D (Fradin et al. 2012). More recently, a report confirmed the 
effect of hyperglycaemia on the methylome of the beta cell in the NOD model (Rui et al. 2016). The 
presented data showed that Ins1/Ins2 gene was becoming hypermethylated as T1D progressed in the 
NOD mouse model. Therefore, studying the effect of hyperglycaemia on the methylome of a CpG is 




Table 1.6: Different DNA methylation-profiling technologies. 


















Array-based technique for 














Most tissue-specific DMR occurs 
at CpG island shores but not at 









A sequencing technology that 
relays on proteins to capture 








-Allow detecting methylated cytosine in 
dense CpG-dense regions and regions 
with lower CpG density. 
-MBD proteins can discriminate 5mC 
from 5hmC. 
- Low resolution in comparison to other 
single base resolution technologies. 
-Detect the hypermethylated cytosine 
only. 
-DNA region with low-density 












Identified and confirmed 11 CpG 
islands that were methylated in 







5mC-specific antibodies are 
used to study cytosine 
modifications in isolated, 
methylated DNA from 







- Covers CpG and non-CpG methylated 
cytosines throughout the genome. 
- Detect methylation in dense, less 
dense, and repeat regions. 
- Antibody-based selection is 
independent of DNA sequence. 
-Specific-antibodies are biased towards 
hypermethylated cytosines only. 
-Antibody specificity and selectivity 














Analysis of 6,000 CpG islands in 
the inactive X chromosome 
showed that aberrant 
methylation of CpG island 
promoters in malignancy might 
be less frequent than previously 
hypothesised. (3) 
CHARM: Comprehensive high-throughput array for relative methylation. MBDCap-Seq: Methyl-CpG binding domain-based capture and sequencing. MeDIP: Methylated DNA 
immunoprecipitation sequencing. WGBS: Whole-genome bisulfite sequencing. RRBS: Reduced-representation bisulfite sequencing. TAB-Seq: Tet-assisted bisulfite sequencing. The 
information was based on (Plongthongkum et al. 2014). 


















A BeadChip technology that 
uses Infinium I and Infinium II 
probes to generate 
comprehensive genome-wide 








-Do not require a significant amount of 
input DNA. 
-No PCR is needed, which means that 
there will be no selection bias towards 
shorter fragments. 
- Process up to 8 samples per chip 
allowing high throughput processing. 
- The ability to integrate data between 
other platforms (E.g. gene 
expression and microRNA profiling). 
- Provide genome-wide methylation 
patterns coverage as the method looks 
at ~2 CpG sites per CpG island. 
-Available for the human genome only. 
-The CPG coverage is dependent on the 
array design (27K, 450K, and 850K). 
 








Estimate of nucleated cells types 
in cord blood is a DNA 





A protocol to detect 
methylated cytosines in 





- Covers CpG and non-CpG methylated 
cytosine throughout the genome. 
- Detect methylation in dense, less 
dense, and repeat regions. 
-High cost. 
-Risk of DNA degradation due to 
bisulfite treatment. 









Identify differentially methylated 
regions proximal to genes 
involved in pluripotency and 
differentiation in human 





A protocol that uses one or 
multiple restriction enzymes 







-The technique of choice to study 
specific regions of interest. 
-Useful in high dense methylation 
region as in promoters and repeat 
regions. 
- Genome-wide covers CpGs in islands 
at single-base resolution. 
- Limited methylation analysis. 
-Risk of DNA degradation due to 
bisulfite treatment. 
-Do not distinguish between 5mC and 
5hmC. 
- Does not cover non-CpG areas, 
genome-wide CpGs or CpGs in regions 











stem cells possess unique 
epigenetic signatures that may 
play essential roles in the 














A technology for DNA 
methylation analysis of target 
regions using a hybridisation-
based step on platforms 
containing pre-designed 
oligos to the target region. 
<<<1% 250 ng 
- Analyse the methylation of DNA at 
single-base resolution DNA of particular 
regions. 
- Cost effective. 
- Differentiate between SNPs and 
methylation status. 
 
-Risk of DNA degradation due to 
bisulfite treatment. 











Epigenetic dysregulation of Wnt 
signalling and the pathogenesis 
are linked to the progression of 






A novel method that uses 
bisulfite conversion and Tet 
proteins to study 5hmC. 
>90% 1–3 μg 
- Distinguish 5hmC from 5mC in single 
base resolution. 




-Substantial DNA degradation after 
bisulfite treatment. 
-Tet protein with low efficiency might 
miss methylated bases. 
-Deep sequencing is required to cover 
the low abundant 5hmC in the whole 
genome. 
-Harsh oxidation can lead to substantial 







Profile the methylation of 
primordial germ cells from the 
migrating stage to the gonadal 
stage at single-cell and single-





Islet autoantibody titration and the measurement of beta cell function are the best current 
methods for T1D diagnosis and progression prediction. These biomarkers still have some limitations 
particularly in clinical practice trials as they have been shown to be indirect and not specific for 
measuring beta cell mass. Therefore, the lack of current biomarkers to measure the efficacy of 
preventative and interventional therapeutic approaches still poses an immense challenge. Recently, 
accumulating evidence suggesting that epigenomic biomarkers such as differentially methylated INS 
promoter assays have shown themselves to potentially be powerful tools to detect real-time beta cell 
injury. Multiplexing several DMR targets had also shown to increase the sensitivity and the specificity 
of the assay during the preclinical stage of T1D that may cure T1D. In this research project, we identify 
multiple novel targets to facilitate designing a multiplex assay that monitors real-time beta cell injury.  
Project Rationale  
Hypothesis 
Differential methylation patterns of beta cell-specific CpG sites can be used as biomarkers to 
detect dying beta cells in the circulation. The sensitivity and specificity of the designed assay can be 
increased by multiplexing several different differentially methylated targets.  
Aims 
1. Identify novel differentially methylated CpG sites within beta cell-specific genes (Chapter 4). 
a. Verify the specificity of the identified targets in other somatic tissues methylome 
conducted from the Roadmap and ENCODE Studies.  
b. Design and optimise methylation sensitive probe-based assays for the identified CpG 
targets. 
c. Optimise a multiplex assay of the designed probe-based assays and confirm the 




2. Test the effect of hyperglycaemia and proinflammatory cytokines on the methylation of the 
identified CpG targets in the genome of the beta cell line (EndoC-βH1) (Chapter 4).  
3. Optimise the method of cfDNA extraction from human liquid biopsy samples, i.e. plasma/ 
serum and urine (Chapter 5).  
4. Test the performance of the developed methylation sensitive multiplex assay in detecting 
beta cell DNA in the circulation of children and adults with recently diagnosed T1D, at 







   
 





2. General Methods 
2.1. Samples 
2.1.1. Human Tissue  
Islet samples, which was used for the whole genome methylation sequencing (Illumina EPIC 
BeadChip), were either provided by Dr Stephen Hughes from the Oxford Centre for Diabetes (JDRF, 
Oxford, UK) or by Professor James Shaw from the University of Newcastle. Details of the islets are 
provided in Table 2.1 (Purity: 40-75%, mean Purity: 61%). Peripheral blood mononuclear cell (PBMC) 
samples (n=3) were obtained locally from healthy adult female donors from the Department of 
Diabetes and Metabolism, University of Bristol (Bristol, UK). Healthy human cortex kidney tissue 
samples (n=2) were provided by Dr Gavin Welsh, (Bristol Renal Group, University of Bristol, UK). The 
normal human spleen, heart, liver, and lung tissue samples obtained from an anonymised male 
cadaver with scleroderma were provided by Professor Lee Nelson (Fred Hutchinson Cancer Research 
Centre, Seattle, US). All samples were collected with informed consent.  
2.1.2. Cell Lines  
2.1.2.1. EndoC-βH1 
For experiments involving human cell beta line, we used EndoC-βH1 cells, which were kindly 
provided by Professor Aniko Varadi, (Department of Applied Sciences, University of West England, 
Bristol, UK). EndoC-βH1 is a genetically engineered human pancreatic beta cell line derived from 
human foetal pancreatic buds. Briefly, human foetal pancreatic ducts were transduced with a lentiviral 
vector expressing the oncogene Simian Virus 40 large T antigen (SV40LT) under the control of the rat 
insulin promoter. The foetal ducts were then grafted into severe combined immunodeficiency (SCID) 
mice to allow cell expansion. Prior to re-grafting into other SCID mice to allow proliferation, beta cells 
that express SV40LT were isolated and transduced with human telomerase reverse transcriptase to 
induce cell immortalisation. The resulting beta cells were further expanded in culture to form cell lines 




2.1.2.2. Prostate and Breast Cancer cell lines 
Both prostate and breast cancer cell lines were kindly provided by Professor Jeffrey Holly (IGFs 
and Metabolic Endocrinology Group (IMEG), University of Bristol, UK). All cell lines were provided as 
a cell pellet from which the DNA/microRNA were extracted. All Prostate cell lines (LNcaP, DU145, VcaP 
and PC3) were obtained from the American Type Culture Collection (ATCC) except for the 
differentiated prostate epithelial cell line (PNT2) which was obtained from the European Collection of 
Authenticated Cell Cultures (ECACC). Breast cell lines HS 578T, MCF7, MDA-MB-231, T47D and ZR-751 
were obtained from the American Type Culture Collection (ATCC). Details of all the human prostate 
cell lines are summarised in Table 2.2; the breast cell lines details are summarised in Table 2.3. 
2.2. Cell Culture  
2.2.1. EndoC-βH1 Cell Culture 
EndoC-βH1 cells were cultured in Dulbecco's modified Eagles Medium (DMEM) low glucose 
(1 g/L) medium containing 2% foetal bovine serum (FBS) fraction V, 50 μM 2-mercaptoethanol, 10 mM 
nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite and Penicillin (100 
units/mL)/Streptomycin (100 μg/mL). Under normal circumstances, the cells were incubated in a 
humidified atmosphere of 95% air and 5% CO2 at 37°C in which they were routinely passaged when 
they reached 70-80% confluence. The cells were fed every two days.  
For the experiment of examining the effect of hyperglycaemia on the methylome of the beta 
cell, EndoC-βH1 cells were grown in T25 flasks for 5 days until confluent. Then each flask was grown 
in normal media with 25 mM glucose instead of the usual 5.5 mM up to 48 hours. One control flask 
was kept in 5.5 mM glucose throughout the experiment. After the treatments, the flasks were washed 
with 1X Phosphate-buffered saline (PBS) and trypsinised to remove cells from the flask. Neutralisation 
medium was then added (80% of 1X PBS and 20% Bovine serum albumin (BSA)), and the cells were 
spun down at 700x g for 5 minutes. EndoC-βH1 cells were then resuspended in 200 μL PBS and frozen 




For the experiment studying the effect of the proinflammatory cytokines on methylation 
stability, TNF-α, IFN-γ and IL-1β were used as these three cytokines are widely utilised to mimic T1D 
and induce beta cell death in vitro (Liu et al. 2000, Rabinovitch and Suarez-Pinzon 1998). The effect of 
cytokines was examined after 1, 3 and 7 days of culture in the presence of recombinant murine IFN- γ 
(14 U/mL “10.3 ng/mL”, eBioscience), recombinant human IL-1β (60 U/mL, “4.4 ng/mL”, Abcam), and 
recombinant murine TNF-α (185 U/mL, “8.7 ng/mL”, Abcam). These concentrations of cytokines are 
commonly used in beta cell research (Lortz et al. 2000, Mandrup-Poulsen et al. 1987, Nerup et al. 
1994). Control EndoC-βH1 cells were grown in the absence of test proinflammatory cytokines.  
2.2.2. Prostate and Breast Cell Lines Culture 
The DU145, PC3, and PNT2 cell lines were maintained in 25 mM, 4.5g glucose/L DMEM, 
(BioWhittaker, Verviers, Belgium) supplemented with 10% heat-inactivated FBS (Gibco, Paisley, UK) 
and 5% L- Glutamine (LG, Lonza Ltd). The LNCaP cell line was maintained in 25 mM, 4.5 g glucose/L 
RPMI-BW12-702F media, with 5% L-glutamine and 10% FBS. Stock cultures of DU145 and PC3 cells 
were grown in T175 cm2 flasks (T175, Greiner Bio-one) while PNT2 and LNCaP cell lines were grown in 
T75 flasks (T75, Corning) to approximately 80-90% confluency before passaging. Breast cell lines were 
maintained in either normal (5 mM, 1 g/L) or high (25 mM, 4.5 g/L) glucose-containing DMEM (Sigma, 
Dorset, UK). The media were supplemented with 10% of FBS and 1% L-glutamine. The normal human 
mammary epithelial cell line (MCF10A) was maintained in Ham’s F12 medium and DMEM. The media, 
which was supplemented with 1% L-glutamine (DMEM: F12, Gibco), 5% horse serum (v/v HS, Gibco), 
20 ng/mL EGF (Calbiochem, Nottingham, UK), 100 ng/mL cholera toxin (Sigma), 10 μg/mL insulin (Novo 
Nordisk, West Sussex, UK) and 0.5 μg/mL hydrocortisone (Sigma), were maintained in 5.5 mM, 4.5g 
glucose/L DMEM, (BioWhittaker, Verviers, Belgium) supplemented with 10% heated inactivated FBS 




2.3. Serum and Plasma Samples 
2.3.1. Locally Collected Samples (Assay Optimising Experiments) 
Peripheral whole blood samples were collected in a 5 mL SST™ tube (Becton Dickinson) 
containing a gel barrier to separate the serum after centrifugation. All samples were processed at 
room temperature within 2 hours from the time of venepuncture. Serum was separated from the 
cellular fraction by centrifugation at 2,000xg for 15 minutes. After centrifugation, each serum sample 
was transferred into a sterile Lobind Eppendorf tube and re-centrifuged at 16,000 g for 10 minutes. 
Afterwards, the supernatant was divided into aliquots of 300 μL. Aliquots were stored immediately at 
-80°C until cfDNA was extracted. Plasma was separated from the cellular fraction of peripheral whole 
blood samples collected in 8.5 mL cell-free DNA collection tubes (Roche) by centrifugation at 1,600xg 
for 15 minutes. The separated plasma samples were divided into aliquots of 1 mL in an appropriate 
Lobind Eppendorf tube and were stored immediately at -80°C until cfDNA was extracted. 
2.3.2. Recently Diagnosed Paediatric Cohort 
Serum samples from a small cohort of children with recent onset T1D (n=9, age range: 4-14 
years) was provided by Dr Chloe Bulwer (University College London Hospital and the Institute of Child 
Health, University College London, UK). Each sample was collected into serum-separation tubes 
(SSTTm, BD, Oxford, UK). Serum was separated within 1-4 hours post venepuncture by centrifuging at 
1000xg for 10 minutes and were stored at -80⁰C until they were shipped to the University of Bristol 
for further analysis. The data for each participant is summarised in Table 2.4. Serum samples from a 
control group of non-diabetic children (n=12, age range: 6-15 years) were provided by Dr Danijela 
Tatovic (Brecon Cohort, Diabetes Research Group, University of Cardiff). Each sample was collected 
into SSTTM tubes and was separated within 2 hours post venepuncture by centrifuging at 2000xg for 
15 minutes. Serum samples were stored at -80⁰C until they were shipped to the University of Bristol 




2.3.3. Recently Diagnosed Adult Cohort  
2.3.3.1. Bristol Cohort 
Plasma samples were collected from males who were recently diagnosed with T1D (n=7, 
median duration of 4 months, range 1-7.9 months) as well as from healthy controls (n=4) (Table 2.6). 
The median age of patients at the time of sampling was 26.9 year (range 22.3 - 37.0 years) and of 35.0 
years in controls (range 25.2 - 44.5 years). Patients were recruited from the Southwest Newly 
Diagnosed Diabetes Collection (SWENDIC) and had a clinical diagnosis of T1D according to World 
Health Organization criteria. Control Subjects lived in the same region and were recruited between 
October 2007 and October 2010. Up to 70 mL of venous blood was drawn from each individual and 
processed within one-hour post venepuncture.  
2.3.3.2.  StartRight (Exeter) Cohort  
We studied the level of hypomethylated singleplex, and multiplex DNA in plasma samples (n=9, 
female = 4, male = 5) collected from individuals participating in StartRight Young Adults with diabetes 
Study (University of Exeter). The median age of patients at venepuncture was 26 years (range 18 - 26 
years) and of controls 25.5 years (range 22 - 49 years). Samples were collected within 3 months of 
diabetes diagnosis (Table 2.7). Plasma from age-matched nondiabetic control subjects (n= 12) were 
collected from the local bank of control samples (Table 2.8). Peripheral blood was collected in 8.5 mL 
Roche cfDNA tubes; plasma was separated within 1-hour post venepuncture by spinning the sample 
at 1600xg for 10 minutes. Plasma samples were then stored at -80⁰C until further analysis.  
2.3.4. At Risk for Developing T1D Cohort 
Peripheral blood samples were obtained from blindly selected relatives of individuals with T1D 
(n= 15) participating in the TrialNet Natural History study as part of an Ancillary study 
(https://www.trialnet.org/). These subjects were classified as “at risk” of future developing T1D, as 
they were positive for at least one autoantibody against GAD65, ICA512/IA-2, ZnT8, insulin or ICA. All 




diabetes and samples were collected between 17/08/2017 and 16/05/2018 (Table 2.8). The samples 
were collected in Cell-Free DNA Collection Tube (Roche, Roche Diagnostics GmbH, Germany). Plasma 
was separated by centrifugation at 1,600xg for 15 minutes, and then frozen at -80⁰C until further 
analysis. Sera from age-matched nondiabetic control subjects were collected from the local bank of 
control samples. 
2.3.5. Islet Transplantation T1D Recipients 
Plasma samples from longstanding T1D patients (n= 2) who underwent allo-islet transplantation 
were provided by Dr Vito Lampasona (IRCCS San Raffaele Scientific Institute, Italy). The patients were 
participating in either the Bone Marrow vs Liver as a Site for Islet Transplantation (IsletBOM2) or in a 
study assessing the efficacy and safety of Reparixin in pancreatic islet transplantation (REP0211). From 
each participant, whole blood samples were drawn in EDTA collection tube before the islet infusion, 
and then at 1, 3, 6, 12, and 24 hours, and 2, 3, 5 and 7 days after the end of islet infusion. Plasma was 
separated by 2500xg for 10 minutes at 4°C; Samples were then frozen at -80⁰C until further analysis. 
2.3.6. Urine Samples 
Urine samples used for studying cfDNA stability were collected by taking midstream of the 
first-morning urine sample from healthy volunteers and were processed within 2 hours post collection 
(Table 2.10). Upon collection, urine samples were spun at maximum speed for 10 minutes to 
precipitate the cellular component. The Supernatant was transferred into a new sterile 50 mL 
centrifuge tube. The sample was then aliquoted (1 mL, in appropriate Eppendorf tube) and incubated 








Islet ID Form Source Date of Receiving Cell count& Storage method Purity Viability Donor Age BMI 
LD117 islet pellet Newcastle   NA NA NA NA NA 
HP14-50 islet pellet Oxford 26/01/2015 ~3000 islets one aliquot extracted -20⁰C 60% 80% M 49 26 
HP15-20 islet pellet Oxford 10/04/2015 
17,000 islets divided into 5 aliquots in 100 μL PBS -
20⁰C 
70%  F 56 29.76 
HP15-35 islet pellet Oxford 18/06/2015 
10,000 islets divided into 2 aliquots in 200 μL PBS -
20⁰C 
60% 75% F 41 34 
HP1557 islet pellet Oxford 22/10/2015 
10,000 islets divided into 3 aliquots in 200 μL PBS -
20⁰C storage 




Table 2.2: Human Prostate Cell Lines Characterizes 




Organ: Prostate  
Disease: Carcinoma 




ATCC: HTB-81 26 
PC-3 
Organ: Prostate  
Disease: Adenocarcinoma 
Tumour Grade: IV 




ATCC: CRL-1435 24 
LNCaP 
Organ: Prostate  
Disease: Carcinoma 





ATCC: CRL-1740 24 
PNT2 
Organ: Prostate  
Cell Type: Epithelial 
Growth mode: Adherent 
Tissue derived from Prostate 
Age: 33 
Gender: Male 
ECACC: 95012613 18 
VCaP 
Organ: Prostate  
Disease: Cancer 










Table 2.3: Human Breast Cell Lines Characterizes 
Cell Line Source Catalogue Number Provided Passage 
MCF-7 
Organ: Breast 
Disease: breast adenocarcinoma 




ECACC: 86012803 18 
MCF-10A 
Organ: Breast 





ATCC: CRL-10317 16 
MDA-MB-231 
Organ: Breast 
Disease: metastatic breast cancer 
Tissue derived from: Pleural Effusion 
Age: 51 
Gender: Female 
Ethnicity: Not specified 
ECACC: 92020424 26 
T47D 
Organ: Breast 
Disease: ductal carcinoma of the breast 
Tissue derived from Pleural Effusion 
Age: 54 
Gender: Female 
Ethnicity: Not specified 
ECACC: 85102201 23 
HS-578-T 
Organ: Breast 





ATCC: HTB-126 24 
ZR-75-1 
Organ: Breast 
Disease: ductal carcinoma of the breast 













Table 2.4: Recently Diagnosed T1D Paediatric Samples (UCL Cohort) 
 
 

























BCD1 Serum F 10 315 
within 1 hour – 1000x g for 10 minutes and frozen to -
80⁰C 
BCD2 Serum F 13 280 within 1 hour -1000x g for 10 minutes and frozen to -80⁰C 
BCD3 Serum F 7 372 within 1 hour -1000x g for 10 minutes and frozen to -80⁰C 
BCD4 Serum M 9.5 25 within 4 hour -1000x g for 10 minutes and frozen to -80⁰C 
BCD5 Serum M 8 58 within 4 hour -1000x g for 10 minutes and frozen to -80⁰C 
BCD6 Serum F 6 296 within 4 hour -1000x g for 10 minutes and frozen to -80⁰C 
BCD8 Serum F 14 388 within 1 hour -1000x g for 10 minutes and frozen to -80⁰C 
BCD9 Serum M 11.5 191 within 1 hour -1000x g for 10 minutes and frozen to -80⁰C 
BCD 10 Serum F 4 8 
within 2.5 hour -1000x g for 10 minutes and frozen to -
80⁰C 
Study ID Sample Gender 
Age 
(Years) 
UHWBC002 Serum Female 6 
UHWBC005 Serum Male 6 
UHWBC006 Serum Male 15 
UHWBC007 Serum Female 15 
UHWBC010 Serum Female 8 
UHWBC011 Serum Female 6 
UHWBC012 Serum Female 9 
UHWBC013 Serum Male 9 
UHWBC016 Serum Female 7 
UHWBC023 Serum Male 14 
UHWBC024 Serum Female 7 




Table 2.6: The Characteristics of Recently Diagnosed Adult Plasma Samples (Bristol Cohort) 
 




















PATSI 1 25.2 M 5.2 No 0.23   
PATSI 2 27.7 M 5.5 No 0.62   
PATSI 3 44.5 M 5.4 No 0.52   
PATSI 4 42.2 M 7.4 T2D 0.52 0.17 2.0 
PATSI 5 24.1 M 5.6 T1D 0.09 0.20 2.4 
PATSI 6 25.9 M 7.7 T1D 0.2 0.08 1.0 
PATSI 7 26.9 M 7.1 T1D 0.28 0.15 1.8 
PATSI 8 37.0 M 7.3 T1D 0.28 0.66 7.9 
PATSI 9 22.3 M 13.5 T1D 0.23 0.46 5.5 
PATSI 10 34.1 M 11 T1D 0.04 0.52 6.3 
PATSI 11 36.7 M 6 T1D 0.1 0.47 5.6 
Sample ID Age Gender Ethnic Origin 
SR110293 21 Male White British 
SR110453 18 Male White British 
SR110122 48 Female White British 
SR110123 23 Male Other Mixed 
SR110126 26 Female White Irish 
SR110130 21 Female White British 
SR110285 35 Male Any Other Group 
SR110468 39 Female Other White 




Table 2.8: The non-Diabetic Healthy Adult Samples Characteristics. 
CFDNA_ID Gender Age 
SCF2101 M 37 
SCF2102 F 30 
SCF2103 F 25 
SCF2104 M 36 
SCF2105 F 49 
SCF2106 M 29 
SCF2107 F 26 
SCF2108 M 33 
SCF2109 M 28 
SCF2110 F 26 
SCF2111 F 22 
SCF2112 M 24 
SCF2113 M 15 
SCF2114 M 24 



































TNID0001 189896 PH1 50 Male Positive Negative Negative Negative Negative Indeterminate Normal Absent Absent 
TNID0002 251453 HAF 15 Male Positive Negative Negative Negative Negative Normal Normal Absent Present 
TNID0003 251743 EMA 16 Female Positive Negative Negative Negative Negative Normal Normal Present Absent 
TNID0004 205410 SAO 17 Male Positive Positive Negative Positive Positive Normal Normal Absent Absent 
TNID0005 2323200 EF 12 Female Positive Negative Positive Positive Negative Normal Normal Absent Present 
TNID0006 427709 RUS 9 Female Positive Negative Positive Negative Negative clinical Alter Normal Absent Present 
TNID0007 428879 SAA 47 Female Positive Negative Positive Negative Negative Normal Normal Absent Present 
TNID0008 189896 PHI 50 Male Positive Negative Negative Positive Negative Indeterminate Normal Absent Absent 
TNID0009 432363 GIJ 9 Male Negative Negative Positive Negative Negative Normal Normal Absent Present 
TNID0010 447149 AIN 6 Female Positive Negative Negative Negative Negative Impaired Normal Absent Present 
TNID0011 433709 PAF 19 Male Positive Negative Negative Positive Negative Normal Normal Absent Present 
TNID0012 251453 HAF 16 Male Positive Negative Negative Negative Negative Normal Normal Absent Present 
TNID0013 347666 HES 9 Male Negative Negative Negative Negative Positive Normal Normal Absent Present 
TNID0014 433478 OWF 6 Male Positive Negative Positive Negative Positive Impaired Normal Absent Absent 






Table 2.10: The Non-Diabetic Urine Samples Characteristics. 
 
2.4. DNA Methylation Public Data 
DNA methylome data for adult human liver, lung, thymus, left and right ventricle, adipose 
tissue, bladder cells, placenta primary tissue and spleen primary tissue were downloaded from 
Epigenomics Roadmap database (Kundaje et al. 2015). The methylome data was used as a guidance 
to exclude the CpG sites that are not exclusively hypomethylated in the islet genome. The methylation 
level and the genomic sequence data were aligned using the Integrated Genome Browser (IGB, 
http://bioviz.org/). 
2.5. Design of Oligonucleotides 
The bisulfite specific primers that were used in this project were designed using EpiDesign online 
software (Agena Bioscience, https://www.epidesigner.com/), with human sequences available from 
the Genome Reference Consortium Human Build 37 database (GRCh37/hg19). The primer pairs were 
selected using the following criteria: primer Tm (54-58°C), primer length (18-30 bp), and amplicon size 
(80-120bp). Probes were designed manually around the desired CpG site. Primers/probes compatibly 
were checked using Primer Express™ Software (version 3.0.1). All primers were obtained from Sigma 
Aldrich (Synthesis scale 0.025 μM, Desalted purification). Probes, which were HPLC purified, were 
Control ID Gender Age Time of sample collection 
001 F 30 08:40 AM 
002 M 25 10:45 AM 
003 M 58 10:00 AM 
004 F 25 08:00AM 
005 F 24 06:20 AM 
006 M 34 09: 00 AM 
007 M 32 08:40 AM 
008 M 32 08:12 AM 
009 F 32 08:30 AM 
010 F 24 06:32 AM 




obtained from Life Technologies. The full details for all oligonucleotides used in this project are listed 




2.6. Polymerase Chain Reaction (PCR)  
PCR is a technique that amplifies a single copy of DNA into thousands of folds of copies in vitro 
(Mullis and Faloona 1987). During a typical PCR reaction, a new (daughter) DNA strand is synthesised 
from the template DNA strand under the action of the polymerase. The reaction is completed in the 
presence of a buffer that contains primers, flanking the desired DNA segment, polymerase enzyme, 
and deoxynucleotide triphosphates (dNTPs). Once the template DNA strands are denatured, the 
primers anneal to complementary sequences on the DNA template; then the DNA polymerase adds 
nucleotides in the 5’→ 3’ DNA direction to create a new strand in each PCR cycle.  
 
2.6.1. Droplet Digital PCR (ddPCR) 
The idea of the droplet digital PCR was first defined in the late 1990’s (Vogelstein and Kinzler 
1999). Similar to the quantitative PCR (qPCR), ddPCR involves adding primers and probes to detect the 
targeted sequences. However, ddPCR is more sensitive and precise in comparison to qPCR. The major 
difference between the two methods, in the ddPCR, the samples are randomly distributed using a 
water-oil emulsion droplet (microfluidics) technology that partitions the sample into nanoliter 20,000 
droplets before PCR cycling to the endpoint. After endpoint PCR, the presence or absence of template 
DNA in each droplet is determined individually. Since the partitioning is random, the absolute copy 
numbers of DNA fragments can be calculated using Poisson statistics (Hindson et al. 2011) (Bio-Rad 
droplet digital application guide). 
2.6.2. Probe-Based ddPCR 
The ddPCR reaction mixture contains 1X ddPCR Supermix for Probes (12.5 μL, Bio-Rad), 
appropriate concentration of primers and probes, 0.4X Q-solution (Qiagen), the bisulfite converted 
DNA sample and nuclease-free water (Qiagen) to a total volume of 25 μL. To minimise the pipetting 
errors, all components, except the bisulfite converted DNA sample, were premixed in LoBind 
Eppendorf tubes (Sigma Aldrich), and the final PCR mix was prepared individually by combining the 




70 μL of the Droplet Generation Oil for Probes (Bio-Rad) were pipetted into the appropriate wells in 
the Droplet Generator DG8™ Cartridge (Bio-Rad). For each sample, the assay was run in duplicate. 
2.6.3. Droplet Generating, PCR Cycle Conditions 
Once samples and appropriate oil was loaded in the cartridge, the DG8 cartridges were covered 
by the Gaskets (Bio-Rad) and then placed in a QX200™ Droplet Generator (Bio-Rad). Next, the droplets 
were gently transferred into a semi-skirted and PCR clean 96-well PCR plate (Eppendorf) using an E4 
XLS Multichannel pipette with the range 5-50 μL (Rainin). The PCR plate was sealed with pierceable 
foil (Bio-Rad) using a PX1™ PCR Plate Sealer for 10 seconds (Bio-Rad). Afterwards, the PCR 
amplification was performed by placing the plate in a C1000 Touch™ Thermal Cycler (Bio-Rad). For the 
probe-based droplets the PCR, the standard PCR protocol was used in the single plex and duplex 
experiments (Figure 4.5); the touchdown PCR protocol was used in the multiplex probe experiments 
(Figure 4.6). For the EvaGreen based ddPCR, the PCR cycle conditions were as follows: 95°C for 5 
minutes; 40 cycles of 95°C for 30 s, 58°C for 1 minute (Ramp-Rate 1.6 °C /s), 4°C for 5 minute and a 
final step at 90°C for 5 minutes (Figure 7.1). The reaction plates were then held at 4°C until reading. 
The droplet readings and analyses were performed with the QX™ 200 Droplet Reader (Bio-Rad) with 
a ddPCR™ Droplet Reader Oil (Bio-Rad). The data analyses were performed using the software package 
QuantaSoft™ (Bio-Rad, V 1.6.6.0320). The threshold of fluorescence amplitude, which distinguishes 
the positive from the negative droplets, was set manually. The same threshold was applied to all the 















Although developed methylation sensitive insulin promoter assays have been shown to be a 
potential biomarker measure that measure beta cell destruction during the pathogenesis of T1D, they 
were difficult to replicate in other laboratories. Therefore, the main aim of this project was to identify 
other differentially methylated CpG sites in beta cell-specific genes (other than INS). The identified 
CpG targets will be used to develop singleplex and multiplex assays that would be able to discriminate 
circulating cfDNA of beta cell-origin with high sensitivity and specificity. In this chapter, the initial 
approach that was used to identify differentially methylated CpG sites will be described.  
The methylome of the gene the Pancreatic Duodenal Homeobox-1 (PDX-1) (Chr13:28,494,168-
28,500,451), was studied. PDX-1, which is also known as insulin promoter factor 1, is a member of 
homeobox factors that plays a key role in pancreas development (Jonsson et al. 1994). During the 
early embryonic period of life, PDX-1 is expressed in the gut region when the foregut endoderm 
becomes committed to common pancreatic precursor cells. This expression persists in pancreatic 
tissue with high levels at around 4 weeks of gestation, but then declines until it becomes restricted to 
adult human beta cells (Lyttle et al. 2008). It is now well acknowledged that PDX-1 plays a crucial role 
in pancreas development, differentiation and in maintaining mature beta cell function, and more 
importantly, its central role in glucose-dependent insulin secretion (Hui and Perfetti 2002). PDX-1 is 
also essential for beta cell phenotype maintenance as PDX-1 knockout specifically in beta cells results 
in phenotype loss (Ahlgren et al. 1998) and pancreas agenesis (Stoffers et al. 1997). Furthermore, PDX-
1 is required for beta cell survival as cells with reduced PDX-1 were shown to have a higher rate of 
apoptosis (Johnson et al. 2003, Johnson et al. 2006). Treating diabetic mice with recombinant Pdx-1 
protein induces beta cell regeneration, transient hepatocyte reprogramming and prevented the onset 
of T1D in pre-diabetic NOD mice (Koya et al. 2008). Moreover, a successful acinar cell reprogramming 
in mice into functional insulin-producing beta cells required acinar cells viral transduction infection 




another group reprogramed a rat pancreatic exocrine cell line (AR42J) into a beta cell using Pdx-
1, Ngn3 and MafA (Akinci et al. 2012). 
In order to fulfil our goal, we studied the methylation pattern of the distal promoter region 
(Chr13: 28,493,260 - 28,493,696) of PDX-1. As this assay will be used in the future to discriminate beta 
cell fragments in the circulation, it was important to consider the sources of circulating DNA 
contamination that is derived from other cells and tissues. The primary source of contamination would 
be from PBMC; other circulating DNA contamination would potentially originate from apoptotic cells. 
Consequently, the pattern of PDX-1 promoter methylation in islets was compared to the PBMC 
genome. Next, the specificity of the identified differentially methylated CpG sites toward the islet 
genome was examined by comparing its methylation level to a panel of DNAs from locally available 
tissues. It was also important to test the methylation level of the biomarker developed in the duodenal 





3.1.1. DNA Extraction from Human Cells and Tissues 
Genomic DNA was extracted from frozen tissue samples (described in General Methods, 
Chapter 2: Section 2.1.1) using a QIAamp DNA mini kit (Qiagen) following the manufacturer’s 
instructions. Approximately 50 mg of each sample was thawed at room temperature, and then 20 μL 
of Qiagen Proteinase K and 200 μL of lysis buffer was added to break down the proteins. The samples 
were mixed by vortexing for 15 seconds and then incubated at 56°C for 10 minutes. 200 μL of 100% 
ethanol was added to the samples, mixed well and transferred to the QIAamp Mini spin column. The 
columns were spun for 60 seconds then the flow-through was discarded. Next, 500 μL of Buffer AW1 
was added to wash the columns, and the tubes were spun for 60 seconds. The columns were placed 
into a new 2 mL collection tube and were rewashed with 500 μL Buffer AW2. The tubes were spun at 
maximum speed for three minutes. The columns were placed in new 1.5 mL tubes and centrifuged at 
maximum speed for 60 seconds to remove any remaining buffer left in the columns. Next, the columns 
were transferred to a new 1.5 mL tube and 50 μL buffer AE (pre-warmed 45°C) was added directly to 
the column membranes to elute the DNA. The tubes were incubated at 45⁰C for 10 minutes and then 
centrifuged for 2 minutes at maximum speed. The DNA was recovered and measured using the 
Quantus™ Fluorometer instrument according to manufacturer’s instructions.  
3.1.2. DNA Quantification  
Genomic double-stranded DNA was quantified using the QuantiFluor® dsDNA system (Promega) 
following the manufacturer’s protocol. The Standard curve was constructed using Lambda DNA 
(provided within the kit) in the range of 0-200 ng/µL from which the concentration of unknown 
samples was extrapolated. The DNA concentration readings were performed using the Quantus™ 





3.1.3.  Bisulfite Conversion  
After DNA extraction of the samples, 500 ng of genomic DNA from each sample was bisulfite 
converted using the EZ DNA Methylation-Lightning™ Kit (Zymo Research) in accordance with the 
manufacturer’s protocol. In summary, the 500 ng of genomic DNA sample was made up to a volume 
of 20 µL with nuclease-free water. 130 µL of CT conversion reagent was then added to the genomic 
DNA sample and mixed, and the mixture was run in a thermal cycler using the following programme: 
98°C for 10 minutes, 54°C 1 hours, then 4°C up to 20 hours. The sample was subsequently loaded into 
a Zymo spin column with 600 µL of M-binding buffer, mixed and centrifuged at maximum speed for 
30 seconds and the flow-through discarded. Next, 100 µL of M-wash buffer was added to the column, 
followed by a further centrifuge at maximum speed for 30 seconds. The column was then incubated 
for 20 minutes with 200 µL of M-desulphonation buffer protected from direct light. This step was 
followed by two additional wash steps with 200 µL of M-wash buffer. Finally, the columns were 
transferred into a new 1.5 mL tube, 10 µL of M-elution buffer was added to the column and incubated 
at room temperature for 2 minutes. Then columns were centrifuged at maximum speed for 1 minute 
and stored at -20⁰C until further analysis. 
Typically, post sodium bisulfite treatment, all cytosines are converted to uracil bases except for 
those located within methylated CpG dinucleotides which remain intact. In subsequent amplification 
reactions, unmethylated cytosines produce thymine whereas the protected methylated cytosines 















Following sodium bisulfite treatment of the DNA samples, PCR amplification was performed 
with primers that were designed to amplify bisulfite treated DNA strands (Bisulfite specific primers). 
The PCR master mix was prepared using reagents from the Hot Start Taq Polymerase kit (Qiagen). The 
10 μL PCR mixture contained 1 μL of 10X PCR buffer, 500 μM MgCl2, 200 nM dNTPs, 500 nM desired 
primers, 0.05 μL Qiagen HotStar Taq and 5 ng bisulfite treated DNA. The PCR cycle was: 95⁰C for 10 
minutes, 50 cycles of 95⁰C for 30 seconds and 58⁰C for 50 seconds, 72⁰C for 50 seconds, followed by 
incubation step of 98⁰C for 10 minutes and then a final storage incubation at 4⁰C. PCR products were 
visualised under UV light after staining with Midori Green in a 1.8% agarose gel.  
3.1.4. Gel Electrophoresis 
In experiments that needed DNA products to visualise, PCR products were run on a 1.8 % agarose 
gel. The gel was prepared using molecular biology grade agarose (MelFord), 1X Tris/Borate/EDTA (TBE) 
buffer (OmniPure) and stained with MedoriGreen (Nippon Genetics). Ten μL of PCR product and 4 μL 
of 60% Sucrose Creosol Red (SCR) DNA loading dye were loaded into each gel well. A 50 bp DNA ladder 
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Figure 3.1: Bisulfite Conversion of DNA 
DNA with methylated cytosine nucleotide was not affected by the sodium bisulfite treatment whereas the unmethylated 
cytosine nucleotides have been changed chemically into uracil. In the subsequent PCR, the converted uracil bases were 




(size range 50 - 1350 bp; BioLabs) was run alongside the samples at 120 mV for 75 minutes. DNA 
fragments were visualised on a UV transilluminator (183 nm) and photographed with the ChemiDoc 
MP System and ImageLab software (Bio-Rad, Version 5.2). When needed, the desired sized DNA 
fragment was excised from the gel using a clean scalpel. Purification was carried out using the 
MinElute Gel Extraction Kit (Qiagen) following the manufacturer’s instructions. The purified DNA 
fragments were then stored at -20°C until the time of processing.  
3.1.5. Vector Amplification 
PCR products of the PDX-1 promoter were cloned into DH5α competent bacterial cells using 
the pGEM-T Easy vector system I (Promega, detailed protocol in appendix A). A single colony was 
inoculated in 5 mL of Terrific broth containing 100 μg/mL Ampicillin (Sigma) shaking at 170 rpm 
overnight at 37°C. On the following day, the cells were pelleted at >8000 rpm for 3 minutes. The 
plasmids were then purified using the QIAprep Spin miniprep kit (Qiagen) in accordance with the 
manufacturer’s protocol. 50-100 ng/μL of purified plasmid was sent to the Eurofins Genetic Service 
(https://www.eurofins.co.uk/genomic-services/) for sequencing.  
3.1.6. Whole Genome Amplification 
Whole genome amplification of the PCR products was initially carried out using QIAGEN’s 
REPLI-g Mini Kit according to the manufacturer’s instructions. REPLI-g kit works on a principle is known 
as Multiple Displacement Amplification (MDA) method, where random primers (hexamers) bind to 
the template and generate fragments at a constant temperature with the help of a high-fidelity DNA 
polymerase enzyme, usually ‘Φ29 DNA polymerase’. The resulting fragments of DNA are larger than 
conventional PCR products and with lower error frequency (Dean et al. 2002).  
3.1.7. Bisulfite Sanger Sequencing 
Sanger sequencing was performed using Eurofins Genetic services (Eurofins Genomic, UK). The 
PCR, DNA fragment visualisation and DNA cloning were performed following the standard protocols 




H2O) along with 2 μL of 10 μM primer targeted at the desired region of sequencing were sent to 
Eurofins Genetic service for sequencing. All sequences were generated using BigDye terminator 
(version 3.1) of Applied Biosystems (Foster City CA, US) following standard protocols. For sequencing 
reactions, Primus 96 HPL Thermocyclers (MWG AG, Ebersberg, Germany) or DNA engine Tetrad 2 
cyclers (Bio-Rad, Munich, Germany) were used. Finally, all reactions were run on ABI3730xl capillary 








3.2.1. The Pancreatic Duodenal Homeobox-1 
We aimed to investigate whether islet-specific, differentially methylated CpG sites exist within 
the PDX-1 promoter that might be targeted in a cfDNA assay. To achieve this aim, it was first necessary 
to bisulfite sequence the promoter region of the gene for which the sequence had been previously 
defined (Yang et al. 2012). Consequently, bisulfite specific primers flanking the proximal (Chr13: 
28,494,048 - 28,494,141) (P1), distal (Chr13: 28,493,260 - 28,493,696) (P2) promoter and the enhancer 
(Chr13: 28,490,368 - 28,490,973) (E) regions were designed. Bisulfite-treated genomic DNA from 
PBMCs and islets was used as the DNA template for validating the primers. The PCR products were 
then visualised on a 1.8 % agarose gel with a 50 bp DNA marker for size verification. The result showed 
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Figure 3.2: Amplification of the PDX-1 promoter region 
The Figure is a representative of the PCR products from BS-DNA extracted from healthy PBMCs donors. Lane 1 represents 
the 50 bp ladder, lanes 2+3 show the PCR product of PDX-1 distal promoter, lane 5+6 represents the proximal promoter 




3.2.2. PDX-1 Promoter Region Sequencing in Islet and PBMC Genome 
The next goal was to identify specific CpG sites that are differentially methylated in islet 
compared with PBMC DNA. This was achieved following the approach used by two leading groups 
(Akirav et al. 2011; Kuroda et al. 2009). Briefly, extracted DNA was subjected to bisulfite conversion, 
which was used as a template for PCR amplification with bisulfite specific primers, designed to target 
the region of interest. The PCR amplicons are then used as a template for Sanger sequencing.   
This approach proved to be ineffective as the PCR products failed to produce readable signals. 
We noticed that extracting DNA from the desired band of the agarose gel results in severely decreasing 
the DNA concentration. Therefore, we assumed that could be causing the improper sequencing signal. 
Consequently we tried to troubleshoot the low DNA concentration of the PCR product post gel 
extraction by amplifying the gel extracted DNA with a whole genome amplification method. This 
approach also failed to produce good quality sequencing. An alternative strategy was amplifying the 
gel extracted DNA by cloning in pGEM-T vectors. Although this approach resulted in informative 

















































































































The Chromatogram illustrates that most CpG sites within the distal promoter of PDX-1 (-908: -472 bp upstream TSS) are 
hypermethylated. 
Figure 3.3: A representative example of a distal PDX-1 promoter sequencing chromatogram from one clone of bisulfite 
treated islet DNA. 
Figure 3.4: A representative example of a distal PDX-1 promoter chromatogram sequencing from one clone of 
pancreatic PBMC bisulfite treated DNA. 
The sequence chromatogram here shows that the majority of the CpG sites within the distal promoter of PDX-1 (-908: -




 The bisulphite sequencing results suggested that CpG -857 (Chr13:28,493,310) was 
predominantly hypomethylated in the PBMC genome while it was 66% hypermethylated in the islet 
genome. Acknowledging that islets consist 60-80% beta cells, the 34% hypomethylation could have 
originated from the non-beta cell genome (e.g. alpha and delta cells). Furthermore, a comprehensive 
look at the results suggested that there is a similar trend in the methylation status of the neighbouring 
CpG sites. When CpG -857 is hypomethylated, the neighbouring CpG sites -852, -822, -799, -777, -764, 
-746 and -741 upstream TSS, were also hypomethylated and vice versa, suggesting that these CpG 
sites are acting in clusters and are mostly hypomethylated or hypermethylated in tandem (Table 3.1 
and Table 3.2). To test this hypothesis, the beta cell DNA sample was used as the template for 
amplifying the PDX-1 distal promoter. The PCR products were cloned and bisulfite sequenced as 
described previously. The beta cell DNA was obtained in small quantities from a historical experiment 
where freshly obtained islets were FACS sorted following collagenase treatment and Newport Green 
staining. Twenty-one independent beta cell clones showed that CpG sites -857, -852, -822, -799, -777, 
-764, -746 and -741 are predominately hypermethylated, together, in the beta cell genome (Table 
3.3), confirming our assumption that the 34% hypomethylation signal of CpG-857 observed in the islet 
sequencing results came from other cells of non-beta cell origin. Collectively the data suggested that 
CpG -857 is differentially hypermethylated in islet and beta cell genomes when compared to the PBMC 




Table 3.1: The methylation status of the distal PDX-1 promoter in PBMC genome. 
The rows represent the methylation status in each clone. The columns represent the methylation status of each CpG 
dinucleotide in each clone. Genomic DNA samples obtained from human PBMC were analysed for methylation of the PDX-1 
distal promoter (-908 to -472 bp upstream TSS), which contains 14 CpG sites. Note that 0 of 26 (0%) of PBMC clones exhibited 
CpG hypomethylation.           ● Indicates hypermethylated C base,     ○ indicates hypomethylated C base. 
CpG -857 -852 -842 -822 -799 -779 -777 -764 -746 -741 -633 -582 -567 -552 
Clone 1 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 2 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 3 ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ UKN 
Clone 4 ○ ○ ○ ○ ● ● ● ○ ○ ○ ● ○ ○ ○ 
Clone 5 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 6 ○ ○ ● ○ ● ● ○ ○ ● ● ○ ○ ○ ○ 
Clone 7 ○ ○ ○ ● ● ○ ○ ● ● ○ ○ ○ ○ ○ 
Clone 8 ○ ○ ○ ○ ○ ○ ● ○ ○ ○ UKN UKN UKN UKN 
Clone 9 ○ ● ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ 
Clone 10 ○ ○ ○ ○ ○ ● ● ○ ○ ○ ● ○ ○ ○ 
Clone 11 ○ ○ ○ ○ ● UKN ● ● ○ ○ ○ ○ ○ ○ 
Clone 12 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 13 ○ ○ ○ ○ ● ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 14 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 15 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN 
Clone 16 ○ ○ ○ ○ ● ● ● ○ ○ ○ ○ ○ ○ ○ 
Clone 17 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 18 ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ ○ 
Clone 19 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 20 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 21 ○ ○ ○ ○ ○ UKN ○ UKN ○ ○ UKN UKN UKN UKN 
Clone 22 ○ ○ ○ ○ ○ ○ ○ UKN ○ ○ UKN UKN UKN UKN 
Clone 23 ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ○ 
Clone 24 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ● ○ ● 
Clone 25 ○ ○ ○ ○ UKN ○ ○ UKN UKN UKN ○ ○ ○ ○ 
Clone 26 ○ ○ ○ ○ ○ ○ UKN UKN ○ ○ UKN UKN UKN UKN 






Table 3.2: The methylation status of the distal PDX-1 promoter in the islet genome. 
CpG -857 -852 -842 -822 -799 -779 -777 -764 -746 -741 -633 -582 -567 -552 
Clone 1 ● ○ ● ● ● ● ● ● ○ ● ● ● ● ● 
Clone 2 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Clone 3 ● ● ● ● ● ● ● ● ○ ● ● ○ ● ● 
Clone 4 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● 
Clone 5 ● ● ● ● ● ● ● ○ ○ ○ ● ○ ○ ● 
Clone 6 ● ● ○ ○ ○ ○ ● ● ● ● ● ○ ○ ● 
Clone 7 UKN ● ○ ○ ○ ○ ● ○ ○ ○ UKN UKN UKN UKN 
Clone 8 ○ ○ ○ ○ ○ ● ● ○ UKN UKN UKN UKN UKN UKN 
Clone 9 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 10 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 11 ● ● ● ● ● ● ● ● ● ● ○ ● ● ● 
Clone 12 ● ● ● ○ ● ● ● ● ○ ○ ○ ○ ○ ○ 
Clone 13 ○ ○ ● ○ ● ● ● ● ● ● ● ● ● ● 
Clone 14 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 15 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Clone 16 ● ● ● ○ ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 17 ● ● ● ● ● ● ● ● ● ● ● ● ○ ● 
Clone 18 ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ● ● ○ 
Clone 19 ● ● ● ○ ● ● ● ○ ● ● ● ○ ● ● 
Clone 20 ● ● ● ● ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 21 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Clone 22 ● ○ ● ● ● ● ● ● ○ ● ● ● ● ● 
Clone 23 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 24 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 25 ● ● ● ○ ● ● ● ● ● ○ ● ● ● ● 
Clone 26 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ UKN UKN UKN UKN 
Clone 27 ● ● ● ● ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 28 ● ● ● ● ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 29 ● ● ● ● ● ● ● ● ○ ● ● ● ● ● 
Clone 30 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
methylation 66% 60% 63% 50% 67% 53% 60% 60% 48% 59% 64% 56% 77% 91% 
The rows represent the methylation status in each clone. The columns represent the methylation status of each CpG 
dinucleotide in each clone. Genomic DNA samples obtained from human islet were analysed for methylation of the PDX-
1 distal promoter (-908 to -472 bp upstream TSS bp), which contains 14 CpG sites. Note that 10 of 29 clones (34%) of the 
clones in the islet exhibited CpG hypomethylation, which is consistent with the percentage of non-beta cell content (60-
80% beta cell, 40-20% non-beta cell). The orange boxes highlighted the trend in the methylation status of the 





Table 3.3: The methylation status of the distal PDX-1 promoter in the beta cell genome. 
CpG -857 -852 -842 -822 -799 -779 -777 -764 -746 -741 -633 -582 -567 -552 
Clone 1 ● ○ ● ● ● ● ● ● ○ ● ● ● ● ● 
Clone 2 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Clone 3 ● ● ● ● ● ● ● ● ○ ● ● ○ ● ● 
Clone 4 ● ● ● ● ● ● ● ○ ○ ○ ● ○ ○ ● 
Clone 5 ● ● ○ ○ ○ ○ ● ● ● ● ● ○ ○ ● 
Clone 6 UKN ● ○ ○ ○ ○ ● ○ ○ ○ UKN UKN UKN UKN 
Clone 7 ● ● ● ● ● ● ● ● ● ● ○ ● ● ● 
Clone 8 ● ● ● ○ ● ● ● ● ○ ○ ○ ○ ○ ○ 
Clone 9 ○ ○ ● ○ ● ● ● ● ● ● ● ● ● ● 
Clone 10 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Clone 11 ● ● ● ○ ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 12 ● ● ● ● ● ● ● ● ● ● ● ● ○ ● 
Clone 13 ● ● ● ○ ● ● ● ○ ● ● ● ○ ● ● 
Clone 14 ● ● ● ● ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 15 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Clone 16 ● ○ ● ● ● ● ● ● ○ ● ● ● ● ● 
Clone 17 ● ● ● ○ ● ● ● ● ● ○ ● ● ● ● 
Clone 18 ● ● ● ● ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 19 ● ● ● ● ● ○ ○ ● ● ● ○ ○ ● ● 
Clone 20 ● ● ● ● ● ● ● ● ○ ● ● ● ● ● 
Clone 21 ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
Methylation 95% 86% 91% 67% 91% 72% 81% 86% 67% 81% 70% 55% 80% 95% 
 
  
The rows represent the methylation status in each clone. The columns represent the methylation status of each CpG 
dinucleotide of each clone. Genomic DNA samples obtained from human, FACS sorted, beta cells were analysed for 
methylation of the PDX-1 distal promoter (-908 to -472 bp upstream TSS), which contains 14 CpG sites. Note that 19 of 
20 clones (95%) of the clones in the islet exhibited CpG hypermethylation. 











3.2.3. Developing a PDX-1 Beta cell-Specific Biomarker  
The direct bisulfite sequencing results from PBMC, islet and beta cell genomes indicated that 
CpG-857, relative to the TSS, could be a potential differentially methylated biomarker candidate. 
Although CpG -878 and CpG -868 were shown to be potential targets, we needed to have two 
neighbouring CpG sites that have the similar hypermethylation levels in order to design a stable probe 
(Technical requirement for probe design). As CpG -857 and CpG -852 were within 5 bp of one another, 
we decided to choose these sites for targeted probe design. Our next goal was to develop a probe-
based assay that amplifies either hypomethylated CpG -857/CpG-852 or hypermethylated CpG -857/ 
CpG-852 amplicons (as described in General Methods, Chapter2, section 2.5). To fulfill this goal, two 
differentially methylated dual labelled probes were designed, one of which detected hypermethylated 
CpG -857 and CpG -852 (labelled with VIC dye) and the other detects the hypomethylated DNA 
fragments at the same CpG sites (labelled with FAM dye) (The sequence of the primers and probe are 
listed in Appendix A, Table A.1). The methylation status of these CpG sites was further examined in a 
panel of locally available tissues: Liver, Kidney, Lung, Heart, Spleen, PBMC, pancreatic islet and human 
beta cell line (EndoC-βH1) (Figure 3.6 and Figure 3.7). The results indicated that contrary to the data 
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Figure 3.5: The CpG methylation pattern of the distal PDX-1 promoter. 
The column represents the hypermethylation percentage of each CpG site within the distal promoter. The result shows 






generated earlier in this study, hypermethylated CpG -857 and CpG -852 are not specific to the beta 
cell genome. The results show that the CpG -857 is 50% hypermethylated in both liver and islet 
genome. Counterintuitively, the data also showed that CpG -857 and CpG -852 are hypomethylated in 
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Figure 3.6: The methylation status of CpG -857 of PDX-1 gene (from TSS) in DNA from an “in house” tissue panel. 
 
 
DNA samples were extracted by QIAamp DNA tissue kit and subjected to bisulfite conversion. Next 5 ng of each DNA 
sample was analysed by droplet digital PCR utilizing beta-actin and differentially methylated PDX-1 probe assays. The 
DNA copies in each sample was normalised to 100 copies of beta-actin. The columns represent the DNA copy number per   
μL in the PCR reaction mix after amplifying 5 ng DNA sample. The result shows that islet and beta cell line genome are 
not completely hypermethylated in the tested CpG sites. It shows that CpG -857 and CpG -852 are almost 50% 



























Hypermethylated CpG -857 /-852 
 










































Hypermethylated CpG -857 /-852 
 




















Hypermethylated CpG -857 /-852 
Figure 3.7: 2-D amplification plots from droplet digital data generated for tissue analysis of differentially methylated PDX-1 assay. 
The FAM channel represents the hypomethylated DNA copies of CpG -852/-857 (blue cluster) while the VIC channel (green cluster) represents the hypermethylated DNA copies of CpG -852/-




3.2.4. Defining the Threshold for Droplet Digital PCR Experiments 
During this project, ddPCR data analysis was viewed as the 1-D plot in single plex probe/EvaGreen 
experiments or 2-D plot in duplex and multiplex probe experiments. In 1-D plots (Figure 3.8 A &B), 
droplets were plotted in a graph of fluorescent intensity vs droplet number. All positive droplets, those 
above the pink threshold line are considered as “positive”, and each is assigned a value of 1. All 
negative droplets, those below the threshold line are scored as negative with score value of 0. ddPCR 
data from duplex (two targets amplified in the same reaction) and triplex (three targets amplified in 
the same reaction) assays were viewed in a 2-D plot where channel 1 fluorescence (FAM) is plotted 
against channel 2 fluorescence (VIC/HEX) for each sample. The threshold in these experiments was 
adjusted manually across an entire plate in comparison to their parallel cluster position in positive 


















Negative Droplets  


















Positive Droplets  
Negative 
Droplets  
Figure 3.8: Defining the threshold in 1-plex an EVAGreen ddPCR experiment run on the same plate. 
The blue dots represent the positive amplified droplets; the grey dots represent the negative droplets. A) 1-D plot of a 






Double Positive Cluster 



























VIC Amplified Cluster 
Double Positive Cluster 
B 
Figure 3.9: Defining the threshold in 1-plex an EVAGreen ddPCR experiment analysed on the same plate. 
 
The plots represent an experiment of amplifying a multiplex assay of the duplex probes. The Blue cluster represents FAM amplified probe, the green cluster represents the VIC amplified 
probe and the orange cluster represents the double positive (FAM + VIC) amplified probes. The grey cluster represents the negative empty droplets. A) 2-D plot of a duplex-probe assay 




Figure 3.10: 2-D Plot of droplets of Fluorescence amplified multiplex assay. 
 
The plots represent an experiment of amplifying a multiplex assay of the triple probes. The Blue cluster represents FAM amplified probe 1, the green cluster represents the VIC amplified 
probe 2, the orange cluster represents the amplified (70 %FAM + 30 %VIC) of probe 3 and the grey cluster represent the negative empty droplets. A) 2-D plot of a triplex-probe assay 
























The INS gene was the first target for developing DMR based biomarkers for monitoring beta 
cell death. It was a logical choice because INS is expressed exclusively in beta cells and it has an 
essential role in beta cell function. The first year of this PhD was, therefore, dedicated to identifying 
DMR with other genes that are known to be vital for the specific function of beta cells such as the 
genes for PDX-1, NeuroD1 and MafA. To achieve this aim, we followed the approach used by two 
leading groups in the field (Akirav et al. 2011, Husseiny et al. 2014, Husseiny et al. 2012). In summary, 
they isolated genomic DNA from islet cells and other control tissues, e.g. kidney, liver, PBMC, and the 
DNA was bisulfite treated and sequenced by the Sanger method for verification and identification of 
methylation differences at specific CpG sites. Based on the results obtained, the bisulfite specific 
primer set and methylation specific primers were designed for a nested PCR approach. We chose to 
replace the nested PCR method with a probe-based ddPCR technique because of the enhanced 
sensitivity of this approach. Generally, healthy individuals have a low level of circulating cfDNA due to 
the efficient cfDNA clearance from the circulation by phagocytes (Fleischhacker and Schmidt 2007). 
Usually, cfDNA is eliminated from the periphery by phagocytosis, kidney and liver and has a half-life 
of 10 - 15 minutes (Khier and Lohan 2018, Rumore et al. 1992, Schwarzenbach et al. 2011). Conversely, 
due to rapid destruction, the level of cfDNA is dramatically increased in the case of diseases such as 
cancer and developing autoimmunity (Jiang and Lo 2016). Nevertheless, the methylation level in other 
tissues was studied to eliminate possible false positive results that could be generated due to cell 
turnover.  
Our initial investigations focused on PDX-1, Although Yang et al. have previously described the 
DNA methylation of PDX-1 promoters and enhancer, he did not compare it to other non-islet tissues. 
Their research aimed to compare the PDX-1 methylation pattern of type 2 diabetic population to 
normal controls (Yang et al. 2012a). They showed that in islets, the methylation of CpG islets within 




822, -799, -777, -764, -746 and -741, relative to TSS. We were able to confirm their published results 
in our healthy population. Here we were aiming to compare the methylation profile of PDX-1 in 
pancreatic islets to other tissues such as PBMC, spleen, liver and kidney tissue in healthy individuals. 
Among the predominantly hypermethylated CpG sites, we chose to design a differentially methylated 
assay based on CpG-857 and CpG -852 as a stable probe design for ddPCR requires including more 
than one SNP (based on initial optimising experiments). The data showed that hypermethylated CpG 
-852/-857 was not specific for the islet and beta cell genome as it has a similar methylation level in 
liver.  
PDX-1 expression is also essential for the development of the proximal duodenum and 
maintenance of the duodenal enterocytes and entero-endocrine cells, gastro-duodenal junction and 
Brunner's glands (Chen et al. 2009, Holland et al. 2013). Therefore, it was necessary to study the 
methylation of targeted CpG sites in the duodenum genome and compare it to the methylation level 
in islets. Unfortunately, the available in-house human tissues do not include the duodenum, but as 
the CpG -857 was shown not to be unique for the islet genome, further study of CpG -857 methylation 
levels in the duodenum genome was not further investigated.  
Overall, we concluded that while using the Sanger bisulfite sequencing method to identify 
novel differentially methylated CpG sites can work, it has proven to be very laborious and time-
consuming for a time-limited project, and a weakness of the approach is that the best potential 
biomarkers to measure beta cell death may be missed. It was therefore decided to adopt a hypothesis-
free, genome-wide methylation sequencing approach: the Illumina Infinium® Methylation EPIC 
BeadChip to identify novel DMR to compare methylation profiles in islets with PBMC and to develop 
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Bisulfite genomic sequencing of multiple clones of genes is considered to be the gold standard 
method to study the CpG methylation status of the underlying DNA sequence. Nevertheless, this 
strategy proved to be impractical for obtaining results for whole-genome bisulfite sequences as it 
requires huge efforts in time, labour, and budget. DNA methylation microarrays are an alternative 
strategy for studying genome-wide methylation of DNA and now are widely adopted in many genome-
wide association studies. The Illumina Infinium Human Methylation EPIC BeadChip array (EPIC) 
involves hybridisation of bisulfite converted DNA into BeadChip array. The array generates a 
methylation profile of 853,307 CpG sites distributed among the 22 autosomes as well as the two sex 
chromosomes (X & Y chromosomes) per sample at single-nucleotide resolution (Moran et al. 2016, 
Pidsley et al. 2016). The beadchip can analyse up to 8 samples per array and only requires 250 ng of 
bisulfite-converted DNA per sample.  
In this chapter, the Illumina Infinium Human Methylation EPIC BeadChip was used to identify loci 
that are uniquely hypo-/hyper-methylated in the pancreatic islet. As the differentially methylated 
biomarker would ultimately be used in peripheral samples, and as the main source of genomic 
contamination in the peripheral samples is the DNA from PBMC, PBMC DNA samples were also 
included in the EPIC array. Genes that have differentially methylated CpG regions and reached 
genome-wide significance (p < 10E-10) were considered to be potential targets for differentially 
methylated biomarker design. Among these target CpG sites, we decided to focus on those which lay 
within beta cell-specific genes only. Then the methylation level of the chosen CpG targets will be 
compared in a variety of other tissues (data conducted from public data; ENCODE annotation data) in 
order to rule out contamination of serum with genomic DNA resulting from normal cell turnover. 
Finally, the results will be confirmed by testing the methylation level of the target CpG site in a locally 
available tissue panel. Based on these results, methylation sensitive dual-probe assays were designed 




Furthermore, an interesting differentially methylated locus identified by EPIC array; the mutual 
promoter of the adjacent genes MIR-200c/MIR-141, was further studied using a high throughput 
methylation sequencing technique: The targeted Next-Generation Bisulfite Sequencing (tNGBS). The 
tNGBS sequencing allows the study of specific regions or genes of interest with higher quality data 
because of the significantly higher coverage of each single CpG site within the region of interest. This 
high throughput technique allows measurement of the methylation level percentage of several 
target regions and multiple samples in a single run. Here, the tNGBS was performed to assess the 
methylation pattern of all CpG dinucleotides in the promoter region of MIR-200c/MIR-141 in the 
beta cell line genome (EndoC-βH1) as the whole genome methylation sequencing, EPIC array was 
performed on an islet genome. Further, we intended to examine the effect of high glucose exposure 






4.1.1. The Illumina Infinium Human Methylation EPIC 850K BeadChip Array 
The Illumina Infinium EPIC array is a methylation sequencing platform that uses bead 
technology to perform high-resolution multiplexed methylation sequencing for > 850,000 CpGs in 
enhancer regions, gene bodies, promoters, and CpG islands. The protocol involves bisulfite conversion 
and whole genome amplification of genomic DNA, followed by hybridisation of the converted DNA to 
arrays containing predesigned probes that discriminate hypermethylated from hypomethylated 
cytosine nucleotides. The bead-chip comprised two bead types, Infinium type I and type II (Figure 4.1), 
each has a 50 bp specific probe that is complementary to specific human bisulphite converted DNA 
with a CpG site at the 3′ end of the probe. Once hybridised to the specific region, single base extension 
occurs assembling a sequence of fluorescent-labelled ddNTPs at the 3′ end of the CpG site. The 
majority of the probes are designed to target CpG sites within the gene body (35.9%), 32.3% of the 
probes are directed to CpG sites located in the promoter area (9.4% of the probes are within the 
proximal promoter10, 13.9% are within the distal promoter11 of these genes; Figure 4.2A). Genomically, 
the targeted sites include 9.5% on chromosome 1, the rest of the probes are shown to be distributed 
almost equally amongst the autosomal chromosomes (Figure 4.2B) (Moran et al. 2016; Pidsley et al. 
2016). The fluorescent signal (beta value “β”) is calculated as the ratio of hypermethylated (C) to hypo-
methylated (T) signal using the following equation:  
𝛽 =
The  Intensity of the Hypermethylated Signal
The Intensity of Hypomethylated Signal  +  The Intensity of Hypermethylated Signal  +  100
 
The completely hypermethylated site is defined as β = 1, whereas the fully hypomethylated sites are 
defined as β = 0. 
 
                                                          
10 Proximal Promoter: DNA region located 200 bp upstream of TSS 









A) The Illumina Infinium Type I probe has two separate probe versions per CpG site, a probe for a hypermethylated sequence 
and another for hypomethylated CpG sites. B) The Illumina Infinium Type II probe has only one probe sequence specific for a CpG 
site. Each probe type has an advantage over the other. Compared to type II probes, Type I probes use the double physical space 
on the Bead Chip but its design (with two sequence versions) is more efficient in sequencing the high density CpG regions.  
Embedded from: Illumina.com (https://www.illumina.com/content/dam/illumina-
marketing/documents/products/datasheets/humanmethylationepic-data-sheet-1070-2015-008.pdf) 







A) The distribution of EPIC array probes in gene regions. B) The genomic distribution of the probes location across the 
chromosomes. The data is based on the information introduced in (Pidsley et al. 2016) 
A 
B 




4.1.1.1. Sample Processing for the EPIC Array 
DNA extraction of the samples used in the array was carried out in-house (University of 
Bristol). The purity of the DNA was confirmed by measuring the sample’s absorbance spectrum using 
the NanoPhotometer® (IMPLEN, P330) and calculating the A260/A280 ratio which was in the range of 1.8 
and 2.0. The sample concentration was quantified using the QuantiFluor® dsDNA System. Then 500 
ng of genomic DNA (20 ng/ 45 μL H2O) was submitted to AROS Applied Biotechnology A/S (Aarhus N, 
Denmark) where the sample was bisulfite converted and whole genome methylation sequenced.  
Bisulfite conversion of genomic DNA carried out using the EZ DNA Methylation Kit (Zymo 
Research). The PCR conditions for bisulfite conversion were as follow (95⁰C for 30 sec., 50⁰C for 60 
minutes) for 16 cycles, then "hold" at 4⁰C. Immediately following elution, all samples were processed 
through the EPIC array protocol (Figure 4.3). Briefly, 7 μL of converted DNA was denatured with 1 μL 
of 0.1N sodium hydroxide before whole genome amplification was performed on the MSA4 plate. All 
other steps were carried out as recommended by the manufacturer’s protocol. Array bead chips were 
scanned on Illumina iScan or HiScan system (Qiagen). 
4.1.1.2. EPIC Array Data Normalisation and Statistics 
The resulting raw data (IDATs) were represented as a beta value, as mentioned earlier, of 
fluorescence intensity ratio for each CpG site between 0 (unmethylated) and 1 (fully methylated). 
IDATs were further analysed by Dr Matthew Suderman (Lecturer in Genetic Epidemiology, School of 
Social and Community Medicine, University of Bristol). Data were normalised, and background 
corrected using the functional normalisation (Fortin et al. 2014). The DMRs were identified using the 
meffil R package (Ritchie et al. 2015).  
4.1.1.3. Bioinformatics Analysis of Microarray Data and Data Visualising (Heat map) 
The data visualisation was done in collaboration with Dr Jody Ye (the University of Bristol, 
Bristol/Albert Einstein College of Medicine, New York). The methylome signature of liver, aorta and 




statistical programme (http://www.r-project.org) associated with packages including ggplot2 
(Wickham 2009), and reshape2 (Wickham 2007) were used to compare the methylation level of islet 
and PBMC methylome (EPIC data) to liver, aorta, spleen and pancreas. Using R, scripts of tissues 
methylome were saved in comma-separated values format (.csv). After installing and loading the 
appropriate R package, .csv files were loaded and read into R. The scripts were then applied to the 







 Pre Amplification Stage  
Make the bisulfite-converted 
DNA (BCD) Plate. 
500 ng of gDNA was converted 
via EZ DNA Methylation Kit. 
After the treatment, 
unmethylated cytosines 
convert to uracil, though 




 Pre Amplification Stage  
Make MSA4 Plate: 
1. Denature the BCD samples 
with 0.1N NaOH 
2. Whole Genome amplification; 
the denatured Samples are 
incubated with random primer 
mix overnight to increase the 
amount of the DNA sample by 
several thousand folds 
 
Day 3 
 Post Amplification Stage  
Fragment the WGA samples: 
This process enzymatically 
fragments the amplified DNA 
samples. An endpoint 
fragmentation is used to 
prevent over fragmentation. 
 
Precipitate The DNA: 
The DNA samples are 
precipitated by adding 
precipitation solution and 
isopropanol in the MSA4 
plate.  
 
Day 3 (Continue) 
 
Re-suspend DNA: 
The precipitated DNA is re-
suspended in Hybridization 
Buffer. 
 
Hybridize to BeadChip: 
In this step the fragmented 
DNA is dispensed into the 
BeadChips   
Incubate the BeadChips in the 
Illumina Hybridization Oven 
overnight to hybridize the 
samples onto the BeadChips. 
 
Day 4 
 Post Amplification Stage  
Wash BeadChip: 
In this step, Unhybridized and 
nonspecifically hybridized DNA 
is washed away and the 
BeadChip is prepared for 
staining and extension. 
 
Extend and Stain (XStain) 
BeadChip: 
Single-base extension of the oligos 
occur on the BeadChip, and, 




The Illumina HiScan or iScan 
System scans the BeadChip. 
The following figure graphically represents the Infinium HD Methylation Assay protocol as recommended by the manufacturer. The figures were adopted 
from the Infinium Methylation Assay manual (https://support.illumina.com/content/dam/illumina-support/documents/documentation/ 
chemistry_documentation/infinium_assays/infinium_hd_methylation/infinium-hd-methylation-guide-15019519-01.pdf)  
 




4.1.2. Targeted Next-Generation Bisulfite Sequencing (tNGBS): 
 Human MIR-200c and MIR-141 genes share a promoter with an Ensembl regulatory built ID: 
ENSR00000048377 (Chr12: 6,963,000-6,964,001) (Figure 4.4). Seven bisulfite sequencing assays were 





4.1.2.1. DNA Isolation and Bisulfite Conversion for tNGBS: 
Genomic DNA was isolated in-house from tissue and cell lines (described in General methods, 
Chapter 2, Section 2.1.2) using the QiaAmp Blood and Tissue Kit (Qiagen). Next, 500 ng DNA samples 
(40 ng/μL) were shipped to EpigenDX (Hopkinton, Massachusetts, USA) where samples were sodium 
bisulfite treated using the EZ DNA Methylation Kit (Zymo Research). Nucleotide sequences for the 
human MIR-141 gene (Gene ID: 406933) were obtained from GenBank. tNGBS was used to assess the 
methylome at the targeted DNA region extracted from multiple cells/ tissues. 
4.1.2.2. Multiplex PCR Optimisation for tNGBS 
All assays were initially divided into multiple groups based on the amplicon size, primer Tm, 
GC content, and ΔG values, while also avoiding overlapping primer pairs. A Gradient PCR was 
performed at two different magnesium concentrations (1.5 mM and 3.0 mM), followed by capillary 
electrophoresis (CE) of the PCR products using the QIAxcel Advanced System (Qiagen). Final multiplex 
PCR conditions were determined based on the optimal annealing temperature (Ta), magnesium 
concentration, and overall amplification efficiency. Based on the CE results, 8 PCR amplicons were 











4.1.2.3. tNGBS PCR Protocol 
For PCR amplification, the bisulfite-converted DNA was PCR amplified in a 20 μL reaction as 
following, 0.5 U of HotStar Taq Polymerase (Qiagen), 2 µL 10× PCR buffer (Contains 15 mM MgCl2), 
200 M dNTPs, 4 pmoL of each Primer pair and 1-5 µL of bisulfite treated DNA. The cycling condition 
for the reaction was 95⁰C for 15 minutes; 45 x (95⁰C 30s; proper annealing temperature 30 s; 68⁰C 
30s); 68⁰C for 5 minute and 4C forever. 
4.1.2.4. tNGBS Library Preparation and Sequencing 
 Libraries were prepared using the KAPA Library Preparation Kit for Ion Torrent platforms (Cat# 
KK8310) and Ion Xpress™ Barcode Adapters (Thermo Fisher, Table 4.1). Next, library molecules were 
purified using Agencourt AMPure XP beads (Beckman Coulter) and quantified using the Qiagen 
QIAxcel Advanced System. Barcoded samples were then pooled in an equimolar fashion before 
template preparation and enrichment were performed on the Ion Chef™ system (Thermo Fisher) using 
Ion 520™ & Ion 530™ Chef reagents. Following this, enriched, template-positive library molecules 
were then sequenced on the Ion S5™ sequencer using Ion 530™ sequencing chips (Thermo Fisher). 
Table 4.1: The DNA target region sequenced by the targeted bisulfite-sequencing assay. 
 
Assay ID Assay Location 
Location From 
TSS 
GRCh38/hg38 # of CpGs 
ADS5466 
5-Upstream of MIR-200c& 
MIR-141 
-595 to -586 chr12:6963104-6963113 2 
ADS5467 -524 to -359 chr12:6963175-6963340 12 
ADS5465 -280 to -135 chr12:6963419-6963564 14 
ADS5468 -97 chr12:6963602 5 
ADS995- FS1 
5-Upstream of MIR-200c & 
MIR-141 & MIR-2000C Exon 
-56 to +30 chr12:6963643-6963728 5 
ADS995BFS2 
MIR-200c Exon & 5'- 
Upstream of MIR-141 
+53 to +166 chr12:6963751-6963864 5 
ADS996 
5'-Upstream of MIR-141 & 
MIR-141 Exon 
+261 to +403 chr12:6963959-6964101 8 
ADS5469 
MIR-141 Exon & 
Downstream of MIR-
200c/MIR-141 
+483 to +580 chr12:6964181-6964278 3 






4.1.2.5. tNGBS Data Analysis 
FASTQ files from the Ion Torrent S5 server were aligned to the local reference database using 
open-source Bismark Bisulfite Read Mapper with the Bowtie2 alignment algorithm. Methylation levels 
were calculated in Bismark by dividing the number of methylated reads by the total number of reads. 
4.1.3. Universal Human Methylated DNA Standard Controls 
A predominately hypermethylated and hypomethylated human DNA set (Zymo Research) was 
used to generate a standard methylation curve that was used in assay optimisation experiments.  
4.1.4. Droplet Generating and PCR Cycle Condition 
Once samples and appropriate oil was loaded in the cartridge, the DG8 cartridges were covered 
by the Gaskets (Bio-Rad) and then placed in a QX200™ Droplet Generator (Bio-Rad). Next, the droplets 
were gently transferred into a semi-skirted and PCR clean 96-well PCR plate (Eppendorf) using an E4 
XLS Multichannel pipette with the range 5-50 μL (Rainin). The PCR plate was sealed with pierceable 
foil (Bio-Rad) using a PX1™ PCR Plate Sealer (Bio-Rad). Afterwards, the PCR amplification was 
performed by placing the plate in a C1000 Touch™ Thermal Cycler (Bio-Rad). For the probe-based 
droplet PCR, the standard PCR protocol was used in the single plex and duplex experiment (Figure 
4.5) and touch down PCR was used in the multiplex experiments (Figure 4.6). The Touchdown PCR is 
a modified PCR in which the initial annealing temperature is higher than the optimal temperature and 
is gradually decreased in the subsequent cycles until reaching the optimal temperature. Amplification 
is then continued using this annealing temperature (Don et al. 1991). The reaction plates were then 
held at 4°C until reading. Droplet reading and analysis were performed with the QX™ 200 Droplet 
reader (Bio-Rad) via ddPCR™ Droplet Reader Oil (Bio-Rad). The data analyses were performed using 
the software package QuantaSoft™ (Bio-Rad, V 1.6.6.0320). The threshold of fluorescence, which 
distinguishes the positive from the negative droplets, was set manually. The same threshold was 
applied to all the wells of one PCR plate. The average droplet number that was accepted for the valid 






Polymerase Activation/ Denaturing Step 95⁰C, 10 minutes 
Annealing-Extension Step 
Tm⁰C, 1 minute 
Denaturing Step 95⁰C, 30 S 
X40 
Enzyme Deactivation Step 98⁰C, 10 minutes 
Sample Storing, 4⁰C, ∞ 





Annealing-Extension Step 58⁰C, 30 S 
Denaturing Step 95⁰C, 30 S 
X2 
Annealing-Extension Step 56⁰C, 30 S 
Denaturing Step 95⁰C, 30 S 
X2 
Annealing-Extension Step 52.5⁰C, 30 S 
Denaturing Step 95⁰C, 30 S 
X49 
Enzyme Deactivation Step 98⁰C, 10 minutes 
Droplet Stabilizing Step 12⁰C, 10 minutes 
Sample Storing, 4⁰C, ∞ 
Polymerase Activation/ Denaturing Step 95⁰C, 10 minutes 




4.1.5. Methylation Data Alignment and Statistical Analysis 
In all candidate CpG sites, the methylation state of the candidate CpG sites in multiple tissues 
were aligned for comparison using the Integrated Genome Browser software (Nicol et al. 2009) 
(http://bioviz.org/). The number of copies per 1 μL of the target was analysed by the Quantasoft 
software (Bio-Rad, version 1.6.6.0320). The direct comparison between the levels of circulating 
hypomethylated beta cell-specific targets in test VS control group was achieved by Mann-Whitney 
testing for nonparametric data. For all statistical comparisons, a p value of < 0.05 was considered to 
be statistically significant. Statistical analyses were performed with GraphPad/Prism 6 (version 6.07).  
The relative methylation/unmethylation level in DNA extracted from tissues was determined by 




(in 5 ng DNA sample) =
gene DNA copies per 1 μL
𝐵𝑒𝑡𝑎 𝑎𝑐𝑡𝑖𝑛 𝐷𝑁𝐴 𝑐𝑜𝑝𝑖𝑒𝑠 𝑝𝑒𝑟 1 𝜇𝐿
∗ 100 ∗ 25 
The absolute level of beta cell-specific targets cfDNA in this thesis has been presented as the 
cfDNA copies in 1 mL of serum/plasma sample. The level of circulating hypomethylated DNA was 
calculated as follows: 
Number of copies in 1 mL sample = 
Copies
μL
in duplicate 1 +
Copies
μL
in duplicate 2 ∗  25 ∗ (
1000








4.2.1. The Illumina Infinium® Methylation EPIC BeadChip Analysis 
In order to gain a more comprehensive insight into the methylation pattern of the islet genome, 
the methylome profile of islet tissue samples from five brain-stem death adult donors was compared 
to the methylome of PBMC samples obtained from three healthy adult donors. The methylation 
signature of both tissues was profiled in the Illumina methylation EPIC array. The analysis was 
performed using meffil package in R software. Quality control and normalisation of the EPIC array 
were performed and resulted in the final probe set of 867,926 of a total 867,926 (100%). Genome-
wide comparison of methylation signature between islets (n=5) and PBMC (n=3) at the Bonferroni 
threshold of 5.9e-8 identified 8856 CpG sites that reached epigenome-wide significance (P<10E-10). 
The analysis was not based on gender or batch variability of the samples. Of DMR identified in the islet 
genome, 3866 CpGs were hypomethylated, and 4990 were hypermethylated (Figure 4.7A). Another 
comparison was made within islet-DMS, which showed that the majority of the identified DMS (37%) 
were located within the gene body, 15% were located at the proximal or distal promoters (Figure 
4.7B).  
The methylation profile of islet and PBMC genomes were further compared to the methylation 
signature data of liver, lung, thymus, spleen, pancreas as well as aorta that were identified from the 
Roadmap and ENCODE methylation signature studies (Figure 4.8). Aligning data in Heatmap showed 
that the overall methylome of islets and pancreas are opposite to those in PBMC, thymus and spleen. 
The data also showed that the methylome of liver, lung and aorta had a considerable level of 
homogeneity to the methylation level of the islet genome. Selecting for islet differentially methylated 
CpG sites versus other non-beta cell tissue methylomes had reduced the number of islet-specific 
hypomethylated CpG sites into 425 CpG targets (Appendix A, Table A.3) and islet-specific 















A) The quantification of hypomethylated vs hypermethylated CpG sites in the islet genome; B) and C) UCSC gene region feature 
categories (proximal promoter, distal promoter, 5´UTR, 1st Exon, Gene Body, 3´UTR) of the hypomethylated CpG sites (B) and 
the hypermethylated sites (C). 






Figure 4.8: Heatmap of the methylation status of islet and PBMC DNA related to methylomes of various tissues.  
 
Data on the methylation status of DNA from liver, lung, thymus, spleen, pancreas and aorta was provided by the roadmap 
study. Each cell represents the CpG level of methylation for one site in one sample. The methylation scale indicates the 
level of methylation: green= sample predominantly hypomethylated (0-49% methylated); orange = 50% of the sample is 
hypermethylated; red = sample predominantly hypermethylated (51-100%). As expected, the pancreas methylome was 
similar to the islets, whereas the methylome of PBMC, spleen and thymus was mostly the opposite of the islet’s 
methylome. Those data further illustrate that there is considerable methylome homology between the islet, aorta, liver 
and lung.  




4.2.2. Developing DMR based Beta Cell-Specific Biomarkers  
As mentioned previously, the analysis of the EPIC data resulted in identifying 3866 CpG sites 
that were differentially hypomethylated in islets when compared to the PBMC methylation signature. 
Among those, the CpG +49678, relative to TSS, in the gene nuclear receptor corepressor 2 (NCOR2), 
and the CpG +20459 in the gene solute carrier family 45 member 4 (SLC45A4) were in the top ten 
differentially hypomethylated sites. Therefore, these two sites were considered to candidate targets 
for designing DMR assays that could be specific for islet genome.  
Initially, we tried to compare the methylation level of these specific sites (CpG +49678 of 
NCOR2 and CpG +20459 of SLC45A4) to their methylation level in other tissues from published 
databases downloaded from Human Epigenome Atlas library 
(http://www.genboree.org/epigenomeatlas/multiGridViewerPublic.rhtml) and the genome browser 
of University of California Santa Cruz library (UCSC; 
http://smithlab.usc.edu/trackdata/methylation/hub.txt). Unfortunately, we found some conflicting 
data across different studies, most probably due to the use of different sequencing platforms and the 
adoption of different normalisation and analytic methods. Consequently, we were unable to compare 
the islet methylation level at these two sites, to other tissues. Instead, differentially methylated dual-
labelled probes were designed to confirm the methylation specificity on a locally available tissue panel 





4.2.2.1. Nuclear Receptor Corepressor 2 (NCOR2)  
NCOR2 (Chr12: 124,808,957-125,052,079) is a pancreatic beta cell-specific gene (Bramswig et al. 
2013). According to EPIC sequencing data, NCOR2 was shown to be specifically differentially 
methylated between PBMC and islets at several CpG sites. Among the significantly hypomethylated 
sites, CpG +49678 in exon 2 (Chr12: 125,002,332), relative to TSS, was shown to be predominantly 
hypomethylated in islet DNA (89% hypomethylated in islet and only 11% in PBMC genome). Bisulfite 
specific primers and a pair of methylation differentiating probes were designed. The assay was used 
to investigate the methylation status of CpG +49678 and CpG +49671 in various locally available tissue 
samples (primer and probe design is described General Methods, Chapter 2, section 2.5). The assay 
amplifies a 270 bp DNA fragment that flanks a hypermethylated (VIC) and a hypomethylated (FAM) 
CpG +49678 and CpG +49671 probes. The optimum annealing temperature was identified by 
incorporating a temperature gradient into thermal cycling conditions for the annealing-extension step 
of amplification. The PCR was performed on eight samples containing the same final concentrations 
(400 pg/μL) of a template of 50% methylated bisulfite converted human DNA standard, following the 
standard ddPCR assay conditions (Figure 4.9). The sensitivity of the assay was confirmed when a linear 
correlation between the DNA methylation concentration and the expected positive droplets was 
observed (Figure 4.10 E & F).  
Subsequently, the assay was run on a panel of 12 locally available tissue samples containing 
the same concentration of bisulfite converted DNA (5 ng/μL, Figure 4.11 and Figure 4.12). In parallel, 
the beta-actin assay was analysed as a normalising internal control. The results conducted from this 
tissue panel confirms both 1) the methylation differences between the islet and PBMC genome 
suggested by the EPIC array and 2) the non-specificity of the hypomethylated CpG + 49678 towards 












64⁰C 63.3⁰C 62.2⁰C 60.5⁰C 58.4⁰C 56.7⁰C 55.6⁰C 55⁰C 
A 
* 
A temperature gradient PCR was used to determine the optimal annealing temperature for the multiplexed assay. The tested 
annealing temperature per sample ranged from 55-64 degrees and was indicated in each ddPCR well in degrees Celsius (⁰C). 
An asterisk indicates the optimal ddPCR temperature. A) 1-D plot of 8 ddPCR amplification results of optimal annealing 
temperature for hypomethylated NCOR2 CpG +49678 assay. B) 1-D plot of 8 ddPCR amplification results of optimal annealing 
temperature for hypermethylated NCOR2 CpG +49678 assay. 
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Synthesised hyper- and hypo-methylated human genomic DNA control was used as DNA template in this experiment. Both DNA standards were subjected to bisulfite conversion. The bisulfite 
converted DNA controls were mixed according to the percentage indicated in B) and C) and then amplified and analysed using ddPCR. A-D) Amplitude 2-D analysis plot of the results. The FAM 
channel represents the hypomethylated DNA copies of CpG +49678 (blue cluster) while the VIC channel (green cluster) represents the hypermethylated DNA copies of CpG +49678. E) &F) Linear 
regression analysis - graph plotted as DNA copies values in 1 μL ddPCR reaction (x-axis) and input methylated DNA (y-axis), as a way of evaluating the assay sensitivity. The hypomethylated 
assay line has the equation Y = -0.8629*X + 80.00 with the R2 value of 0.9103 (p = 0.0459). The hypermethylated assay line has the equation Y = 0.4355*X + 0.2200 with the R2 value of 0.9639 






























Hypermethylated CpG +49678 
Hypomethylated 
CpG +49678 
The FAM channel represents the hypomethylated DNA copies of CpG +49678 (blue cluster) while the VIC channel (green cluster) represents the hypermethylated DNA copies of CpG +49678. The 
data here reflect graph 4.12 showing that CpG +49678 is predominately hypomethylated in many tissues, which confirms the difference in the islet genome.  
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Figure 4.12: The methylation level of CpG +49678 of NCOR2 exon 2.  
 This CpG site was chosen based on EPIC array data that showed that CpG +49678 is 89% hypomethylated in islets. The graph shows the number of hypomethylated and hypermethylated DNA 
copies of CpG +49678 of NCOR2 exon 2 in 5ng of DNA samples extracted from different locally available tissue. The total copy number of NCOR2 was normalized to 100 copies of beta-actin. The 
data confirm the conclusion of EPIC array data which suggested that there is a differential methylation between the PBMC and islet methylomes. The data of both graphs illustrate that 




4.2.2.2. Solute Carrier Family 45 Member 4 (SLC45A4) 
SLC45A4 (Chr8: 142,217,273-142,310,241) was another discriminating biomarker candidate. This 
gene is beta cell-specific based on published data (Bramswig et al. 2013). The CpG +20459 (Chr8: 
142,289,782) was shown to be predominantly hypomethylated in the islet genome (83% 
hypomethylated in islet and only 17% hypomethylated in the PBMC genome). Following the same 
steps to investigate specificity as for NCOR2, the methylation rate of this CpG site was studied in nine 
locally available tissue samples containing the same concentration of bisulfite converted DNA (5 
ng/μL, Figure 4.13).  In parallel, the beta-actin assay was run as a normalising internal control. The 
results from this tissue panel confirm the methylation differences between the islet and PBMC 
genome suggested by the EPIC array, and it further indicates the non-specificity of the 
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Figure 4.13: The methylation status of CpG +20459 from TSS of SLC45A4 gene in various tissues. 
 According to the EPIC array data, CpG +20459 is predominately hypomethylated in the islet genome. The columns in this 
graph represent the number of hypomethylated DNA copies of CpG +20459 of SLC45A4 in 5 ng of DNA samples in different 
locally available tissue DNA samples. The total copy number of SLC45A4 was normalized to 100 copies of beta-actin. The data 
confirm the conclusion of EPIC array data, which suggested that this CpG site is differentially hypomethylated in islets. Yet, 
the degree of methylation difference of this CpG in the other tested tissues was not high enough to be considered as specific 





4.2.2.3. microRNA-141 (MIR-141) 
The series of experiments validating the methylation specificity of NCOR2 (CpG +49678) and 
SLC45A4 (CpG +20459 ) had led us to conclude that the data obtained from both the RoadMap study 
(Kundaje et al. 2015) and ENDCODE methylation library (Consortium 2012) were in agreement with 
our methylation data results. Therefore, we downloaded the liver, thymus, spleen and aorta 
methylation sequencing data from the Roadmap study database and the pancreas methylome data 
from the ENCODE methylation database. We then compared the methylome of these tissues to the 
islets in order to further exclude CpG sites that are not uniquely hypomethylated in the islet. The 
comparison resulted in a reduction in the number of islet-specific hypomethylated CpG sites from 
3866 to only 425 (Appendix A, Table A.3). Among these sites, the CpG -20 of the gene MIR-141 (relative 
to the TSS) had been shown to be predominantly hypomethylated in the islet genome and therefore 
was considered to be a candidate site for developing a DMR islet-specific assay.    
MIR-141 (Chr12: 7,073,260-7,073,354) is a member of a gene family that was shown to induce 
apoptosis in a beta cell (Belgardt et al. 2015, Filios et al. 2014). The EPIC data suggested that CpG -20 
(Chr12: 7,073,239) of the MIR-141 gene promoter is predominantly hypomethylated in islets (72% 
hypomethylated in islet and 23% hypomethylated in the PBMC genome). Therefore, a methylation-
sensitive probe-based assay was designed to detect hypermethylated and hypomethylated MIR-141 
at CpG -20 and CpG -18, relative to TSS. The annealing temperature for the assay was optimised, as 
for the previous two biomarkers, by incorporating a temperature gradient into thermal cycling 
conditions for the annealing-extension step of amplification. The PCR reaction was performed for 
eight samples containing the same concentrations (400 pg) of the template of bisulfite converted 50% 
methylated human DNA standard following the ddPCR conditions (Figure 4.14). Next, the assay 
specificity was tested on ten locally available tissue samples containing the same concentration of 
bisulfite converted DNA (5 ng/μL, Figure 4.15 & 4.16). In parallel, the beta-actin assay was run as a 
normalising internal control. The data shows that CpG -20 is specifically hypomethylated in the islet 




that were taken from the public Roadmap and ENCODE methylation databases (as described in 
General Methods, Chapter 2, section 2.4 of).  The data were in agreement with the conclusion from 
the tissue panel experiment, confirming the specificity of CpG-20 hypomethylation to the pancreatic 
islets and suggesting that CpG -20 of MIR-141 is a potential valid biomarker candidate (Figure 4.17). 
During the experiments optimising the hypermethylated CpG -20 MIR-141 probe (FAM), we 
noticed that the amplification of the FAM probe resulted in the production of two distinct clusters in 
the ddPCR 2-D results. The reason why two droplet clusters were generated was further investigated, 
and consequently, a new set of probes that amplify either the hypermethylated CpG -18 or the 
hypermethylated CpG -20 were designed. The PCR reaction was performed for both probes containing 
the same concentrations of DNA template (50% hypermethylated bisulfite converted human DNA 
standard, 400 pg). The data showed that the predominant amplification was to CpG -20 (Figure 4.18). 
Nevertheless, due to technical issues with the amplification stability of the new probes, the first 
designed FAM probe (Hypermethylated at CpG -18 and CpG -20) was used in the subsequent 






The figure shows the droplet populations for duplex of fluorescence amplitude for each droplet. Blue (FAM) and green (VIC) dots represent the positive droplets, generated from amplifying 400 
pg of 50% methylated human DNA standard, for hypermethylated and hypomethylated CpG-18/-20 probes, respectively. The grey dots below the pink horizontal threshold represent the negative 
droplets. A temperature gradient PCR was used to determine the optimal annealing temperature for the multiplexed assay. The annealing temperature tested per sample ranged from 51.7-56 
degrees that was indicated in each ddPCR well in degrees Celsius (⁰C). An asterisk indicates optimal ddPCR temperature. A) 1-D plot of 8 ddPCR amplification results of optimal annealing 
temperature for the hypermethylated MIR-141 CpG -18 and CpG-20 assay. B) 1-D plot of 8 ddPCR amplification results of optimal annealing temperature for hypomethylated MIR-141 CpG -18 
and CpG-20 assay. The data indicate that the temperature of 52⁰C is the optimum temperature that sufficiently separates the positive signal from the negative in both assays. 
A B 
56⁰C 55.3⁰C 54.4⁰C 53.4⁰C 52.6⁰C 52⁰C 51.7⁰C 
55.8⁰C 56⁰C 55.3⁰C 54.4⁰C 53.4⁰C 52.6⁰C 52⁰C 51.7⁰C 55.8⁰C 
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Hypomethylated Probe (VIC) 
EndoC-βH1 
The FAM channel represents the hypermethylated DNA copies of CpG -18/-20 (blue cluster) while the VIC channel (green cluster) represents the hypomethylated DNA copies of CpG -18/-20. 
The data here reflect the graph 4.16 showing that CpG -20 is specifically and predominately hypomethylated in islets and beta cell line model. 
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Figure 4.16: The methylation status of CpG -20 (Chr12:7,073,239) and CpG -18 (Chr12:7,073,241) of MIR-141 gene. 
 These CpG sites were chosen based on EPIC array data, which showed that CpG -20 is 72% hypomethylated in islets. The level of methylation of the MIR-141 assay in a panel of different locally 
available tissues. The data presented here are the copy number of MIR-141 in 200 pg of each sample that was normalised to 100 copies of beta-actin. The data supports the conclusion from the 
EPIC array data, which suggested that this CpG site is differentially hypomethylated in islets and suggests that hypomethylated CpG -18 and CpG -20 of MIR-141 promoter is specific for islets as 






Figure 4.17: The methylation status of CpG -20 (Chr12:7,073,239) and CpG -18 (Chr12:7,073,241) of MIR-141 gene. 
These CpG sites were chosen based on EPIC array data, which showed that CpG -20 is 72% hypomethylated in islets. The data were aligned using the Integrated Genome Browser (IGB). The 
methylation rate of CpG -18 and CpG -20 of MIR-141 in different tissue methylomes obtained from the Roadmap methylation signature study. The data suggest that both CpG sites are highly 







CpG -18 (FAM) CpG -20 (FAM) 
The Blue (FAM) dots represent the positive droplets, generated by amplifying 400 pg of 50% methylated human DNA standard, while the grey dots below the pink horizontal threshold represent 
the negative droplets. 400 pg of bisulfite converted 50% methylated human DNA standard was used as the DNA template A) The hypermethylated FAM probe amplifies MIR-141 at CpG -18 
(from TSS). B) The hypermethylated FAM probe amplifies MIR-141 at CpG -20 (from TSS). The plots confirm that the dense cluster that was seen in the previous experiment represents 
hypermethylated CpG-20 amplification.   




4.2.3. Developing Triplex Assay to Detect Beta Cell Death 
In addition to the MIR-141 assay, another two single plex assays had been developed locally. 
They were the CpG +367/+374 INS exon 2 and CpG -1052 of MIR-200c (from TSS) assays which were 
developed and validated by Dr Jody Ye.  The gene for MIR-200c is adjacent to MIR-141, and both share 
the same promoter (Neves et al. 2010). The next experiments aimed to multiplex these assays with 
the hypomethylated MIR-141 probe to increase the sensitivity of the beta cell death assay.  
4.2.3.1. Optimising the Triplex Assay 
A touchdown PCR reaction (as described in section 4.1.4) was used in the amplification of multiplex 
assay in order to increase the specificity of the PCR. The temperature gradient ddPCR experiment had 
shown that 52.5⁰C was the optimum annealing temperature for the triplex assay.  Next, the sensitivity 
of the multiplexed assay toward the hypomethylated DNA fragments was evaluated. A serial 
concentration of hypomethylated synthesised DNA (0, 12.5, 25, 50, 75, 100 pg) was added to the 
reaction in the presence of a fixed concentration of hypermethylated synthesised DNA standard (100 
pg). The ddPCR analysis showed that the positive droplets number declined in parallel with the 
hypomethylated DNA concentration decreases and was not affected by the presence of the 
hypermethylated DNA (Figure 4.19). Additionally, the R2 value (R2 = 0.9972) shows a linear correlation 
between expected and measured percentage of the hypomethylation (Figure 4.19B). Subsequently, 
the specificity of the assay was tested by running the assay on the locally available tissue samples 
(n=11) containing the same concentration of bisulfite converted DNA (5 ng/μL, Figure 4.20 and Figure 
4.21). In Parallel, the beta-actin assay was run as a normalising internal control, and each sample was 
normalised against 100 DNA copies of beta-actin. The results conducted from the tissue panel 
experiment confirms the observation of previous experiments, which indicates that hypomethylated 
CpG -1052 of the MIR-200c promoter, CpG -20 of the MIR-141 promoter and CpG +367+374 of INS 
















Hypomethylation sample (pg/ul) 
A gradient of hypomethylated bisulfite converted DNA controls were mixed with a fixed concentration of hypermethylated bisulfite converted DNA control (100 pg) as indicated in figure A. A) 
The raw plot of gradient hypomethylated DNA yield (0, 12.5, 25, 50, 75, 100 pg) in the presence of fixed hypermethylated DNA yield (100 pg). The data are presented as the DNA concentration 
per 1 μL reaction. B) Linear regression analysis – the graph plotted as DNA copies values per 1 uL ddPCR reaction (x-axis) and the percentage of input methylated DNA (y-axis), as a way of 
evaluating the assay sensitivity. The triplex hypomethylated assay line has the equation Y = 1.297*X + 1.622with the R2 value of 0.9972 (p <0.0001). The plots show that there is a linear 
relationship between the expected and the measured percentage of hypomethylated DNA.    
 





































INS (70 FAM + 30 VIC) 
INS + MIR-200c 
MIR-141 + MIR-200c 
INS + MIR-141 
Amplification of 5 ng bisulfite converted islet’s DNA. The FAM channel represents the hypomethylated DNA copies of CpG -1052 (blue cluster) of MIR-200c, the VIC channel (green cluster) 
represents the hypomethylated DNA copies of CpG -20 of MIR-141 while the central orange cluster represents a mixed probe (70% FAM + 30% VIC) of the hypomethylated CpG +367+374 of INS 
exon 2.  
 






 Figure 4.21: The level of hypomethylated DNA copies of the triplex assay in different tissues available “in house”. 
The columns represent the normalised DNA copy number of hypomethylated CpG -20 MIR-141, CpG -1052 of MIR-200c and CpG +367+374 of INS gene in 1 μL of DNA sample. The data 
presented here are the copy number of MIR-141 in 200 pg of each sample normalised to 100 copies of beta-actin. The data support previous conclusions confirming the specificity of the 




4.2.4. The Effect of Adding EcoRI to Minimise Droplet Rain 
Although positive and negative droplets are clustered separately from the negative (empty) 
droplets, some droplets fall between the negative and positive clusters and are usually referred to as 
droplet rain. Droplet rain is problematic sometimes because it makes drawing the threshold line 
challenging. The possible sources of such intermediate droplets vary. It could be due to damaged and 
irregular droplet size, coagulation of multiple droplets, partial PCR inhibition, non-specific or 
suboptimal amplification or suboptimal PCR amplification due to sequence variances (Witte et al. 
2016). Adding restriction enzymes was recommended by Bio-Rad to minimise intermediate droplet 
rain as, according to their ddPCR guidance book: “restriction digestion separates tandem gene copies, 
ensuring proper random partitioning into droplets, restriction digestion also reduces sample viscosity 
and improves assay performance by improving template accessibility”. Therefore, one unit of EcoRI 
(0.5 μL of 50X) was added to the multiplex ddPCR reaction (25 μL) and compared to a reaction without 
EcoRI. Adding a restriction enzyme was shown to have a “cluster condensing” effect but did not 

















A fixed concentration of bisulfite converted 0% methylation DNA template was added to the reaction (350 ng). The reactions 
were amplified following a touchdown PCR protocol. A)  2-D plot of ddPCR reaction without EcoRI. B) 2-D plot of ddPCR 
reaction with 1x EcoRI. Adding the restriction enzyme resulted in narrowing the margin between MIR-200c and INS cluster, 
but no other effect e.g. minimizing the droplet rain was observed.  




4.2.5. Targeted Next-Generation Sequencing 
4.2.5.1. The level of Methylation Differences Between the Pancreatic Islet and EndoC-βH1 Cell 
Line 
As our EPIC analysis was based on the methylation level of the entire islet genome, we were 
concerned that there might be important differences between the beta cell and islet methylomes 
(which is composed of 60-80% beta cells). Another reason for our query was raised in a the talk given 
by one of the leading researchers in the field, Dr Kevan Herold, Immunology of Diabetes Society 
Congress 2017 in San Francisco, indicating that based on their data, the methylome differences 
between islets and the beta cell is 5-10%. Therefore, we aimed to investigate the methylation 
differences in DNA between a pancreatic islet and a pure beta cell methylome at the mutual promoter 
of MIR-200c/MIR-141. To attain this goal, DNA was extracted from normal pancreatic islets as well as 
from the EndoC-βH1 cell line (described in sections in General Materials, Chapter 2, section 2.1 and 
2.2.1). The DNA samples were then sent to EpigenDX for further analysis as described earlier in the 
Methods Section 4.1.2. The data showed that there is a 5.3 % methylation difference between the two 
samples (Table 4.2; Figure 4.23). 
Table 4.2: Summary of methylation differences between EndoC-βH1 cell line and a pancreatic islet sample. 








 Methylation Percentage 
Average 0.26 % 5.52 % 
Maximum  2.89 % 9.94 % 
Minimum 0 % 0 % 
Median 0 % 5.55 % 
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Figure 4.23: The methylation status of a pancreatic islet sample and a beta cell line model.  




















4.2.5.2.  The Effects of High-Glucose Exposure on DNA Methylation in the MIR-200c/MIR-141 
Promoter Region 
The influence of hyperglycaemia on the methylation profile of the beta cell line in the 
promoter region of MIR-141 was investigated. To achieve this, a targeted next-generation bisulfite 
sequencing technology was used to assess methylome differences in the pancreatic beta cell line 
(EndoC-βH1) model, which was exposed to normal (5.5 mM) or high glucose (25 mM) concentration 
for 48 hours. The data showed that hyperglycaemia exposure has a minimum effect on the methylome 
profile of the targeted region (Figure 4.24). The average difference in methylation change of the 
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Figure 4.24: The effect of high glucose exposure on the methylation profile of the EndoC-βH1 beta cell line model. 






















4.2.6. The effect of Hyperglycemia and Proinflammatory Cytokines of the Methylation 
Stability in the Developed Multiplex Assay 
To investigate whether high glucose and proinflammatory cytokines exposure could affect the 
methylation stability of the developed multiplex assay, we treated EndoC-βH1 cells with high glucose 
concentration up to 48 hours, as described in General Methods, Chapter 2, section 2.2.1. The 
methylation level of the treated cells was measured relative to the control EndoC-βH1 cells that were 
grown in the presence of physiological glucose concentration (5.5 mM) and the absence of test 
cytokines. As shown in Figure 4.25 and Figure 4.26, compared to the control cells, there were no 
significant changes (p > 0.05) in the relative hypomethylation levels for all three cfDNA targets when 
either treated with hyperglycemic nor proinflammatory conditions. 
 
Figure 4.25: The effect of high glucose exposure on the methylation profile of the designed beta specific targets. 
The figure illustrates that there is no significant (p > 0.05) change in the relative methylation level of the INS, Cluster 1 





Figure 4.26: The effect of pro-inflammatory cytokines exposure on the methylation stability of the designed beta specific targets. 
The figure illustrates that there is no significant change (p > 0.05) in the relative methylation level of the INS, Cluster 1 or Cluster 2 single plex assays nor in the multiplex assay when 





The genome-wide methylation sequencing approach resulted in a library of differentially 
methylated CpG loci that are specific for the islet genome. Comparing the islet and PBMC methylation 
signature data to other tissue methylation signatures available from the Roadmap and ENCODE 
studies revealed that there are 425 hypomethylated and 228 hypermethylated CpG targets specific to 
the islet genome. It is important to highlight here that there were some difficulties in comparing tissue 
methylome data available from the UCSC Genome Database (https://genome.ucsc.edu/index.html) 
with the data generated by the EPIC array analysis. There was variation in the methylation levels of 
the tissue methylomes reported by different studies, for instance, the liver methylome. This variation 
most probably arose due to the use of different sequencing techniques as well as different analysis 
and annotation methods in representing the methylation of the tissue. Comparing our in-house 
sequencing of different CpG sites, e.g. CpG +49678 in exon 2 of the NCOR2 gene, CpG +20459 of 
SLC45A4, led us to conclude that the Roadmap methylation signature data was the most reliable 
database that could be used as a reference database.  It is also worth highlighting here that none of 
the DMRs identified as beta cell-specific were located within genes that are well-known to be crucial 
for beta cell function (PDX-1, MafA, and NeuroD1). This could suggest an issue with the original 
candidate approach used in this project. However just because they were not identified, it does not 
mean that there are no differentially methylated CpG sites within these genes. The EPIC BeadChip 
covers only 3% of the total number of human genome CpG dinucleotides (total number of human CpG 
dinucleotides is 27,999,538, and the EPIC BeadChip array sequenced only 850,000 CpG sites). There 
is, therefore, a significant chance that there are DMRs within these genes that were not sequenced 
via the EPIC array.  
Among the uniquely hypomethylated 425 CpG sites, several CpG loci within the mutual promoter 
of MIR-200c/MIR-141 shown to be possible candidates for designing beta cell-specific biomarkers 




suggested that the identified candidates may be able to detect and differentiate beta cell fragments 
in the circulation. The MIR-200c/MIR-141 genes are reported to play an important role in beta cell 
survival and the pathophysiology of diabetes. Multiple studies have shown that the MIR-200c/MIR-
141 genes are actively involved in apoptosis of islet cells through pathways that induce endoplasmic 
reticulum stress (Belgardt et al. 2015, Filios and Shalev 2015, Filios et al. 2014, Klein et al. 2013). Two 
combinations of the human hypomethylated sensitive multiplexed assay were developed (MIR-200c 
cluster 1 + INS exon 2 + MIR-141) and (MIR-200c cluster 1+ INS exon 2 and MIR-200c cluster 2; 
developed by Dr Jody Ye). Both combinations showed a high degree of specificity towards the islet 
and human EndoC-βH1 genomes. The sensitivity of both assays was confirmed when the amplification 
preserved a linear pattern throughout a different range of artificially hypomethylated DNA 
concentrations in the presence of a fixed concentration of hypermethylated DNA control. Further, the 
specificity of the multiplex assays toward beta cells was not affected when the cells were exposed to 
hyperglycaemia or to a mixture of pro-inflammatory cytokines that mimic the microenvironment of 
T1D. As these biomarker assays will be used on biofluid samples collected from patients having a 
condition involving beta cell death, e.g. preclinical T1D, islet transplantation and at risk for developing 
T1D, it was essential to define the optimum the volume of biofluid sample required to perform 
downstream analysis, e.g. ddPCR. Optimising the ideal volume of starting material was important due 
to the limited number and volume of samples available. It was also important to optimising the volume 
of the starting material in-house as conflicting starting material volumes was reported by other groups 







Chapter 5: Optimising Cell 






At the time of T1D onset, 70-80 % of beta cells will be destroyed by autoimmune mechanisms 
(Cnop et al. 2005; Notkins and Lernmark 2001). Consequently, the nucleic acid content of dying beta 
cells is released into the peripheral circulation. One of the approaches for discriminating beta cell-
derived DNA fragments is by designing an assay that amplifies DNA fragments that have a distinct 
differentially methylated nucleotide. These types of assays are known as methylation sensitive assays. 
The employment of methylation-sensitive biomarkers has already been used to study cancer (Delpu 
et al. 2013; Esteller 2007; Fukushige and Horii 2013; Leygo et al. 2017; Szyf 2012; Verma et al. 2006; J. 
Wang et al. 2017b; Wang et al. 2017a; Yi et al. 2012) and recently in T1D (Akirav et al. 2011, Husseiny 
et al. 2014, Lehmann-Werman et al. 2016). Estimates of the concentration of cfDNA in the circulation 
of healthy individuals vary wildly as it is highly dependent on the used extraction method 
(Fleischhacker et al. 2011; Sharma et al. 2011; Xue et al. 2009). Exploring the published literature 
discussing cfDNA extraction revealed that the most commonly used extraction methods relied on 
commercial kits (e.g. QIAamp Circulating Nucleic Acid and QIAmp DNA blood kits from QIAGEN) that 
employed column-based extraction chemistry (Sharma et al. 2011). Additionally, we found that the 
volume of the starting extraction material (plasma/serum) varied in different studies that investigated 
similar hypotheses, from 50 μL of serum (Tersey et al. 2016), to 200 μL serum (Akirav et al. 2011) and 
ultimately to 0.2-1 mL of serum/plasma (Lehmann-Werman et al. 2016). It was, therefore, essential 
to standardise an internal protocol for isolating cfDNA from biofluid samples. 
In this Chapter, we aimed to compare the absolute cfDNA yield extracted from serum/plasma 
samples using different DNA isolation protocols; the QiaAmp mini blood DNA extraction kit according 
to the manufacturer’s protocol, a modified pH-column based method and a modified 
Triton/Heat/Phenol (THP) protocol. Then, we aimed to determine the efficiency and reproducibility of 




Urine is a non-invasive and easy to collect clinical sample (Cannas et al. 2009; Streleckiene et al. 
2018), so we further aimed to, in parallel with optimising cfDNA extraction from human sera, study 
the viability of extracting cfDNA from urine samples. Urinary cfDNA, is another important source of 
cfDNA that has attaracted significant attention in the past decade. Urinary DNA is derived either from 
cells shedding from the urogenital tract or from the peripheral circulation after ultrafiltration by the 
renal glomeruli. Urinary short sequence cfDNAs, which are typically between 150-250 base pairs (bp) 
in length, are known as “transrenal DNA” (Su et al. 2004). Transrenal DNA contains important genomic 
information from various positions all over the body. The presence of transrenal DNA has been 
confirmed by various studies (Bryzgunova and Laktionov 2015, Bryzgunova et al. 2006, Melkonyan et 
al. 2008, Su et al. 2004, Tsui et al. 2012). The clinical utility of urinary cfDNA as a potential diagnostic 
biomarker for a variety of cancers and infectious diseases has been evaluated by studying the genetic 
variation of transrenal DNA such as mutations and methylation status, as well as DNA integrity and 
concentration (Bryzgunova and Laktionov 2015). Most recently, transrenal DNA was shown to yield 
sufficient concentrations of high-quality DNA for DNA methylation profiling in a study of diabetic 
chronic kidney disease (Lecamwasam et al. 2018). Therefore, in this chapter, we sought to optimise 
the required conditions for transporting urine samples (from the source of collection) and the storage 






5.1.1. Locally Collected Samples  
Serum: Peripheral whole blood samples from randomly selected healthy volunteers were 
collected in a 5 mL SST™ tube (Becton Dickinson) containing a gel barrier to separate the serum after 
centrifugation. All samples were processed at room temperature within 2 hours from the time of 
venipuncture. Serum was separated from the cellular fraction by centrifugation at 2,000 g for 15 
minutes. After centrifuging, each serum sample was transferred into a sterile Lobind Eppendorf tube 
and re-centrifuged at 16,000x g for 10 minutes. Afterwards, the supernatant was divided into aliquots 
of 300 μL. Aliquots were stored immediately at -80°C until cfDNA was extracted. The details of 
volunteers are summarised in General Methods, Chapter 2, Table 2.4. 
Plasma: Peripheral whole blood samples from randomly selected healthy volunteers and were 
collected in 6 mL tri-potassium ethylenediamine tetra-acetic acid (K3EDTA, VWR) tubes. Plasma was 
separated from the cellular fraction by centrifugation at 2,000 g for 15 minutes. After centrifuging, 
each plasma sample was transferred into a sterile Lobind Eppendorf tube and re-centrifuged at 
16,000x g for 10 minutes. Afterwards, the supernatant was divided into aliquots of 300 μL. Aliquots 
were stored immediately at -80°C until cfDNA was extracted. The details of volunteers are summarised 
in General Methods, Chapter 2, Tables 2.6-2.9. 
 Urine: All urine samples used in this project were collected locally from healthy adult donors, 
University of Bristol, (Bristol, UK). 4 samples were used (males n = 2, females n = 2) in the experiment 
investigating the effect of DNA preservative on the stability of cfDNA. In the experiment comparing 
the effect of a commercial preservative with 40 mM EDTA on the stability of the cfDNA in urine, seven 
urine samples were used (males n=3, females n=4). The details of volunteers are summarised in 




5.1.2. Processing the Urine Samples (Experiment Design) 
In order to study the effect of adding EDTA on cfDNA preservation in urine samples, the 
samples were divided into two groups; a control group (group A), where the samples were stored 
without any additions, and a test group (group B) where a final concentration of 40 mM EDTA was 
added to the samples. The final concentration of the preservative was achieved by adding 3.2 mL of 
sterile 0.5 M EDTA stock (pH 8.5) to exactly 40 mL urine sample. Next, 1 mL of sample from both groups 
were then aliquoted into sterile 1.5 mL Eppendorf tubes and stored as required and this is detailed in 
Figure 5.1. 
In the experiment comparing efficiency of a commercial cfDNA urine preservative (Streck, 
Omaha, USA) to the 40 mM EDTA preservative in stabilising the cfDNA in urine samples, 5 mL of the 
Streck cfDNA urine preservative was added to 25-100 mL of urine sample as recommended by the 
manufacturer’s instructions. The urine samples + streck preservative (Group C), Urine samples + 40 
mM EDTA (Group B) were compared to a control group in which urine samples had no additives (Group 
A). One mL samples from groups A, B and C were aliquoted and stored at ambient temperature for 
cfDNA extraction at different time points (Immediately and then after 1, 3, 5 and 8 days).  
 
Figure 5.1: The experiment design of storage conditions and duration of Group A and Group B urine samples 
processing. 
1 mL from both groups were stored at either room temperature (RT), 4⁰C for 1, 3 and 7 days. cfDNA sample from each 
group was extracted immediately and was used as a control for comparing the level of beta-globin cfDNA in the studied 
time points. Samples from both groups were stored in -80⁰C for long-term studies and was analysed after 3 and 8 months 
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5.1.3. DNA Preservative 
5.1.3.1. Ethylene-Diamine-Tetra-Acetic Acid (EDTA) 
A stock solution of 0.5M EDTA was prepared as described in the materials section in Appendix 
B. A final concentration of 40 mM EDTA was added to the urine samples. 
5.1.3.2. Commercial cfDNA Urine Preservative 
A liquid reagent that stabilises cfDNA in urine specimens was purchased from Streck (Omaha, 
USA). Five mL was added to 25-100 mL urine specimens as recommended by the manufacturer’s 
instructions. 
5.1.4. DNA Extraction 
Plasma/ Serum 
cfDNA was extracted from 0.2-2 mL of serum/plasma samples (as available for optimisation 
experiments) using three cfDNA extraction methods; the QiaAmp mini blood DNA extraction kit 
according to the manufacturer’s protocol, the modified pH-column based method and the modified 
Triton/Heat/Phenol (THP) protocol (Keshavarz et al. 2015). The exact steps of the latter two methods 
are explained in Appendix A, Figure A.1 and Figure A.2. 
Urine 
In the first experiment, both QiaAmp Blood mini Kit (Qiagen) and QIAamp Circulating Nucleic 
Acid Kit (Qiagen) were used to extract cfDNA from urine samples following the manufacturer’s 
protocol. In later experiments of optimising the cfDNA preservative, the cfDNA was extracted from 
1mL urine sample using the QiaAmp Blood mini Kit only. Extracted cfDNA samples were stored at -
20°C for later use.  
5.1.5. cfDNA Quantification in Biofluid Samples 
During this project, the assessment of cfDNA quantity in biofluid samples was carried out using 




treated), samples. Both the bisulfite specific beta-actin assay and the beta-globin assay were available 
locally from previous projects. The full details of the assays are summarised in Appendix A, Table A.1. 
5.1.6. Droplet Digital PCR 
The DNA concentration was measured using a standard droplet ddPCR protocol as described 
previously (Chapter 4, Section 4.5). The amplification conditions were as follows:  
Polymerase Activation/ Denaturing 95°C 10 minutes X1 
Denaturing 94°C 30 seconds 
X40 
Annealing-Extension Step Optimum Tm 1 minute 
Enzyme Deactivation 98°C 10 minutes X1 
Droplet Stabilizing 12°C 10 minutes X1 
Incubation 4°C ∞ ∞ 
 
5.1.7. Statistical Analysis 
The number of DNA copies per 1 μL of the target was analysed by the Quantasoft software 
(Bio-Rad, version 1.6.6.0320). The direct comparison between the levels of circulating 
hypomethylated beta cell-specific targets in test VS control group was achieved by Mann-Whitney 
testing for nonparametric data. For all statistical comparisons, a p-value of < 0.05 was considered to 
be statistically significant. Statistical analyses were performed with GraphPad/Prism 6 (version 6.07). 
The absolute level of beta cell-specific target cfDNA was presented in this thesis as the cfDNA copies 
in 1 mL of serum/plasma sample. The absolute level of circulating hypomethylated DNA was calculated 
as follows: 
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5.2.1. cfDNA extraction using different extraction methods 
Serum samples were collected from healthy local adult control volunteers (n=7) and were used 
for cfDNA extraction. In this experiment, we were interested in quantifying the concentration of cfDNA 
in 300 μL serum samples. Therefore, the extracted cfDNA was analysed by ddPCR utilising a dual 
fluorescence beta-globin assay. Three extraction methods, THP and QIAamp DNA Blood Mini Kit, 
modified pH-column based methods were employed to compare cfDNA concentration in adult non-
diabetic healthy individuals’ samples. cfDNA was subjected to ddPCR to detect beta-globin 
concentration in the serum of non-diabetic healthy volunteers (n=7). Quantification of ddPCR data 
was fulfilled using cfDNA copies exploited to 1 mL sample. The mean ± SD of beta-globin cfDNA copies 
gained by the THP protocol was 2342 ± 1330 (range: 119-3967), the QIAamp DNA Blood Mini Kit was 
5143 ± 3006 (range: 2158-9975), while for the pH-column based method was 6625 ± 4089 (range: 
2358-13,418). Evaluation of the results of three extraction methods showed the higher efficiency of 
cfDNA extraction was gained when the modified pH-column based protocol for cfDNA extraction was 
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Figure 5.2: Comparison of beta-globin cell-free DNA (cfDNA) recovery from serum using three DNA isolation methods. 
cfDNA was extracted from 300 µL serum collected from adult healthy volunteers (n=7). cfDNA was extracted via the THP 
protocol, the pH modified column protocol and the standard protocol of QIAamp blood mini kit. Each sample was 
quantified by droplet digital PCR utilizing beta-globin assay in duplicates. A) The columns represent the absolute 
quantification of beta-globin cfDNA copies per 1 mL serum sample. B) The scatter dot plot represents the absolute 
number of cfDNA copies in all tested samples, the middle line indicates the mean value ± SD (error bar). C) The Data are 
presented as mean of the duplicate value (column) ± SD (error bar). The absolute yields of cfDNA generated by the pH-





5.2.2. Comparing the Modified pH Column-Based Method to Other Published Protocol 
 Recently, an enhanced Qiagen cfDNA isolation protocol has been described by (Tersey et al. 
2016). The authors reported that this enhanced protocol was able to extract cfDNA in detectable yield 
from as low as 50 μL starting material. We, therefore, sought to compare the cfDNA yield from our pH 
modified protocol to the published enhanced DNA extraction protocol using two plasma volumes, 0.5 
and 2.5 mL, collected from local healthy adult volunteers (n=3), samples were described in General 
Methods, Chapter 2, section 2.3.6. Due to limited availability, plasma samples were used in this 
experiment. Based on previous optimising experiments (carried out by Dr Jody Ye), we did not observe 
a significant difference in cfDNA quantity between plasma and serum samples that were separated 
within 2 hours post venepuncture. The extracted cfDNA by both methods were subjected to ddPCR in 
a beta-globin probe-based assay. The mean ± SD of cfDNA concentration corrected to 1 mL plasma 
obtained by the modified pH-column based protocol was 197 ± 59 (range: 125-215), while for the 
published enhanced DNA extraction protocol the yield was 44 ± 17 (range: 19-42) from 0.5 mL plasma. 
The beta-globin cfDNA obtained by modified the pH-column based protocol was 220 ± 98 (range: 159-
265), while for the published enhanced DNA extraction protocol was 32 ± 17 (range: 25-59) from 2.5 
mL plasma. Collectively, the data show that the pH modified protocol was significantly more efficient 
in extracting cfDNA from both tested plasma volumes (Wilcoxon matched-pairs signed rank test, 












The data comparing the cfDNA extracted from 0.5 mL and 2.5 mL of plasma samples using two modified protocols for 
the QIAamp blood mini DNA extraction kit; enhanced column protocol and our developed pH column-based protocol. 
Plasma was isolated from healthy blood samples donated by 3 volunteers; cfDNA was quantified by droplet digital PCR 
utilizing the beta-globin assay. The dot plot represents the absolute beta-globin concentration in 1 mL of plasma sample. 
The results suggest that cfDNA extraction using the pH-modified column protocol significantly enhanced (*p < 0.05) 





5.2.3. The Optimum Plasma Volume Needed for cfDNA Extraction  
Next, we aimed to determine the effect of starting material volume on extracted cfDNA yield 
and whether there is a linear correlation between the cfDNA concentration and the initial plasma 
volume extracted. To achieve this goal, three different plasma volumes of 2.5 mL, 1 mL and 0.5 mL 
were obtained from the same healthy donors used in the previous experiment. The cfDNA yield 
extracted by each method was analysed by ddPCR utilising a dual fluorescence-based human beta-
globin assay. The results showed that the beta-globin cfDNA average was 110± 49, 201± 30 and 493± 
98 copies /μL in 0.5, 1.0 and 2.5 mL gained from 3 plasma samples respectively (Figure 5.4A). Next, we 
tested the consistency of DNA extraction from each plasma volume. Therefore, the absolute beta-
globin cfDNA copy number/1 mL was determined for each sample in each group (Figure 5.4B). 
Interestingly, the average of the absolute beta-globin copy number was around 200 copies/mL in all 
tested samples (Figure 5.4B). The ddPCR analysis also revealed a linear correlation (R2= 0.9998) 
between the cfDNA concentration obtained and the plasma volume extracted. The beta-globin cfDNA 









   
















































































































cfDNA was extracted from either 0.5, 1 or 2 mL plasma samples donated by 3 healthy volunteers. cfDNA was extracted 
using the pH modified column-based protocol and each sample was quantified by droplet digital PCR utilizing the beta-
globin assay. A) The column represents the absolute beta-globin cfDNA copy number in 1 mL plasma sample B) The 
columns represent mean ± SD (error bar) of absolute beta-globin cfDNA copy number per 1 mL in each tested plasma 
volume. C) The dot plot represents the mean value of the absolute beta-globin copy number of 3 samples in each tested 





5.2.4. The Effect of DNA Preservative on Protecting cfDNA from Degradation in Urine Samples 
5.2.4.1. The Integrity of Extracted cfDNA in Urine Sample 
Morning and mid-day urine samples (4 mL) collected from a single adult healthy donor were 
used for cfDNA extraction. The extracted cfDNA was then subjected to bisulfite treatment and 
amplified with bisulfite specific beta-actin primers. The PCR products were then visualised on a 1.8 % 
agarose gel (Figure 5.5). The result shows that cfDNA extracted from urine was intact and confirms 





Figure 5.5: The PCR products of bisulfite converted cfDNA extracted from 4 mL control urine samples. 
The urine sample was collected from a healthy donor (n=1) and cfDNA was extracted from 4 mL samples using the 
QIAamp Circulating Nucleic Acid Kit. cfDNA was then subjected to bisulfite treatment and was amplified with beta-actin 
primers (133 bp). The samples were visualized in a 1.8% agarose gel by staining them with Midori Green and the PCR 
product sized with an adjacent 50 bp ladder. These data indicate that cfDNA extracted from urine samples could be a 





5.2.4.2. The Need for a Preservative in the Collected Urine Samples 
 An aliquot of urine specimens that had been stored in -80⁰C for ten days was used in this 
experiment. cfDNA was extracted from different urine volumes: 0.2, 0.4, 0.6, 0.8, 1 mL and 4 mL in 
duplicate using a QiaAmp Mini Blood Kit. The cfDNA samples were bisulfite treated and then analysed 
by ddPCR utilising the beta-actin assay (FAM), and a previously developed differentially methylated 
INS assay at CpG +367+374 (FAM/VIC) by Dr Jody Ye (described in Appendix A, Table A.1). The result 
shows that both assays, beta-actin and the INS had a very low yield in all tested volumes (Figure 5.6). 
This experiment suggests a possibility of cfDNA degradation occurrence in the urine sample and 












The cfDNA was extracted from either 0.2, 0.4, 0.6, 0.8, 1 or 4 mL urine samples via QIAamp DNA blood mini kit. The urine 
sample was collected from a healthy donor (n=1) and was quantified by a droplet digital PCR differentially methylated 
INS (CpG +367+374) probe assay in duplicate. A) The data in this graph are presented as mean of the duplicate value 
(column) ± SD (error bar) of each tested sample. B) The graph represents the absolute INS and beta-actin cfDNA copy 
number per 1 mL of the extracted cfDNA from different urine volumes. Although some amplification was seen in INS, no 





5.2.5. Effects of Adding EDTA and Storage Temperature on the Stability of cfDNA in Urine  
 When the urine from the previous experiment was stored at -80⁰C for ten days without the 
addition of DNA preservative, a decrease in the beta-actin signal was observed (the copy number of 
beta-actin decreased from 200 copies/mL to 4 copies/mL). We sought to examine whether that 
reduction was an effect of nucleic acid degradation, especially when previous reports had reported 
degradation occurrence in urine samples when stored without the addition of nucleic acid 
preservative (Cannas et al. 2009). To investigate this, we studied the effect of adding a DNA 
preservative (40 mM EDTA) to a morning first-urine sample collected from a single healthy adult donor 
which was stored at different storage temperatures and duration conditions that would mimic sample 
transportation collection for the Bart’s Oxford study of type 1 diabetes coordinated from this research 
group.   
5.2.5.1. The Effect of 40 mM EDTA on Short-Term Storage 
To investigate the effect of adding DNA preservative to urine samples which will be stored for 
a short time (≤ 7 days).  In this experiment, we were interested in quantifying the cfDNA concentration 
in 1 mL urine sample. Therefore, the extracted cfDNA was analysed by ddPCR utilising a dual 
fluorescence beta-globin assay. Aliquots of a urine sample (1 mL), conducted from a single healthy 
adult volunteer, were stored either at room temperature or 4⁰C with and without the addition of 40 
mM EDTA. cfDNA was extracted at baseline, 3 and 7 days using a QiaAmp mini blood kit and the beta-
globin yield quantified by ddPCR. The results show that adding 40 mM EDTA was essential to prevent 



















Figure 5.7: The effect of adding 40 mM EDTA on DNA stability in urine samples when stored at different temperatures and 
durations. 
The samples were collected from a single healthy donor and were stored either with or without the addition of DNA 
preservative (EDTA, 40 mM) at ambient temperature (RT) or 4⁰C for 1, 3 and 7 days. The cfDNA was extracted from 1 mL 
urine samples via the QIAamp DNA blood mini kit and were quantified in duplicate by droplet digital PCR utilizing the 
beta-globin assay. A) The data in this graph represents the mean of the duplicate value (column) ± SD (error bar) of each 
tested sample per 1 mL urine sample. B) The graph represents the absolute beta-globin cfDNA copy number per 1 mL 
urine samples. The data show that adding 40 mM EDTA to the urine sample was essential for protecting cfDNA from 





5.2.5.2. The Effect of 40 mM EDTA on Long-Term Storage 
Next, we sought to test the effect of adding EDTA to urine samples stored at -80⁰C and for a 
long-term period (3 and 8 months). Therefore, we stored urine samples collected locally from healthy 
volunteers (n=4; male= 2, female= 2) with and without adding 40 mM EDTA for up to 8 months. As we 
were interested in comparing the cfDNA concentration in the presence or absence of DNA 
preservative, no baseline was included. Instead the cfDNA concentration in Group A samples (no 
preservative) was compared to those in Group B (40 mM EDTA added) at each time point. At the 
appropriate time, cfDNA was extracted from a 1 mL urine sample using the QiaAmp mini blood kit. 
Then, cfDNA samples were amplified with ddPCR utilising the beta-globin assay. The absolute beta-
globin cfDNA copies/ mL of treated samples were compared to the control (No EDTA) samples’ (Figure 
5.8). Although we observed a decrease in the concentration of beta-globin in samples that were stored 
at -80⁰C for 8 months, the data show that there was no statically significant difference between the 








Figure 5.8: The effect of long-term storage on untreated and EDTA treated urine samples. 
 
B 
Urine samples were collected from healthy adult volunteers (n=4), 1 mL of each samples (with or without EDTA addition) 
was stored for 3 and 8 months at -80⁰C. At the appropriate time, cfDNA was extracted from 1 mL sample using the 
QiaAmp mini blood kit, the total cfDNA was used as a template for beta-globin quantification via ddPCR. A) The scatter 
plot represents the absolute beta-globin cfDNA copy number in 1 mL urine sample after storage for 3 months at -80⁰C. 
B) scatter plot represents the absolute beta-globin cfDNA copy number in 1 mL urine sample after storage for 8 months 







5.2.5.3. The Effect of Adding a Commercial Preservative product on cfDNA Stability in Urine 
Samples 
Our next goal was to test a substitute preservative that can be safely delivered to the patients 
at home for urine collection. Therefore, 5 mL commercial preservative from Streck (Omaha, USA) was 
added to 25-100 mL freshly collected urine samples, as recommended by the manufacturer’s 
instructions. Urine samples collected from local adult healthy volunteers (n= 8; male= 4, female= 4) 
with and without adding 40 mM EDTA or the commercial preservative. The samples were divided into 
1 mL aliquots and stored at ambient temperature for 1, 3, 5, 8 days. At appropriate time points, total 
cfDNA was extracted using a QiaAmp mini blood kit and amplified by ddPCR utilising the beta-globin 
assay. The results showed both cfDNA preservatives maintained the stability of the cfDNA in the urine 
for up to 5 days at ambient temperature. The results also showed that the commercial preservative 
failed to stabilise the cfDNA in the sample when stored for a period exceeding 5 days (Figure 5.9).  
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Urine samples were collected from healthy volunteers (n=8), and 1 mL of each sample, with EDTA (40 mM), the 
commercial preservative or without preservative was stored for 0, 1, 3, 5 or 8 days at ambient temperature. At the 
appropriate time, cfDNA was extracted from 1 mL sample using the QiaAmp mini blood kit, the cfDNA was used then as 
a template for beta-globin quantification via ddPCR. The graph represents the absolute quantification of beta-globin 
per 1 mL urine sample, each dot represents the mean of beta-globin absolute value in 8 samples. The data showed that 
adding 40 mM EDTA or a commercial preservative to urine samples stabilized the cfDNA for up to 5 days. Only 40 mM 





5.2.6. Optimising of Urine Volume Required for Successful cfDNA Analysis 
Next, we tried to identify the optimum volume of a urine sample that could be used for cfDNA 
extraction. Another fresh mid-day DNA sample was collected from a single healthy volunteer (80 mL), 
14 mL of the sample was used in this experiment, the rest of the sample was aliquoted into 15 mL 
volumes and stored at -80°C. cfDNA was extracted from 200 μL, 400 μL, 600 μL, 800 μL, 1 mL and 4 
mL 12 in duplicate using two DNA extraction kits; the QiaAmp Circulating Nucleic Acid Kit (NA) and the 
QiaAmp Mini Blood Kit (QBL). The extracted cfDNA was bisulfite treated and amplified by ddPCR 
utilising the beta-globin assay. The result suggests that extraction of cfDNA from urine was more 
efficient when the QiaAmp mini blood kit was used (Figure 5.10). The data also indicated that using 
volumes of less than 0.5 mL could have a positive impact on the resulting cfDNA yield (Figure 5.10D). 
Therefore, a volume of 400 μL will be used in subsequent experiments.   









                                                          














cfDNA was extracted from either 0.2, 0.4, 0.6, 0.8, 1 or 4 mL urine samples via the QIAamp Circulating Nucleic Acid Kit 
(NA) or QIAamp mini blood nucleic acid kit (QBL). The urine sample was collected from a healthy donor (n=1) and 
quantified by droplet digital PCR utilizing the beta-globin probe assay in duplicate. A) The data in this graph is presented 
as mean of the duplicate values (column) ± SD (error bar) of each tested sample. B), C) & D) The graph represents the 
absolute beta-globin cfDNA copy number per 1 mL of the extracted cfDNA from different urine volumes. The data 
suggests that the QiaAmp blood mini kit extracted cfDNA from urine samples more efficiently in comparison to the 






This chapter summarises the work performed to optimise the conditions for cfDNA extraction 
from biofluid samples, e.g. serum, plasma, which are known to be challenging biological samples for 
DNA extraction. The results suggest that a large volume of starting biological material may be 
necessary in order to detect low concentration signals such as fragmented DNA released from dying 
beta cells.  Therefore, where possible 1 mL of plasma/ serum will be used during this project for 
extracting DNA using the modified pH-column based method.  
A series of experiments was also set up to optimise the isolation and analysis of urinary DNA. The 
urinary DNA is another important source of cfDNA, and it has been attracting significant attention in 
the past decade due to the large volume of sample that can be collected from the patient and being 
an easy to access source of sample. In the longer term, it was hoped that the strategies developed 
could be used to collect samples from participants in the Bart's-Oxford (BOX) family study, the longest-
running family study of type 1 diabetes, which is co-ordinated from Bristol. The data in this chapter 
showed clearly that adding cfDNA preservative is essential to protect the cfDNA from degradation 
during sample transport from the source of the collection to the laboratory. One study which 
examined the optimum conditions for storing transrenal DNA at different temperatures, e.g. room 
temperature, 4⁰C and - 80⁰C was carried out by Cannans and colleagues (Cannas et al. 2009). They 
reported that site-specific differences in urine composition significantly affected the stability of 
urinary cfDNA during storage at all temperatures tested. Additionally, they highlighted the importance 
of adding DNA preservative agents, e.g. EDTA at a high concentration (40 mM) to protect the urinary 
DNA from degradation. Therefore, we tested the viability of adding 40 mM of EDTA to 1 mL urine 
samples collected from healthy volunteers and showed that adding 40 mM EDTA was essential to 
protect the urinary DNA from degradation when the samples were stored at ambient and 4⁰C for ≤ 7 
days. Although not statistically different, we noticed that a there was a difference in the number of 




8 months at -80⁰C  compared with controls (n=4, Figure 5.8). This experiment will, therefore, be 
followed up in the future with more samples. As adding 40 mM EDTA was shown to be essential for 
stabilising transrenal DNA in the urine samples, it raises an issue for the Bart’s Oxford team in terms 
of delivering tubes with 40 mM EDTA to the general population who participate in this study. Another 
preservative reagent was therefore researched that could be safely delivered to patients. According 
to the Safety Data Sheet of Cell-Free DNA urine preservative (Streck, Omaha, USA), the product does 
not contain any hazardous chemicals at concentrations of 1% or higher, does not contain any known 
carcinogens, category 1 germ cell mutagens, reproductive toxicants, respiratory or skin sensitizers at 
concentrations of 0.1% or greater (https://www.streck.com/wp-
content/uploads/sync/Collection/Preservatives/Cell-Free_DNA_Urine_Preserve/04_SDS/01_Cell-
Free_DNA_Urine_Preserve_SDS_Exemption_Letter.pdf). Therefore, we tested the efficiency of this 
commercial reagent in stabilizing transrenal DNA when stored at ambient temperature. Our data 
indicated that adding the Streck preservative stabilised the urinary DNA for up to 5 days when stored 
at ambient temperature. The data in this chapter also indicate that using a volume of 0.4 mL is 
recommended as high urine volume e.g. 1 and 4 mL resulted in decreased cfDNA yield, which could 
due to the nature of the urine samples (high salt concentration) that could interact with the column 









Chapter 6: Monitoring Beta 







As shown previously in chapter 4, hypomethylated CpG sites within MIR-200c, MIR-141 and INS 
were found specifically in beta cells. Therefore, any beta cell destruction would release 
hypomethylated DNA (at these specific CpG sites) into the circulation. Circulating cell-free DNA 
(cfDNA) has been used as a biomarker for disease development (Swarup and Rajeswari 2007). Serum 
and plasma are non-invasive, easy to obtain sources of DNA, and when using a highly sensitive analysis 
method such as ddPCR, beta cell-derived cfDNA can be detected at low concentrations. As the primary 
goal of this project was to develop a methylation-based biomarker for monitoring beta cell death, we 
aimed in this chapter to assess whether the developed multiplex assay could detect beta cell genome 
in the circulation of recently diagnosed T1D adult and children patients, those who were at risk of 
developing the condition and T1D patients who received clinical islet transplantation.   








6.1.1. MIR-141/MIR-200c Cluster 1/INS Exon 2 Assay Triplex as a Biomarker for Beta Cell 
Death 
The viability of the triplex assay to detect beta cell death in the circulation was tested on 
recently diagnosed paediatric subjects (n=9) who have T1D duration of 1 year or less against non-
diabetic subjects (n=12) who were age and gender-matched, detailed characterization of the 
participant is described in General Methods, Chapter 2 Tables 2.4 & 2.5. Crucially these samples were 
collected, and serum isolated as rapidly as possible after venepuncture to prevent contamination with 
genomic DNA fragments from PBMC which causes false positive results with the insulin cfDNA assay 
(data not shown). The level of hypomethylated MIR-200c Cluster 1, MIR-141 and INS were analysed in 
bisulfite-converted DNA that was isolated from 900 μL serum via ddPCR. Further, the total number of 
positive droplets in each sample was calculated and referred to as the “multiplex”. The data showed 
that there was a significant difference between the level of circulating beta cell cfDNA in participants 
who were close to diagnosis and their corresponding control subjects (p < 0.01, Mann-Whitney U-
test). A comprehensive look at the data shows that there was a higher level of beta cell cfDNA in 
children who had a disease duration of < 6 months in comparison with those who were sampled post 
six months of diagnosis (Figure 6.1). This trend was consistent in the single plex (Figure 6.1B) as well 
as in the multiplex (Figure 6.1C) results. Next, we tested the ability of the assay to discriminate 
between participants who were sampled after 6 months post-diagnosis (n=6), the Mann-Whitney U-
test shows that there were no significant differences in beta cell fragments level between the tested 
group and their age and gender-matched control subjects (p > 0.05). Further, we sought to investigate 
the effect of multiplexing of several targets in discriminating beta cell cfDNA in circulation. The power 
of discrimination (PD) was calculated by dividing the number of cfDNA copies resulting from the single 
plex assay in all tested samples by those resulting from the multiplex assay. The highly efficient assay 




several beta cell-specific targets increased the power of discrimination three times in comparison with 















BCD10 0.263555251 986.1111 20.8333333 333.3333 1340.278 
BCD4 0.823610158 3194.444 126.388889 1000 4320.833 
BCD5 1.943719973 2125 333.333333 944.4444 3402.778 
BCD9 6.358270419 1555.556 77.7777778 527.7778 2161.111 
BCD2 9.323266987 194.4444 0 177.7778 372.2222 
BCD6 9.883321894 791.6667 31.25 583.3333 1406.25 
BCD1 10.50926561 125 27.7777778 330.5556 483.3333 
BCD3 12.38709677 527.7778 54.1666667 472.2222 1054.167 
BCD8 12.94715168 861.1111 68.0555556 500 1429.167 
 Sum 10361.11 739.583333 4869.444 15970.14 
 Power of 
Discrimination 
0.65 0.046 0.30  
Table 6.1: The effect of multiplexing several targets in enhancing the discrimination power of a beta cell death signal. 
 
Multiplexing several beta cell specific targets had enhanced cluster 1 assay by 1.5 times (PD= 0.65) and almost 3.3 times 








































Figure 6.1: Circulating hypomethylated MIR-200c cluster 1/ INS / MIR-141 cfDNA levels in recently diagnosed paediatric human cohort. 
 
** 
The level of hypomethylated multiplex assay of MIR-200c cluster 1/INS/MIR-141 DNA was measured via ddPCR in serum samples from recently diagnosed T1D (≤ 1-year diagnosis, n=9) and 
age-matched nondiabetic control subjects (n=12) in duplicates. Serum samples were separated rapidly after venepuncture to avoid PBMC genomic DNA contamination. The data are 
represented as the level of hypomethylated cfDNA copies in 1 mL of serum.  A) The columns are presented as mean of the duplicate values (column) ± SD (error bar). B) The absolute level of 
each hypomethylated target in recently diagnosed T1D subjects and non-diabetic controls. C) The level of absolute multiplex targets in 1 mL of T1D and non-diabetic serum samples. D) 
Comparison between the absolute level of circulating hypomethylated cfDNA in recently diagnosed T1D, within 1 year, and healthy control subjects (p = 0.0013, Mann Whitney U-test; **p < 
0.01). E) Comparison between the absolute level of circulating hypomethylated cfDNA in the recently diagnosed T1D, within 6 months, and healthy control subjects (p = 0.0015, Mann 
Whitney U-test; **p < 0.01). The data shows that the level of circulating hypomethylated MIR-200c cluster 1/INS/MIR-141 cfDNA was significantly elevated in recently diagnosed T1D 






6.1.2. MIR-200c Cluster 2 Assay Triplex combination as a Biomarker for Beta Cell Death 
Although the hypomethylated MIR-141 (CpG -20, from TSS) single plex discriminated recently 
diagnosed T1D children from their corresponding control subjects (p < 0.01), the level of discrimination 
was not as efficient as that observed with MIR-200c cluster 1 or INS singleplex. Therefore, we sought 
to replace the MIR-141 assay with the MIR-200c cluster 2 single plex (VIC, developed by Dr Jody Ye). 
Then, we examined the viability of this combination triplex assay (Cluster1/INS/Cluster2) to detect 
beta cell death in the selected recently diagnosed paediatric group (n=4, subject to availability as most 
of the samples had been used up in previous experiments) in comparison with an age and gender-
matched non-diabetic control group (n=6). The sample of new onset T1D children were collected 6-12 
months post-diagnosis.  As expected, the assay showed no significant discrimination between the test 
and the control groups as the tested subjects were diagnosed post six months of T1D onset (Figure 
6.2). Nevertheless, Cluster 2 single plex showed better discrimination performance (0.072) (Table 6.2) 
in comparison with the MIR-141 (0.046) (Table 6.1). Consequently, we decided to use cluster 2 instead 
of MIR-141 in the upcoming experiments. 
 
Sample Duration (months) Cluster 1 Cluster 2 INS Multiplex 
BCD 9 6.36 154.17 23.61 144.44 322.22 
BCD 2 9.32 12.50 12.50 75.00 100.00 
BCD 1 10.51 12.50 12.50 75.00 100.00 
BCD 3 12.39 181.94 26.39 194.44 402.78 
BCD 8 12.95 430.56 54.17 380.56 865.28 




0.44 0.072 0.485 
 
Table 6.2: The effect of multiplexing on enhancing the discriminating power of beta cell death signal. 
The multiplexing of several beta cell specific targets enhanced the discrimination power by 2 times over cluster 1 and INS 
























Figure 6.2: Circulating hypomethylated MIR-200c cluster 1/INS/MIR-200c cluster 2 cfDNA levels in recently diagnosed T1D pediatric human cohort. b 
 C  D 
 
The serum samples were collected 6-12 months post T1D diagnosis (n=6) and age/gender matched of nondiabetic control subjects (n=6). Extracted cfDNA were subjected to bisulfite 
treatment and analysed by ddPCR in duplicates. The columns represent the absolute copy number of hypomethylated cfDNA targets in 1 mL sample. A) The columns are presented as mean 
of the duplicate values (column) ± SD (error bar). B) Comparison of the absolute level of each hypomethylated target in recently diagnosed T1D subjects and non-diabetic controls. C) A 
comparison of the multiplex level of circulating hypomethylated beta cell targets in T1D and non-diabetic 1 mL serum samples. D) Comparison between the absolute level of circulating 
hypomethylated cfDNA of the multiplex assay in the recently diagnosed T1D and healthy control subjects. The data show that there is no significant difference in the level of circulating 





6.1.3. Monitoring Beta Cell Death in the “At-Risk” Autoantibody Positive Cohort 
In addition to measuring beta cell death in recently diagnosed T1D patients, we aimed to test 
the aptitude of the assay in detecting beta cell death in pre-clinical individuals who were at risk for 
developing the disease. To achieve this goal, we studied the level of beta cell-specific hypomethylated 
single plex and multiplex cfDNA in plasma samples blindly recruited from subjects who are at-risk for 
progression to T1D (n=15). The participants were relatives of patients with T1D, participating in the 
Type 1 Diabetes TrialNet Pathway to Prevention trial, and were positive for at least one islet 
autoantibody. The results show that the at-risk subjects had a higher level of hypomethylated 





















The columns represent the level of hypomethylated MIR-200c cluster 1/INS/MIR-200c cluster 2 DNA in 1 mL plasma samples collected from at-risk group and age and gender matched non-
diabetic subjects. A) The columns are presented as mean of the duplicate value (column) ± SD (error bar). B) Comparing the absolute singleplex level of beta cell death biomarkers in each 
at-risk samples and non-diabetic control subjects. C) The level of multiplex beta cell death biomarkers in at-risk and  non-diabetic control subjects. The mean and SD interquartile range is 




6.1.4. Monitoring Beta Cell Death in Recently Diagnosed T1D Subjects.  
In addition to detect ongoing beta cell death in recently diagnosed and at-risk cohorts, we aimed 
to examine the level of beta cell cfDNA in recently diagnosed adult T1D patients. To achieve this aim, 
we studied the level of hypomethylated single plex and multiplex DNA in plasma samples available 
from the StartRight study (n=9) compared to locally available age and gender-matched non-diabetic 
controls (n=12), and in addition to plasma samples (T1D n=7, Control n=4) collected from the Bristol 
cohort. The clinical characteristics available for these samples are shown in General Methods, Chapter 
2, section 2.3.3. When the rate of beta cell death was compared to age and gender-matched non-
diabetic control subjects, both singleplex and multiplex analysis of MIR-200c cluster 1/INS/MIR-200c 
cluster 2 showed no significant differences between recently diagnosed adult T1D patients and the 























Figure 6.4: Circulating hypomethylated MIR-200c cluster 1/INS/MIR-200c cluster 2 cfDNA levels in a recently diagnosed T1D adult cohort. 
The plasma samples were collected from T1D patients who had the condition for 3 months (n=9) and gender/age-matched nondiabetic control subjects (n=12). The columns represent the 
absolute copy number of hypomethylated cfDNA targets in a 1 mL sample. A) and B) The average level of duplicates of each single circulating hypomethylated beta cell target (MIR-200c 
cluster 1/INS/MIR-200c cluster 2 cfDNA in a 0.5 mL plasma samples. C) and D) A comparison of the absolute level of each circulating hypomethylated beta cell target in T1D and non-diabetic 
serum samples. E) Comparison between the absolute levels of multiplex circulating hypomethylated cfDNA in the multiplex assay of the T1D adult patients and healthy control subjects. The 
mean and SD interquartile range is shown. The data show that the was no significant difference in the level of circulating hypomethylated MIR-200c cluster 1/INS/ MIR-200c cluster 2 cfDNA 




6.1.5. Measuring the Beta Cell Death Rate in the Post Islet Allotransplant Patients 
We extended our tested groups to include plasma samples (n=2) collected from clinical islet 
transplant patients. One of the samples was recruited from a study to assess the efficacy and safety 
of Reparixin in pancreatic islet transplantation (REP0211), and the other was from the bone marrow 
vs liver as the site for islet transplantation study (IsletBOM2). As predicted, the level of circulating beta 
cell cfDNA was elevated immediately after islet infusion in both recipients (1-hour post-infusion), the 
peak level declined sharply afterwards, reaching the baseline level after 12 hours post-infusion in the 
IsletBOM2 samples and after 48 hours in the REP0211 sample (Figure 6.5 A and B). The baseline level 
of the hypomethylated circulating cfDNA persists up to one-week post-infusion. The results 
demonstrate that the developed multiplex assay can be used to monitor beta cell death in human 









Figure 6.5: Change in hypomethylated MIR-200c cluster 1/INS/MIR-200c cluster 2 cfDNA pre and post-islet-infusion. 
 
C 
Genomic DNA from plasma samples was bisulfite-converted and used for multiplex ddPCR assays in duplicate. The single 
plex and multiplex beta cell death biomarker level changes post islet-infusion in patient 1 (A) and patient 2 (B).  C) The 
absolute cfDNA copy number of the multiplex assays in 1 mL plasma samples. The data show that the level of beta cell 
cfDNA rises and peaks 1-hour post-infusion, the signal declines through the following hours and reaches the baseline 
level after 12 hours in patient 1 and after 48 hours in patient 2. Although low, there was a fluctuation in the level of beta 





6.1.6. Developing a New Assay for Monitoring Beta Cell Death 
Although the MIR-200c cluster 2 had a better discrimination power in comparison to the CpG 
-20 MIR-141 assays, it still lower in comparison to the cluster 1 and INS assay. Therefore, we sought 
to replace the cluster 2 assay with another assay, which would enhance the total discriminating power 
of the multiplex assay. The data for in-depth analysis of the MIR-141 promoter methylome had 
suggested CpG -449, from TSS, as a potential beta cell-specific DMR biomarker. In order to determine 
whether the level of hypomethylated MIR-141 (CpG-449) singleplex would increase in at-risk 
individuals we examined the level of a hypomethylated duplex of both MIR-141 CpG -20 and CpG -449 
in second elution DNA samples (n=7) isolated from the previous experiment studying the performance 
of a beta cell-specific multiplex assay in age/gender match non-diabetic controls. The genomic DNA 
concentration was relatively low in comparison to the first elusion sample (Table 6.3). The results were 
consistent with the observations seen in the multiplex assay. The single plex and duplex assays were 
not significantly different between the control and test group (p > 0.05 by Mann-Whitney U-test) 
(Figure 6.6); samples that had sufficient DNA yield recovery (Samples number 3 and 4) resulted in DNA 
copy numbers of 200-300. Nevertheless, more experiments will be required to determine the 









st elution (ng/μL) 
in 40 μL elusion 
gDNA 2nd elution (ng/μL) 
in 25 μL elusion 
 1 Ab +ve TNID0001 4.9 1.19 
 1 Ab +ve TNID0002 6.4 2.57 
 1 Ab +ve TNID0003 2.92 1.75 
 4 Ab +ve TNID0004 6.1 7.1 
 3 Ab +ve TNID0005 4.95 7 
2 Ab +ve TNID0006 6.1 2.8 
 2 Ab +ve TNID0007 3.3 1.28 
 SCF2105 1.77 1.32 
 UHWBC006 1.23 0.927 
 UHWBC010 1.57 1.08 
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Figure 6.6: Single plex and duplex analysis of the beta cell death hypomethylated MIR- 141 biomarker in individuals at-risk for T1D. 
A) The columns are presented as the mean of the duplicate values (column) ± SD (error bar). B) The columns represent the absolute level of hypomethylated MIR-141 (CpG-20 and CpG-
449, from TSS) DNA in 1 mL plasma samples collected from the at-risk group and age/gender matched nondiabetic subjects. C) The rate of beta cell death duplex biomarker in at-risk 
individuals and non-diabetic control subjects.  D) A comparison of the MIR-141 (CpG-20 and CpG -449, from TSS) biomarker level in at-risk against non-diabetic control subjects. The mean 
and SD interquartile range is shown. The data suggest that the duplex biomarker assay does not significantly discriminate the at-risk individuals from the non-diabetic control subjects (p > 






Despite the limited number of samples available, the work presented in this chapter suggests that 
young children at diagnosis onset, those who are at-risk of developing T1D and islet transplantation 
recipients are the most promising cohorts to be targeted for further analysis. The results from islet 
transplant recipients, although limited, has shown the validity of our initial hypothesis, that multiplex 
DMR based biomarkers show promise for detecting real-time beta cell death. Previously, DMR 
biomarkers based on differentially methylated CpG sites within the INS gene were successfully 
developed (Akirav et al. 2011, Bellin et al. 2017, Herold et al. 2015a). Although those authors showed 
this biomarker was significantly discriminating beta cell fragments in the periphery, the authors 
reported the presence of detectable hypomethylated INS signals in the control samples that could 
have originated (even partially) from non-beta cell origin. Detecting hypomethylated signals in control 
samples highlights the issue of limited sensitivity. To address this concern, Lehmann-Werman and 
colleagues studied the effect of multiplexing more than one INS CpG target on the sensitivity and 
specificity of DMR based biomarkers. They showed that multiplexing six specific CpG sites in the 
promoter region of the INS gene achieved maximum specificity and decreased the detected 
hypomethylated INS signal from 15-20% to 0.01% in non-beta cell tissue genomes. Consequently, 
multiplexing allowed discrimination of individuals with recent-onset T1D from healthy controls with 
100% sensitivity and specificity (Lehmann-Werman et al. 2016). Collectively, the data highlighted the 
power of multiplexing several adjacent CpGs. In parallel, we showed that multiplexing several CpG 
sites within the promoter region of MIR-200c/MIR-141 enhanced the sensitivity of our assay. We 
further observed that the discriminating power of the MIR-141 assay was low in comparison with that 
of the other singlpex assays developed, so we decided to carry on the project using only the MIR-200c 
cluster 1 plus the INS exon 2 and MIR-200c cluster 2 multiplex combination. Although MIR-141 
detected only low levels of beta cell death in cases, it was significantly different from the control 
samples (p < 0.05 Mann Whitney U Test); we may, therefore, revisit this assay in the future when more 




The cfDNA assays developed appear to successfully discriminate beta cell-derived cfDNA in serum 
from a small cohort of recently diagnosed children. The level of hypomethylated cfDNA was observed 
to be lower in samples taken six months after diagnosis, and this low level seems to persist. There are 
however some limitations to this analysis.  The number of serum samples available taken within one 
hour of venepuncture was small and longitudinal follow up of individuals was not possible as these 
samples were obtained through colleagues at University College London. The experiments require 
relatively large volumes of serum and therefore repeated analysis of individual samples was also not 
possible. Moving forward, samples collected from the Bart’s Oxford study of type 1 diabetes 
(http://www.bristol.ac.uk/translational-health-sciences/research/diabetes/research/box/) will allow 
the number of samples tested to be increased and provide longitudinal follow up. It is worth noting 
that the observation that cfDNA levels are increased close to diagnosis was also described by three 
independent reports that observed a significant upregulation of the level of circulating 
hypomethylated INS level in recently diagnosed T1D patients (Akirav et al. 2011, Fisher et al. 2015, 
Lehmann-Werman et al. 2016). Further, our finding was consistent with the observation reported by 
Fisher and colleagues who noticed that beta cell-specific cfDNA returns to basal levels by one-year 
post-diagnosis (Fisher et al. 2015), even though their samples were also cross-sectional. 
When the multiplex assay (MIR-200c cluster 1+ INS exon 2 and MIR-200c cluster 2) was tested in 
the blinded at-risk cohort, we observed a significant upregulation in hypomethylated cfDNA levels in 
those who were at risk of developing T1D (autoantibody positive) compared to the non-diabetic 
control subjects. This observation confirmed a previous report showing that the beta cell death 
biomarker (hypomethylated INS fragments) was high in 70 % of those at-risk of T1D (7 of 10 individuals 
who progress to clinical T1D) (Herold et al. 2015a). A workshop set up to examine cfDNA levels in 
blinded samples from “at risk” children and age matched-controls based on existing assays targeting 
the INS methylation variants alone, however, failed to replicate the increased levels in “at risk” 
children (Professor Raghu Mirmira, Personal communication). It is worth highlighting that we noticed 




first experimental sample batch. The data conducted from that experiment suggest that 
seroconversion at a younger age as well as having multiple autoantibodies in the circulation are two 
factors that may contribute to more aggressive destruction of beta cells. Unfortunately, we did not 
observe such correlation in the second sample batch tested. Nevertheless, this observation will be 
further explored when a larger number of samples are analysed. Next, the level of beta cell destruction 
in recently diagnosed adult T1D patients was analysed. The analysis of plasma samples showed that 
there was no significant difference between the levels of MIR-200c cluster 1/INS/MIR-200c cluster 2 
in adult T1D patients in comparison to non-diabetic control subjects. A larger sample size is required 
to confirm this conclusion.  
In addition to the early detection of ongoing beta cell destruction, circulating beta cell-specific 
DNA could be of clinical benefit for other purposes such as evaluating the outcome of islet 
transplantation and responses to clinical therapy. Beta cell-specific cfDNA signals were detected in the 
circulation of islet transplantation recipients, provided kindly by Dr Vito Lampasona (IRCCS San 
Raffaele Scientific Institute, Italy), as early as 1-hour post islet infusion when a pulse of beta cell death 
was observed. The striking elevation in hypomethylated cfDNA that was observed in the first-hour has 
also been reported by other groups (Bellin et al. 2017, Lehmann-Werman et al. 2016) and attributed 
to the rapid beta cell death immediately post-transplantation caused by the instant blood-mediated 
inflammatory reaction (IBMIR) and/or beta cell hypoxia (Kanak et al. 2014, Nilsson et al. 2011, Olsson 
et al. 2011). The level of hypomethylated cfDNA dropped sharply within 3 hours and reached baseline 
level 12 hours after infusion. It is postulated that close monitoring of the beta cell death signal in the 
days after islet transplantation will inform future outcomes. What the experiments carried out in this 
study highlighted is the added sensitivity of the multiplex assay developed as part of this project 








Chapter 7: Biomarkers of 






During the in-depth study of the mutual promoter regions of the genes MIR-200c/MIR-141 as a 
potential differentially methylated region in islets and a beta cell line (EndoC-βH1), we found out that 
this region had also been reported previously to be predominantly hypomethylated in prostate and 
breast epithelial cells (Lynch et al. 2016; Neves et al. 2010; Vrba et al. 2010). This encouraged us to 
investigate whether our developed assay could differentiate the normal genome from the genome of 
benign and malignant cells and whether our developed assay could be used in future as a staging 
biomarker for prostate and breast cancer. We initially studied the methylation level of CpG -20, from 
TSS, of the MIR-141 gene in well-established normal and malignant breast and prostate cell lines 
(described in more details in General Methods, Chapter 2, section 2.1.2.2). We further compared the 
level of miR-141-3p/5p expression to the methylation level of CpG-20 (MIR-141) in prostate epithelial 






7.1.1. MicroRNA Extraction 
Total RNA extraction (including microRNA) was performed using the miRNeasy Serum/Plasma Kit 
(Qiagen) according to the manufacturer’s protocol. RNA was eluted in 20 μL of nuclease-free H2O 
(Qiagen) and stored at -80⁰C.  
7.1.2. Quantification of microRNA 
The concentration of all RNA samples was measured using a Quantus™ Fluorometer (Promega) in 
combination with the QuantiFluor® RNA System (Promega) according to the manufacturer’s 
instruction. The High (7.8–500 ng/μL) or low (0.16–10 ng/μL) standard curve was constructed via the 
RNA standard (included in the kit) from which the concentration (ng/ μL) of unknown RNA was 
calculated. Oligonucleotides of miRNA Amplification 
Locked nucleic acid (LNA™) primers that amplify miR-141-3p, miR-141-5p and miR-200c-3p 
were purchased from EXIQON (Qiagen, UK). LNA bases are a class of high-affinity RNA analogues in 
which the ribose ring is “locked” the 3’ end conformation by a bridge of methylene between the 2’ 
oxygen and the 4’ carbon in the idyllic structure for Watson-Crick binding. The “Locked” structure 
improves the organisation of the base backbone and stacking, elevating the melting temperature, the 
stability and the binding affinity (Braasch and Corey 2001). The primer sequences are described in 
Table A.2, Appendix 1). 
7.1.3. Reverse Transcription PCR (RT-PCR) and ddPCR Analysis of Prostate Cancer Cell Lines. 
Ten ng of total RNA was reverse transcribed using a Universal cDNA Synthesis Kit II (Exiqon) 
according to the manufactural protocol. The ddPCR mixture reaction (20 μL) containing 10 μL of ddPCR 
1× EvaGreen ddPCR Supermix (Bio-Rad), a final concentration of 1X LNATM primers (Qiagen) and 9 μL 
of 1:1000 diluted cDNA template. No template (NTC) were used as a negative control. The 20 μL 
Reactions were premixed in LoBind Eppendorf tubes and dispensed along with 70 μL of droplet 




(Bio-Rad). The PCR cycles were as following; 95⁰C for 5 minutes, 40 cycles of 95⁰C for 30 seconds and 
58⁰C for 1 minute (Ramp-Rate 1.6⁰C/s), 4⁰C for 5 minutes, 90⁰C for another 5 minutes and then a final 






Polymerase Activation/ Denaturing Step 95⁰C, 5 minutes 
Annealing-Extension Step 
 58⁰C (ramp-rate 1.6⁰C/S), 1 minute 
Denaturing Step 95⁰C, 30 S 
X40 
Dye Stabilizing Step 4⁰C, 5 minutes 
Enzyme Deactivation Step 90⁰C, 5 minutes 
Sample Storing, 4⁰C, ∞ 





7.2.1. Methylation Analysis of MIR‐141 Promoter in Prostate and Breast Epithelial Cells 
We developed a methylation-specific assay to simultaneously quantitate hypermethylation or 
hypomethylation of MIR-141 DNA at position CpG -20 bp from TSS. We showed previously in chapter 
4 that CpG -20 bp is preferentially hypomethylated in islet and beta cell line (EndoC-βH1). Other 
studies have reported that the MIR-141 promoter is also hypomethylated in breast and prostate 
epithelial cells (Lynch et al. 2016; Vrba et al. 2010). Therefore, we tested our differentially methylated 
developed MIR-141 in a panel of prostate epithelial cell lines that either expressed hormonal androgen 
receptors (AR) such as PNT2 and LNcaP or had lost expression of the hormonal AR such as PC3 and 
DU145. The normal prostate cell line (PNT2) showed a predominant hypomethylation at CpG -20. The 
level of hypomethylation was shown to be increased in the benign (grade I) cell line (LNcaP). As the 
cells became malignant and lost expression of the AR, as in the DU145 cell line (grade II), we noticed 
that CpG-20 was shifting from hypomethylation into hypermethylation. Furthermore, analysing grade 
IV metastasis adenocarcinoma (PC3), showed that CpG -20 lost the hypomethylation completely. 
Collectively, the data suggest that CpG -20 in MIR-141 is hypomethylated in hormone-sensitive 
prostate cell lines and the level of hypomethylation is shifted toward hypermethylation as the 




Next, we aimed to test more cell lines that were or were not hormone responsive. Again, we 
tested our methylation sensitive assay on a prostate cancer grade III cell line (Vcap) and well-
established breast cancer cell lines that either express the progesterone receptor (PR) such as 
MCF10A, MCF7, T47D, ZR751 or do not express the receptors such as HS578T and MDA-MB231. ddPCR 
analysis of CpG -20 showed a similar conclusion (Figure 7.2B). The CpG -20 was hypomethylated in all 
cell lines that express ERs; the methylation status is shifted into hypermethylation when the receptor 






Figure 7.2: The methylation level of CpG -20 of MIR‐141 in Hormone sensitive and Hormone insensitive prostate 
and breast cell lines. 
 
 
The columns represent the level of methylated CpG -20 DNA copies in 1 μL (5 ng DNA sample). Each graph represents a 
single analysis. The DNA copies were normalised to 100 copies of beta-actin. A) ddPCR analysis of CpG-20 of MIR‐141 
methylation in prostate cancer cell lines LNCaP, DU145, and PC3 and normal prostate epithelial cell line PNT2. The data 
indicates that there are shifts from hypomethylation into hypermethylation at the CpG-20 in parallel with cancer 
progression and as hormone sensitivity is lost. B) ddPCR analysis of CpG-20 of MIR‐141 methylation in prostate and breast 
hormone sensitive cell lines (LNCaP, VcaP, MCF7, T46T and ZR-751) and hormone insensitive cell lines (DU145, PC3, HS-
578-T and MDA-MB-231). The data confirm the findings in the first experiment which showed that the methylation shift 





7.2.2. The Expression of miR-141-3p/5p and miR-200c-3p in Prostate Cell Lines 
 In addition to measuring the level of methylation in prostate and breast cell lines, we sought 
to discover whether measuring the expression of the miR-141 and its neighbouring gene miR-200c 
would add greater confirmation value to the assay. To fulfil this goal, we extracted total miRNA from 
cell pellets provided kindly by Professor Jeffrey Holly. The miRNA was converted into complementary 
DNA, which was used as a template for ddPCR analysis. Interestingly, we observed an upregulation in 
the level of expression of both miR-141-3p and miR-200c-3p in the benign cell line LNcaP, which had 
been shown previously (Figure 7.2) to have a higher level of hypomethylation level in comparison to 
the normal prostate epithelial cell line PNT2. The data also show complete suppression of the miR-
141-3p and miR-200c-3p expression in the PC3 cell line, which had shown a complete shift from 
hypomethylation to hypermethylation at CpG -20. We did not detect any change in the level of miR-
141-5p (Figure 7.3). 
  
 
Figure 7.3: The miR-141-3p/5p and miR-200c-3p expression level in prostate cancer cell lines. 
The columns represent DNA copy number in 1 μL DNA sample. The data illustrate that miR-141-3p but not miR-141-5p is 
correlated to the methylation status of CpG -20 of MIR-141. The data also show that the expression of miR-200c is 
correlated with the methylation of the CpG -20 as its expression is upregulated in PNT2 and LNcap cells (CpG -20 is 





7.2.3. The Methylome Level of Prostate Cell Lines at the Promoter of MIR-141 Gene 
There was a correlation between the methylation status of CpG -20 prostate cell lines and the 
expression of miR-141-3p and miR-200c. Therefore, we thought to investigate whether this correlation 
is specific to the CpG -20 site or it was related to the neighbouring CpG sites of the MIR‐200c/MIR‐141 
promoter. Therefore, a targeted next-generation bisulfite sequencing (tNGBS) was performed on 
PNT2, LNcaP and PC3 cell lines to sequence the MIR-200c/MIR-141 mutual promoter area as well as 
the encoding region of MIR-141 Chr12: 6,963,000-6,964,001 (described in Chapter 4; Section 4.1.2). 
The results showed that the MIR‐200c/MIR‐141 promoter was significantly hypermethylated in PC3 
while LNcaP and the normal epithelial (PNT2) cells were predominantly hypomethylated (Figure 7.4). 
Therefore, concluding that the methylation pattern of MIR-200c/MIR-141 could be linked to the 
hormonal sensitivity of the malignant cell, which may allow us to use the MIR-141 assay as a staging 












CpG (from MIR-200c TSS) 
The line chart presents the methylation status of the region Chr12: 6,963,000-6,964,001 where the CpG numbering is related to the transcription start site of MIR-200c. The data here show 
that the DNA methylation is completely shifted from hypomethylation in the normal PNT2 cells and the hormone sensitive LNcaP cells into predominantly hypermethylation in hormone 







The methylation pattern of the MIR-141 promoter has been reported previously to be 
predominantly hypomethylated in prostate and breast epithelial cells (Lynch et al. 2016; Neves et al. 
2010; Vrba et al. 2010). Further, miR-200c and miR-141 had also been reported previously to be 
upregulated in breast and prostate cancer (Brase et al. 2011, Li et al. 2016, Lynch et al. 2016, Vrba et 
al. 2010). Vrba and colleagues had profiled the methylation status of MIR-200c in multiple breast and 
prostate cell lines. Their data suggested that each of the adenocarcinoma cell lines that express miR-
200c and miR-141 (UACC-893, MB-468, UACC-1179, MCF-7, MB-453 and UACC-2087) has a 
hypomethylated MIR-200c promoter. Other malignant breast cancer cell lines where miR-200c and 
miR-141 were suppressed (MB-157, MB-231, HS-578T and BT-549) were predominantly 
hypermethylated at the promoter region of the MIR-200c gene. The study reached a similar conclusion 
in malignant prostate cancer cell lines (PC3 and PC3 B1) in which each cell line that had suppressed 
miR-200c and miR-141 levels are hypermethylated at the MIR-200c promoter. In contrast,  benign and 
less malignant prostate cancer cell lines (LNCaP and DU145, respectively) which is express miR-141 
and miR-200c had a hypomethylated MIR-200c promoter (Vrba et al. 2010). Our observation was in 
parallel with the findings by Vrba et al; the high throughput pyrosequencing data showed that the 
prostate cancer cell line (LNCaP) is predominently hypomethylated at MIR-200c/MIR-141 promoter 
and they express miR-141-3p (but not miR-141-5p) and miR-200c-3p according to our ddPCR analysis. 
On the other hand, PC3 cells that did not express either miR-141-3p or miR-200c-3p had a 
predominantly hypermethylated MIR-200c/MIR-141 promoter. Aberrant DNA methylation was 
hypothesised to co-occur with the cell losing expression of the androgen receptor (prostate cancer 
cells) and oestrogen/progesterone receptor (breast cancer cells). This hypothesis arose from the 
observation that, as mentioned, the expression of miR-141 and miR-200c is lost only in cell lines that 
have no steroid hormone receptors and are hypermethylated at CpG -20 of MIR-141. It would be very 
interesting to investigate this hypothesis in the future by expanding this study into populations of 








Chapter 8: General Discussion 






8. General Discussion  
8.1. Main Findings 
1. The novel finding from studies conducted during this PhD was the identification and confirmation 
of differentially methylated beta cell-specific CpG sites that can be targeted in multiplex assays 
which can be used to monitor beta cell death rate. In total, 867,926 CpG sites were analysed, of 
which, 3866 were differentially hypomethylated, and 4990 were differentially hypermethylated 
in islets when compared to PBMC genome. Comparing the genome-wide methylation EPIC 
analysis carried out in this study with methylation data from other tissues obtained from the 
Roadmap and ENCODE studies narrowed the CpG sites of interest to 425 hypomethylated and 228 
hypermethylated CpG targets that are uniquely differentially methylated in islet but not in liver, 
lung, thymus, pancreas, spleen and PBMC.  
 
2. The promoter region of the MIR-200c/MIR-141 gene (Chr12: 6,963,000-6,964,001) was one of the 
top beta cell methylation discriminating regions. In-depth analysis using a high throughput 
targeted bisulfite sequencing technique confirmed that CpG dinucleotides, within the MIR-
200c/MIR-141 promoter region, are predominately hypomethylated in the beta cell line genome. 
The targeted bisulfite sequencing data have also confirmed that the methylation level of these 
CpG sites is minimally affected by hyperglycaemia (~5%) and they are therefore potentially useful 
for monitoring beta cell death in individuals with diabetes. 
 
3. Multiplex DMR-based cfDNA assays of MIR-200c cluster 1/INS/ MIR-200c cluster 2 were designed 
and verified to be not affected by hyperglycaemia or proinflammatory environment. The designed 
assay shown to successfully discriminate cfDNA from the beta cell genome in the circulation of a 







4. Urine specimens have the potential to be used as an alternative source for cfDNA extraction and 
are attractive because of the non-invasive nature of the samples. Our initial experiments 
demonstrate that adding nucleic acid stabilising reagents such as 40 mM EDTA or commercial 
preservatives, are essential for protecting cfDNA from degradation in conditions where 
transportation of sample to the laboratory is required. It also could be needed for samples that 
will be stored for a long time (more than a year). A volume of < 0.5 mL is recommended for cfDNA 






8.2. General Discussion 
Biomarkers based on differential methylation CpG sites take advantage of two well-acknowledged 
principles of biology. First, cells injured in vivo release their DNA into the circulation, and second, each 
cell type has a unique methylation signature, usually within the genes that are vital for cellular identity 
and functions. Combining these two principles allowed development of a biomarker that can 
potentially discriminate the cfDNA derived from a specific dying cell. A distinctive feature of this 
approach is the ability to discriminate cfDNA derived from normal tissues without the need to identify 
a mutation or rely on a genomic variation analysis as is often the case for cfDNA analysis in cancers. In 
this thesis, we aimed to identify a panel of the beta cell-specific DMRs by generating genome-wide 
methylation profiles of the islet genome and comparing it to the methylome of PBMCs, the primary 
source of genomic contamination in peripheral blood. From these studies, we further aimed to 
establish a reliable DMR based multiplex biomarker assay to detect beta cell injury in the periphery 
for future use in individuals with preclinical T1D and clinical trial participants or those at risk of 
diabetes. The promoter region of the human MIR-200c/MIR-141 genes was found to contain several 
DMRs which were specific for the islet and beta cell line genome. Based on these results, several single 
plex assays that discriminate the beta cell genome were developed and verified. Multiplexing several 
assays novel beta cell-specific CpG targets, along with the previously designed exon 2 INS assay, 
greatly improved discrimination of beta cell cfDNA in the circulation of relatively small cohorts of first-
degree relatives “at-risk” of T1D, recently diagnosed paediatric patients, and islet transplant 
recipients.  
Almost all other reports in the literature describing differentially methylated beta cell-specific CpG 
sites were targeting the INS gene, with the exception of one study based on the Amylin gene (Olsen 
et al. 2016). One of the first reports discussing beta cell differentially methylated CpG sites, (Kuroda 
et al. 2009), had shown the CpG13 −19, CpG −69, CpG −135, CpG −206, and CpG −357, from TSS of the 
                                                          
13 The position of the CpG are related to the Transcription Start Site of the human insulin gene (upstream) and based on 





human INS promoter, were significantly hypomethylated in the beta cell but not elsewhere. Another 
report published similar evidence; revealing that CpGs +396 and +399 in the INS gene exon 1 were 
also specific for the pancreatic islet (Akirav et al. 2011).  
It is worth highlighting here that defining the location where DMRs likely lies within a gene was a 
subject of some controversy. For instance, the CpG dinucleotides within the INS promoter were 
chosen as potential targets for developing DMR based biomarkers for beta cell death (Husseiny et al. 
2014, Husseiny et al. 2012). Sequencing analysis carried out  by the same group showed that only CpG 
sites within the promoter region could be used as targets for developing DMR biomarkers, while other 
CpG sites fall within the intron 1, intron 2 and exon 2 of the INS gene were not explicitly methylated 
in the beta cell genome (Husseiny et al. 2014). A DMR biomarker based on these findings was 
developed and successfully discriminated cfDNA released from dying beta cell in serum/plasma 
samples isolated from T1D patients who received an islet graft (Husseiny et al. 2014) and recently 
diagnosed T1D patients (Fisher et al. 2015). Nevertheless, other groups were able to develop a DMR 
biomarker based on 2 CpG sites within the exon 1 of the gene (Akirav et al. 2011). The assay was 
successfully used to discriminate INS fragments released from dying beta cell in at-risk and recently 
diagnosed T1D patients (Akirav et al. 2011, Herold et al. 2015a, Usmani-Brown et al. 2014), patients 
who received an islet graft (Bellin et al. 2017), and in studying the outcomes of an immune therapy 
trial (teplizumab) (Lebastchi et al. 2013). Despite the fact that methylation sensitive INS assays have 
potential as powerful tools for monitoring beta cell death, a considerable amount of hypomethylated 
cfDNA was reported in control samples, which was not of beta cell origin (Bellin et al. 2017, Herold et 
al. 2015b, Husseiny et al. 2014, Lehmann-Werman et al. 2016).  
Neiman and colleagues have shown recently that the promoter of the INS gene was not solely 
hypomethylated in beta cells even within islets.  They demonstrated that it was also hypomethylated 
in other islet cells such as alpha and delta cells. Using high throughput pyrosequencing technology, 





including insulin and glucagon. Additionally, their data suggest that CpG dinucleotides located 
downstream of the TSS, but not those that are located in the promoter (upstream of the TSS), are 
more associated with the expression of the hormone, e.g. glucagon in alpha cell and insulin in the beta 
cell (Figure 8.1). Furthermore, global methylation analysis of over 450,000 CpG sites in alpha and beta 
cells using the Illumina Methylation 450K array revealed that 75% of DMRs lie within the distal 
regulatory regions (enhancer region) such as gene bodies or intergenic regions rather than in the 
promoter regions. This suggests that cell-type-specific gene expression might be associated with the 
enhancer methylome rather than the promoter methylome (Neiman et al. 2017). In agreement with 
this report, a comprehensive analysis of our EPIC data showed that the majority of DMRs lie within 
the gene body (hypomethylated: 37% and hypermethylated: 28%) while only 15% lie within the 
promoter region (Figure 4.1 in chapter 4). Taken together, these data could be the basis of changing 






Figure 8.1: The DNA methylation of human glucagon and insulin genes in islet cells. 
A) Bisulfite sequencing of CpG sites in the human glucagon promoter, from positions -356 to +271 relative to the 
transcription start site (arrow). B) Bisulfite sequencing of the  human insulin gene promoter, containing 13 CpG 
dinucleotides from positions -234 to +404 relative to the transcription start site (arrow). Adapted from (Neiman et al. 
2017). The figure showed that insulin gene is not only hypomethylated in beta cell but also found to be hypomethylated 
in alpha cell.  






8.3. Biomarkers of Beta Cell Death 
Although discriminating beta cell-derived cfDNA in multiple cohorts, DNA methylation-based 
biomarkers have some limitation that are worth to be highlighted. This approach of identifying beta 
cell death is mainly based on releasing beta cell DNA in the circulation during beta cell damage. As 
described in section 1.4.3 in the Introduction Chapter, beta cell destruction is most likely mediated by 
both necrotic and apoptotic mechanisms. Beta cell death by necrosis results in releasing the cellular 
content in the circulation and thereby, DMR assay can be applied to measure the rate of beta cell 
death. This may not be applied if the cell underwent apoptosis. Apoptosis involves the fragmentation 
of the genome, and therefore, beta cell cfDNA may not be detectable. Another limitation of using the 
differentially methylated biomarker is that circulating cfDNAs have a relatively short half-life in the 
periphery. Herold and colleges have estimated that the half-life of INS cfDNA is 117 ± 37 minutes 
(Herold et al. 2015a) Similar conclusion was also reported for circulating fetal cfDNA (Lo et al. 1999). 
Short half-life means that there is a chance for a pulse of beta cell death missing due to the need for 
rapid sample collection from the patient. Although considered a limitation, having a short half-life 
could be considered as a real-time reflection to beta cell death. Having a biomarker that survives for 
2 hours before clearance means that the levels of this cfDNA at any time could afford an almost “real-
time”  measure of loss of beta cell mass in T1D in a non-invasive manner.  
Another approach of detecting beta cell death is the measuring the level of circulating beta cell-
specific miRNAs. miR-375 is one of the first identified and most abundant islet-specific miRNAs and 
also one of the best-characterised microRNAs regarding its function (Poy et al. 2009). miR-375 plays a 
fundamental role in normal glucose homeostasis, alpha- and beta cell turnover, and adaptive beta cell 
expansion in response to increasing insulin demand in insulin resistance (Dotta et al. 2018, Joglekar et 
al. 2009, Poy et al. 2004, Poy et al. 2009). Dr Vito Lampasona’s laboratory had analysed the same 
plasma samples used detecting beta cell death in the circulation of islet graft recipient (samples were 
described in General Methods, Chapter 2, Section 2.1.2). They found a similar pattern in the levels of 





our laboratory for beta cell death (Figure 8.2). We can see from the figure that the level of the miR-
375 peaked 1-hour post the infusion, was similar to the elevated level of circulating cfDNA (Figure 6.5), 
and the level dropped after that, reaching the baseline level three days post infusion. We hypothesised 
that the longer time that miR-375 took to reach the baseline level is due to the stable nature of 
microRNAs in biological samples when compared with cfDNA. Although limited, the analysis showed 
similar results, and therefore, further studies will be needed to compare the advantages and 






































8.4. Strengths and Limitations  
One of the strengths of this study was the genome-wide bisulfite sequencing approach, and 
the combination of different advanced methods, such as DNA bisulfite conversion and targeted 
bisulfite DNA sequencing and droplet digital PCR analysis. Another strength was the ability of the 
multiplex assay method to identify beta cell fragments in different T1D cohorts, e.g. recently 
diagnosed T1D children, at-risk individuals and acute beta cell death post islet infusion in islet graft 
recipients. Further, the developed assay allowed to measure the rate of beta cell death directly.  
Multiplexing the INS assay with additional different gene was an innovative approach. To the best of 
our knowledge, all other researchers had multiplexed several CpG sites lying within the same gene 
(e.g. INS). We were able to increase the sensitivity of the developed assay through multiplexing CpG 
sites within the exon 2 of the INS gene with other beta cell methylation specific CpG sites in the mutual 
promoter region of MIR-200c/MIR-141. 
The following limitations are worth noting for this project: 
1. Although it is the best available beta cell model (Andersson et al. 2015, Gurgul-Convey et al. 
2015, Ravassard et al. 2011, Tsonkova et al. 2018), EndoC-βH1 cells were derived from human 
foetal pancreas tissue which may have a different methylation profile in comparison to adult 
beta cells. Our in-depth comparison of the methylation pattern in the MIR-200c/MIR-141 
promoter region in adult islet and EndoC-βH1 is ≤ 5.5 %, however; the methylation difference 
in other regions is unknown.   
2. While it is the most widely used approach for most whole-genome methylation analysis 
studies, the utmost advanced available Illumina Methylation EPIC array still covers only 3% of 
total human CpG sites.  
3. The sample size in each of clinical diabetes and “at risk” groups is limited although sample 





hypomethylated cfDNA resulting from normal beta cell turnover.  This is now ongoing within 
the BOX and TrialNet studies. 
4. Due to the limited number and volume of available clinical samples, we were unable to study 





8.5. Future Direction  
The data in this work provides support for a novel biomarker that discriminates beta cell 
fragments in the peripheral of the T1D patients. In order to take this study forward, ongoing 
experiments have been established. The developed assays are being repeated with larger samples 
size, including more control samples which will allow the definition of a threshold for positivity in the 
biofluid samples. In parallel with increasing the sample size of each tested cohort, available islet 
metabolic biomarker data, such as islet autoantibodies, C-peptide levels and the genetic risk test-1 
(GRS) score, will be integrated with hypomethylation level data to give a better understanding of the 
processes underlying T1D.  
Regarding technical approaches, the single plex assay CpG-449 of MIR-141 will be further 
optimised, and more experiments performed to test the impact of replacing the MIR-200c cluster 2 
assay by CpG-449 assay on the total discriminating power of the multiplex assay. It would also be 
useful to investigate the level of circulating miR-200c-3p and miR-141-3p in the sample of controls and 
T1D patients. Therefore the assay for extracting and quantifying miRNAs is undergoing optimisation. 
Another future aim is to optimise and validate a multiplex assay based on MIR-200c/MIR-141 
promoter CpG assays on prostate and/or breast cell lines with knockout hormonal receptors to test 
the hypothesis of changing the methylation pattern of MIR-200c/MIR-141 promoter as the hormonal 
receptor is lost. Furthermore, the multiplex assay will be tested on serum/plasma samples obtained 
from patients diagnosed with benign and malignant prostate and/or breast samples to confirm the 
viability of using MIR-200c/MIR-141 promoter methylation sensitive multiplex assay as a diagnostic 
and staging biomarker for breast and prostate cancer.  
Once the multiplex assay optimisation is finalised, it will be put forward as a candidate 
biomarker for evaluation in an international workshop, e.g. Biomarkers of Beta Cell Stress in Type 1 
Diabetes (BetaMarker), Human Islet Research Network, for discussion. If proven to be effective in the 
workshop setting, the multiplex cfDNA assay would provide a high throughput test for studies of 






In recent years, circulating beta cell-specific, DMR based biomarkers are recognised as 
potentially powerful tools to detect real-time beta cell death in multiple type 1 diabetes cohorts. 
Although highly promising, these differentially methylated cfDNA biomarkers are still in their infancy. 
The multiplex DMR-based, the beta cell-specific assay described here has the potential to track the 
rate of beta cell death in multiple cohorts with high specificity and sensitivity. Data generated by the 
assay may help predict the rate of progression of T1D and the survival of beta cells post-
transplantation. Further studies are required to validate and evaluate our findings in another biofluid 
sample, such as urine, and in larger cohorts as well as confirming the utility of the assay in clinical 
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A. Appendix A 
Detailed Protocols 





























For 1 mL serum/Plasma add: 
100 uL Proteinase K (20 mg/mL)
5 μg carrier RNA
1 mL ACL
335 μL buffer ATL
Incubate for 1 hour at 57⁰C
Add 3 mL buffer ACB
4 mL isopropanol
20 μL Sodium Acetate (3M)
Incubate on ice for 5 min
Pass through Qiagen column, yellow
Wash with 600 μL AW1
Then 500 μL AW2 
and then 500 μL ethanol
Dehydrate membrane for 10 min at 56⁰C
Elute with 40 μL EB buffer, incubate at 56⁰C for 10 min, spin at full speed for 5 min.


























































Cloning Using pGEM-T Easy Vector System I and DH5α Competent Cells 
-80 Reagents (upstairs): 
• Competent Cells (Invitrogen Cat# 18263-012) 
• SOC Medium (Invitrogen, Cat#15544-034) 
-20 Reagents (In Jody Box in post PCR Lab): 
• pGEM-T Easy Vector system I (Promega, Cat# A1360) 
• Ampicillin 100mg/mL (Sigma, Cat# A5354-10ML)  
RT Reagents: 
• imMedia Amp Blue agar media (Invitrogen, Cat# Q602-20) 
• Terrific Broth (Sigma, Cat#T5574-500 mL) 
• QiaPrep Spin miniprep Kit (Qiagen, Cat#27106) 
• Petri dishes, polystyrene (Sigma, Cat# P5731-500EA) 
• Spreader (Fisher Scientifics, Cat# 12322048)  
 
Day 1: 
A. Ligation Reaction: 
1. Briefly Centrifuge the pGEM-T Vector and control insert DNA tubes. 
2. Vortex the 2X rapid ligation buffer variously before each use 
3. Set up the 10 μL reaction in 0.5 mL tube 
 
Reagent Single Reaction volume 
2X Rapid Ligation Buffer 5 μL 
pGEM-T Easy Vector 1 μL 
T4 DNA Ligase 1 μL 
PCR Product14 / H2O 3 μL 
 
4. Set up the control reaction (Total 10 μL) 
 
Reagent Single Reaction volume 
2X Rapid Ligation Buffer 5 μL 
                                                          
14 DNA Product: is the PCR product band extracted from gel (agarose gel); when the band is cut from the gel 





pGEM-T Easy Vector 1 μL 
T4 DNA Ligase 1 μL 
Control Insert DNA 2 μL 
Nuclease Free H2O 1 μL 
 
5. Mix the reaction by pipetting, incubate overnight @ 4⁰C  
Day 2: 
B. Prepare the agar plates: 
1. Mix the imMedia™ pouch contents with 200 mL water. 
2. Microwave on MEDIUM setting for 2-3 minutes. Then mix the solution and reheat for 30 
seconds. 
3. Pour 20 mL into 8-10 agar plates, allow them to solidify at RT. 
 
C. Transformation Reaction: 
1. Thaw the competent cells in ice, once thawed, flick the tube to mix (Do not vortex). 
2. Add 3 μL of ligated reaction mix into ice cold 1.5 mL sterile Eppendorf tube 
(alternatively you can use the 15 mL sterile falcon tubes) 
3. Gently, transform 50 μL of competent cells into the 1.5 tube. 
4. Gently flick the tube to mix and incubate it on ice for 20 min 
5. Heat-shock the reaction @ EXACTLY 42⁰C for 45-50 sec (DO NOT SHACK) 
6. Immediately return the tubes into the ice and incubate it for 2 min. 
7. Add 250 μL of RT SOC medium to each ligation reaction transformation. 
8. Incubate @ 37⁰C for 1.5 hrs shaking (250 rpm) 
9. Plate 100 μL of each transformation culture onto duplicate agar plate. 
10. Incubate the plates overnight @ 37⁰C 
 
Day 3: 
1. In 15 mL sterile falcon tube add 5 mL of terrific broth + 100 μg/mL Amp (5 mL broth + 5 μL 
100mg/mL Ampicillin) 
2. Transfer 1 white colonies with 200 μL tip into the sterile 15 mL falcon tube. 
3. Incubate the plates overnight @ 37⁰C shaking @ 170 rpm 
 
Day 4: 
1. Pellet the 5mL bacterial overnight culture at >8000 rpm (6800 x g) for 3 min @ RT 
2. Follow the QiaPrep Spin miniprep Kit protocol 
3. Measure the eluted DNA concentration using the nanodrop. 
4. Send the proper concentration mixed with forward primer for sequencing 





Blood Collection and Processing using Roche Collection Tubes for cfDNA Study Experiments 
We collect 17mL of blood from patients who have consented to take part in the study. Blood 
is collected in two cell free DNA collection tubes (8.5 mL). Collected blood is stable at ambient 
temperature (18-25⁰C) for 7 days.   
Do not REFRIGERATE OR FREEZE. 
Procedure 
Safety Procedures Treat all blood samples as potentially infections. 
1. Collect specimen (avoid backflow):  
a. Place the patient’s arm in a downward position.  
b. Hold the tube with the stopper uppermost.  
c. Release tourniquet once blood starts to flow in the tube.  
d. Fill tube and confirm that the fill volume is between the minimum fill line and the 
nominal fill line.  
e. Ensure the tube contents do not touch the stopper or the end of the needle during 
collection. 
Do not fill the Cell-Free DNA Collection Tube above the nominal fill line. 
2. Remove tube from adapter. 
3. To avoid hemolysis, immediately mix by gentle inversion 8 to 10 times to ensure adequate 
mixing of the chemical additives with the blood specimen. 
 
Separating the plasma 
1. Separate plasma by centrifuging the sample 1600 x g for 15 minutes 
Do not exceed 1600 x g  
Do not Re-centrifuge. 
 
2. Decap Cell-Free DNA Collection Tube: a. Hold the tube firmly in one hand, using a solid 
base to support the arm.  
3. Twist the safety cap with the other hand to loosen.  
4. Carefully open the tube with a gentle twist and pull motion.  
5. Transfer 1 mL of plasma in 1.5 or 2 mL LoBind Eppendorf tubes. 






DNA Quantification Using the QuantiFluor® dsDNA System (Promega). 
Materials Required 
• QuantiFluor® dsDNA System (Cat. # E2670) 
• Quantus™ Fluorometer (Cat. # E6150) 
• Thin-walled 0.5 mL PCR tubes  
• Nuclease-free water 
Warm all assay components to room temperature before use. 
Note: If the Quantus™ Fluorometer was previously calibrated, you may not need to calibrate it again. 
Therefore, do not prepare blank and standard samples.  
Procedure  
1. Prepare 1X TE Buffer: Dilute the 20X TE Buffer 20-fold with nuclease-free water. 
2. Prepare Working Solution: Dilute the QuantiFluor® dsDNA Dye 1:400 in 1X TE buffer, and mix. 
3. Prepare Blank: Mix 2 μL of 1X TE buffer with 200 μL of QuantiFluor® dsDNA Dye working solution 
in an empty 0.5 mL PCR tube. Vortex well and protect tube from light. 
4. Prepare Standard: Add 2 μL of the provided DNA Standard (100 ng/μL) to 200 μL of QuantiFluor® 
dsDNA Dye working solution in an empty 0.5 mL PCR tube. Vortex well and protect tube from light. 
5. Prepare Unknown(s): Add 1 μL of unknown samples to 200 μL of QuantiFluor® dsDNA Dye working 
solution in 0.5 mL PCR tubes. Vortex well and protect tube from light. 
6. Incubate the prepared samples at room temperature for 5 minutes, protected from light. 
7. Select the dsDNA protocol on the Quantus™ Fluorometer. 
8. If needed, calibrate the Quantus™ Fluorometer by reading the blank (Step 3) and standard (Step 
4) samples in the Calibration screen, then select “Save”. 
9. Enter the volume of the unknown sample (1 μL used in Step 5) and desired concentration units. 








Bisulfite Converted DNA Quantification Using the QuantiFluor® dsDNA System (Promega). 
Materials Required  
• QuantiFluor® ssDNA System (Cat. # E3190)  
• Quantus™ Fluorometer (Cat. # E6150)  
• thin-walled 0.5mL PCR tubes (Cat. # E4941 or Axygen Cat. # PCR-05-C)  
• nuclease-free water  
Warm all assay components to room temperature before use.  
Note: If the Quantus™ Fluorometer was previously calibrated, you may not need to calibrate it 
again. Therefore, do not prepare blank and standard samples.  
Procedure 
1. Prepare 1X TE Buffer: Dilute the 20X TE Buffer 20-fold with nuclease-free water.  
2. Prepare Working Solution: High Standard Calibration: Dilute the QuantiFluor® ssDNA Dye 1:400 in 
1X TE buffer and mix thoroughly. Low Standard Calibration: Dilute the QuantiFluor® ssDNA Dye 
1:2,000 in 1X TE buffer, and mix.  
3. Prepare Blank: Add 200 µL of QuantiFluor® ssDNA Dye working solution in an empty 0.5 mL PCR 
tube. Protect tube from light.  
4. Prepare Standard: High Standard Calibration: Prepare a 400-ng standard by adding 4 µL of the 
provided ssDNA Standard to 200 µL of QuantiFluor® ssDNA Dye working solution in an empty 0.5 
mL PCR tube. Mix, and protect tube from light. Low Standard Calibration: Prepare a 10-ng standard 
by diluting the provided ssDNA Standard 1:100 in 1X TE buffer. Next, add 10 µL of diluted standard 
to 200 µL of QuantiFluor® ssDNA Dye working solution in a 0.5 mL PCR tube. Mix, and protect tube 
from light.  
5. Prepare Unknown(s): Add 1 µL of unknown samples to 200 µL of QuantiFluor® ssDNA Dye working 
solution in 0.5 mL PCR tubes. Vortex well and protect tube from light.  
6. Incubate the prepared samples at room temperature for 5 minutes, protected from light.  
7. Select the ssDNA protocol on the Quantus™ Fluorometer. If needed, calibrate the Quantus™ 
Fluorometer by reading the blank (Step 3) and standard (Step 4) samples in the Calibration screen, 
then select “Save”.  
8. Enter the volume of the unknown sample (1 µL used in Step 5) and desired concentration units. 






RNA Quantification using the QuantiFluor® RNA System (Promega). 
Materials Required  
• QuantiFluor® RNA System (Cat. # E3310)  
• Quantus™ Fluorometer (Cat. # E6150)  
• Thin-walled 0.5mL PCR tubes (Cat. # E4941 or Axygen Cat. # PCR-05-C)  
• Nuclease-free water  
Warm all assay components to room temperature before use.  
Note: If the Quantus™ Fluorometer was previously calibrated, you may not need to calibrate it 
again. Therefore, do not prepare blank and standard samples.  
Procedure 
1. Prepare 1X TE Buffer: Dilute the 20X TE Buffer 20-fold with nuclease-free water.  
2. Prepare Working Solution: High Standard Calibration: Dilute the QuantiFluor® RNA Dye 1:400 in 
1X TE buffer and mix thoroughly. Low Standard Calibration: Dilute the QuantiFluor® RNA Dye 
1:2,000 in 1X TE buffer, and mix.  
3. Prepare Blank: Add 200 µL of QuantiFluor® RNA Dye working solution in an empty 0.5 mL PCR 
tube. Protect tube from light.  
4. Prepare Standard: High Standard Calibration: Prepare a 500-ng standard by adding 5 µL of the 
provided RNA Standard to 200 µL of QuantiFluor® RNA Dye working solution in an empty 0.5mL 
PCR tube. Mix, and protect tube from light. Low Standard Calibration: Prepare a 10-ng standard 
by diluting the provided RNA Standard 1:100 in 1X TE buffer. Next, add 10 µL of diluted standard 
to 200 µL of QuantiFluor® RNA Dye working solution in a 0.5 mL PCR tube. Mix, and protect tube 
from light.  
5. Prepare Unknown(s): Add 1 µL of unknown samples to 200 µL of QuantiFluor® RNA Dye working 
solution in 0.5 mL PCR tubes. Vortex well and protect tube from light.  
6. Incubate the prepared samples at room temperature for 5 minutes, protected from light.  
7. Select the RNA protocol on the Quantus™ Fluorometer. If needed, calibrate the Quantus™ 
Fluorometer by reading the blank (Step 3) and standard (Step 4) samples in the Calibration screen, 
then select “Save”.  
8. Enter the volume of the unknown sample (1 µL used in Step 5) and desired concentration units. 






Amplification of Purified Genomic DNA Using the REPLI-g Mini Kit 
Procedure  
1. Prepare sufficient Buffer D1 (denaturation buffer) and Buffer N1 (neutralization buffer) for the 
total number of whole genome amplification reactions.  
a. Note: The total volumes of Buffer D1 and Buffer N1 given in Tables 1 and 2 are suitable 





















2. Place ▲ 2.5 µL or ● 5 µL template DNA into a microcentrifuge. The amount of template DNA 
should be >10 ng. A DNA control reaction can be set up using 10 ng (1 µl) control genomic DNA 
(e.g., REPLI-g Human Control Kit, cat. no. 150090). Adjust the volume with TE to the starting 
volume of your sample.  
3. Add ▲ 2.5 µL or ● 5 µL Buffer D1 to the DNA. Mix by vortexing and centrifuge briefly.  
4. Incubate the samples at room temperature for 3 min.  
5. Add ▲ 5 µL or ● 10 µL Buffer N1 to the samples. Mix by vortexing and centrifuge briefly.  
6. Thaw REPLI-g Mini DNA Polymerase on ice. Thaw all other components at room temperature, 
vortex, then centrifuge briefly. The REPLI-g Mini Reaction Buffer may form a precipitate after 
thawing. The precipitate will dissolve by vortexing for 10 s.  
7. Prepare a master mix on ice according to following Table. Mix and centrifuge briefly. 
a. Important: Add the master mix components in the order listed in the Table. After the 
addition of water and REPLI-g Mini Reaction Buffer, briefly vortex and centrifuge the 
mixture before the addition of REPLI-g Mini DNA Polymerase. The master mix should be 










Preparation of Buffer D1 
Component Volume (μL) 
Reconstituted Buffer DLB 9 
Nuclease-free water 32 
Total Volume 41 
Preparation of Buffer N1 
Component Volume (μL) 
Stop Solution 12 
Nuclease-free water 68 
Total Volume 80 
Component Volume (μL) 
Nuclease-free water ▲ 10 µl; ● 0 µl 
REPLI-g Mini Reaction Buffer 29 
REPLI-g Mini DNA Polymerase 1 






8. Add ▲ 40 µL or ● 30 µL of the master mix to ▲ 10 µL or ● 20 µL of denatured DNA (step 5).  
9. Incubate at 30°C for 10–16 h. Maximum DNA yield is achieved using an incubation time of 16 h. 
After incubation at 30°C, heat the water bath or heating block up to 65°C if the same water bath 
or heating block will be used in step 10. Note: If a thermal cycler is used with a heated lid, 
temperature of the lid should be set to 70 °C.  
10. Inactivate REPLI-g Mini DNA Polymerase by heating the sample for 3 min at 65°C.  
11. If performing PCR analysis, dilute the amplified DNA 1:20 and use 3 µL of diluted DNA for each 
PCR.  
a. Note: For dilution, add 2 µL amplified to 38 µL water or TE. Use 3 µL of the diluted DNA 
for each PCR. Optical density (OD) measurements do not accurately quantify double-
stranded DNA.  
12. Store amplified DNA at 4°C for short-term storage or –20°C for long-term storage. DNA amplified 
using the REPLI-g kit should be treated as genomic DNA with minimal freeze-thaw cycles. Storage 
of nucleic acids at low concentration over a long period of time may result in acid hydrolysis. We 




































































































































































































































This assay was conducted from  
MethyLight: a high-throughput 























AGCCTG- MGB 3' 
200 
This assay was conducted from 
ThermoFisher 
Assay ID:  Hs01629437_s1 



































































































































Table A.2: The microRNA LNA PCR primer sets. 
Primer Sets Target Sequence Product Number 
hsa-miR-200c-3p 5'UAAUACUGCCGGGUAAUGAUGGA’3 YP00204482 
hsa-miR-141-3p 5'UAACACUGUCUGGUAAAGAUGG’3 YP00204504 







Table A.3: The differentially hypomethylated CpG sites in the islet genome. 
  CpG ID chromosome position Gene Name islet PBMC aorta liver lung pancreas thymus spleen 
1 cg14516100 chr4 186560083 SORBS2 0.97 0.03 0.08 0.47 0.46 0.76 0.00 0.08 
2 cg01241974 chr13 36045613 NBEA 0.93 0.05 0.31 0.27 0.10 0.57 0.05 0.06 
3 cg03953626 chr6 30652396 KIAA1949 0.92 0.03 0.13 0.29 0.30 0.50 0.00 0.00 
4 cg16863795 chr17 79259536 SLC38A10 0.92 0.03 0.43 0.40 0.48 0.52 0.04 0.00 
5 cg04416414 chr19 14260587 LPHN1 0.92 0.09 0.05 0.44 0.23 0.82 0.08 0.03 
6 cg02332696 chr10 21783091 DNAJC1 0.91 0.13 0.31 0.24 0.47 0.94 0.00 0.21 
7 cg24540114 chr7 156812941 LMBR1 0.91 0.15 0.18 0.09 0.12 0.83 0.24 0.15 
8 cg01978215 chr2 145078303 GTDC1 0.90 0.09 0.07 0.32 0.27 0.81 0.17 0.06 
9 
cg10781408 chr1 151810899 
C2CD4D; 
LOC100132111 
0.90 0.03 0.03 0.02 0.26 0.85 0.00 0.03 
10 cg19112359 chr2 169346613 LASS6 0.90 0.05 0.37 0.32 0.35 0.38 0.00 0.07 
11 cg02599716 chr2 10231486   0.89 0.05 0.26 0.38 0.23 0.81 0.05 0.13 
12 cg08004073 chr3 169377725 MECOM 0.89 0.21 0.04 0.16 0.43 0.35 0.07 0.11 
13 cg01156663 chr4 154360462 DCHS2 0.89 0.04 0.30 0.00 0.47 0.67 0.02 0.23 
14 cg24717695 chr7 156809644 LMBR1 0.89 0.15 0.13 0.08 0.05 0.90 0.05 0.09 
15 cg14565903 chr19 14260591 LPHN1 0.89 0.17 0.04 0.45 0.23 0.81 0.00 0.03 
16 cg24922129 chr11 129242530   0.89 0.04 0.06 0.03 0.14 0.70 0.00 0.06 
17 cg01244015 chr2 225266843 FAM124B 0.88 0.08 0.34 0.21 0.17 0.71 0.03 0.02 
18 cg15487334 chr11 130536852   0.88 0.08 0.32 0.30 0.30 0.58 0.16 0.04 
19 cg27603467 chr3 71276631 FOXP1 0.88 0.07 0.03 0.29 0.27 0.77 0.35 0.05 
20 cg00580562 chr10 21789124 DNAJC1 0.88 0.08 0.45 0.11 0.41 0.85 0.05 0.08 
21 cg02789362 chr6 151937260 C6orf97 0.87 0.23 0.45 0.34 0.49 0.81 0.24 0.47 
22 cg09780180 chr16 73097903   0.87 0.06 0.18 0.16 0.46 0.67 0.04 0.18 
23 cg17734243 chr6 16701191 ATXN1 0.87 0.04 0.16 0.26 0.45 0.81 0.06 0.25 





25 cg02244556 chr13 23721125   0.87 0.11 0.30 0.25 0.47 0.79 0.02 0.22 
26 cg06844968 chr18 24131604 KCTD1 0.86 0.09 0.43 0.25 0.43 0.64 0.15 0.13 
27 cg06881639 chr1 89752648   0.86 0.05 0.28 0.03 0.08 0.68 0.00 0.00 
28 
cg20318143 chr19 17516370 BST2; MVB12A; BISPR 0.86 0.10 0.26 0.36 0.37 0.74 0.03 0.00 
29 cg11288670 chr2 54823611 SPTBN1 0.86 0.09 0.19 0.49 0.23 0.75 0.36 0.06 
30 cg25500021 chr7 31990121 PDE1C 0.86 0.29 0.45 0.47 0.41 0.93 0.38 0.37 
31 cg22393436 chr1 168489851   0.86 0.07 0.20 0.38 0.28 0.59 0.03 0.20 
32 cg16672535 chr1 6510652 ESPN 0.86 0.14 0.15 0.09 0.33 0.78 0.15 0.00 
33 cg24944092 chr12 12325234 LRP6 0.85 0.08 0.47 0.47 0.37 0.51 0.04 0.31 
34 cg15703773 chr7 156813342 LMBR1 0.85 0.12 0.20 0.25 0.15 0.59 0.05 0.12 
35 cg15007954 chr3 189348674 TP63 0.85 0.13 0.41 0.08 0.00 0.89 0.08 0.06 
36 cg06864895 chr12 46767683 SLC38A2 0.85 0.05 0.48 0.21 0.15 0.73 0.00 0.06 
37 cg15718448 chr8 111930817   0.85 0.07 0.44 0.48 0.25 0.76 0.03 0.08 
38 cg04026169 chr4 85422265   0.84 0.34 0.41 0.41 0.44 0.71 0.30 0.38 
39 cg12993990 chr1 224023540 TP53BP2 0.84 0.07 0.05 0.29 0.19 0.85 0.38 0.09 
40 
cg05021743 chr1 151810893 
C2CD4D; 
LOC100132111 
0.84 0.02 0.03 0.05 0.08 0.74 0.00 0.00 
41 cg04511697 chr4 173707334 GALNTL6 0.84 0.09 0.02 0.44 0.25 0.50 0.05 0.16 
42 
cg20138749 chr1 1370013 VWA1; LOC102724312 0.83 0.07 0.36 0.17 0.00 0.50 0.00 0.08 
43 
cg12095712 chr6 53803789 LOC101927189; LRRC1 0.83 0.05 0.47 0.45 0.44 0.60 0.03 0.39 
44 cg08424184 chr1 36043633 TFAP2E 0.83 0.08 0.10 0.33 0.20 0.77 0.00 0.08 
45 cg02330078 chr5 163704924   0.83 0.16 0.35 0.49 0.43 0.60 0.23 0.15 
46 cg02082588 chr3 130569372 ATP2C1 0.83 0.05 0.03 0.48 0.12 0.52 0.02 0.17 
47 cg00056468 chr3 88489988   0.83 0.24 0.11 0.33 0.44 0.63 0.20 0.12 
48 cg18517818 chr4 10956577   0.83 0.03 0.30 0.48 0.33 0.39 0.02 0.27 
49 cg05861512 chr14 94442960 SERPINA11 0.83 0.11 0.04 0.39 0.20 0.68 0.06 0.02 





51 cg16576285 chr12 719645 NINJ2 0.83 0.08 0.38 0.48 0.40 0.77 0.10 0.06 
52 
cg04296699 chr1 151810904 
C2CD4D; 
LOC100132111 
0.83 0.02 0.03 0.00 0.21 0.60 0.00 0.00 
53 cg15413430 chr3 122017315 ILDR1 0.82 0.04 0.47 0.35 0.44 0.53 0.07 0.24 
54 cg21429982 chr6 25138047 CMAHP 0.82 0.04 0.33 0.48 0.29 0.67 0.30 0.12 
55 cg20316549 chr7 156810507 LMBR1 0.82 0.15 0.00 0.02 0.03 0.54 0.00 0.09 
56 cg07585069 chr17 27039120 PROCA1 0.82 0.04 0.19 0.29 0.07 0.55 0.12 0.00 
57 cg18910298 chr14 101471487   0.81 0.12 0.46 0.17 0.22 0.58 0.27 0.03 
58 
cg15015892 chr1 151810887 
C2CD4D; 
LOC100132111 
0.81 0.02 0.05 0.07 0.22 0.83 0.00 0.00 
59 cg08703055 chr1 2232481 SKI 0.81 0.05 0.04 0.43 0.22 0.84 0.00 0.00 
60 cg02805890 chr6 27778836   0.81 0.07 0.16 0.13 0.45 0.58 0.04 0.04 
61 cg00449021 chr1 234658467   0.81 0.11 0.44 0.24 0.45 0.82 0.05 0.10 
62 cg22028698 chr6 24229032 DCDC2 0.81 0.06 0.40 0.38 0.25 0.52 0.31 0.02 
63 cg11920269 chr12 12107334   0.81 0.06 0.39 0.11 0.15 0.63 0.03 0.03 
64 cg23015118 chr1 2232527 SKI 0.81 0.01 0.08 0.41 0.28 0.90 0.05 0.00 
65 cg07188513 chr7 156807474 LMBR1 0.81 0.18 0.29 0.36 0.32 0.63 0.18 0.11 
66 cg01413582 chr6 30652688 KIAA1949 0.81 0.03 0.00 0.30 0.21 0.71 0.05 0.00 
67 
cg27083040 chr5 148810061 MIR145; LOC728264 0.80 0.29 0.03 0.29 0.29 0.83 0.35 0.30 
68 cg05267204 chr2 55360999 CCDC88A 0.80 0.07 0.15 0.01 0.27 0.66 0.41 0.10 
69 cg09742918 chr22 39570729 CACNA1I 0.80 0.04 0.47 0.48 0.27 0.39 0.05 0.02 
70 cg17564741 chr22 50060970 MLC1 0.80 0.05 0.24 0.33 0.28 0.45 0.00 0.00 
71 cg12099669 chr7 134035671 EXOC4 0.80 0.11 0.12 0.42 0.34 0.72 0.04 0.06 
72 cg11828180 chr1 41848985 HIVEP3 0.80 0.05 0.24 0.33 0.00 0.44 0.00 0.09 
73 
cg19255477 chr1 151810586 
LOC100132111; 
C2CD4D 
0.80 0.03 0.08 0.00 0.08 0.49 0.06 0.00 
74 cg24044052 chr2 231191662 SP140L 0.79 0.05 0.32 0.00 0.10 0.65 0.20 0.00 
75 cg16498647 chr8 21638104 GFRA2 0.79 0.15 0.33 0.35 0.45 0.32 0.13 0.09 





77 cg11041686 chr2 6780727   0.78 0.11 0.00 0.09 0.41 0.68 0.06 0.10 
78 cg04161194 chr18 42686603 LIN00907 0.78 0.06 0.21 0.38 0.26 0.64 0.09 0.16 
79 
cg21753092 chr2 238071771 SCLY; UBE2F-SCLY 0.77 0.08 0.47 0.43 0.15 0.37 0.13 0.30 
80 cg08636385 chr6 71816668   0.77 0.12 0.05 0.46 0.40 0.53 0.23 0.07 
81 cg01210113 chr16 11352835   0.77 0.14 0.25 0.10 0.18 0.79 0.12 0.06 
82 cg23243378 chr11 65406311 SIPA1 0.77 0.08 0.24 0.16 0.38 0.74 0.33 0.03 
83 cg06144905 chr17 27369780 PIPOX 0.77 0.31 0.46 0.13 0.24 0.49 0.15 0.11 
84 cg10308253 chr6 149803111 ZC3H12D 0.77 0.08 0.02 0.45 0.25 0.58 0.23 0.02 
85 cg01961252 chr12 54955143 PDE1B 0.77 0.24 0.04 0.44 0.24 0.65 0.04 0.04 
86 cg12435551 chr1 118679290 SPAG17 0.76 0.06 0.00 0.43 0.20 0.66 0.10 0.00 
87 cg15174393 chr12 125259081   0.76 0.07 0.02 0.14 0.29 0.46 0.21 0.03 
88 cg05246303 chr2 182321354 ITGA4 0.76 0.14 0.23 0.24 0.36 0.29 0.03 0.08 
89 
cg15039365 chr12 54806893 ITGA5; LOC102724050 0.76 0.10 0.27 0.21 0.44 0.80 0.05 0.35 
90 
cg15402210 chr2 63274857 LOC100132215; WDPCP 0.76 0.03 0.43 0.39 0.33 0.76 0.00 0.09 
91 cg26365776 chr10 23493947 LINC01552 0.75 0.12 0.05 0.20 0.00 0.44 0.08 0.00 
92 cg14799482 chr1 90135931 LRRC8C 0.75 0.09 0.13 0.30 0.37 0.55 0.16 0.25 
93 cg06492744 chr11 65406254 SIPA1 0.75 0.03 0.21 0.28 0.16 0.68 0.14 0.00 
94 cg00308914 chr5 17436715   0.75 0.21 0.49 0.48 0.40 0.51 0.14 0.09 
95 cg19246944 chr2 57926355 VRK2 0.75 0.06 0.43 0.40 0.18 0.42 0.00 0.14 
96 cg02187406 chr5 159933519 ADRA1B 0.74 0.03 0.21 0.34 0.23 0.49 0.03 0.13 
97 cg07991044 chr4 37782572   0.74 0.04 0.37 0.26 0.22 0.43 0.00 0.00 
98 cg22463795 chr19 13215292 CACNA1A 0.74 0.04 0.35 0.47 0.39 0.56 0.05 0.11 
99 cg15212266 chr1 21879311 ALPL 0.74 0.06 0.00 0.17 0.23 0.36 0.02 0.15 
100 cg11122351 chr1 214731459   0.74 0.07 0.45 0.43 0.39 0.55 0.04 0.00 
101 cg11543957 chr7 151536312 PRKAG2 0.73 0.03 0.25 0.33 0.40 0.50 0.00 0.06 
102 cg14100181 chr3 120613445   0.73 0.05 0.06 0.36 0.11 0.26 0.00 0.02 





104 cg03619352 chr5 179219098 ADAMTS2 0.73 0.15 0.19 0.43 0.28 0.47 0.15 0.03 
105 cg12640176 chr13 59527967   0.72 0.05 0.05 0.29 0.18 0.37 0.00 0.03 
106 cg02424365 chr16 73098356   0.72 0.15 0.04 0.26 0.28 0.68 0.00 0.04 
107 cg03226454 chr1 198608163 PTPRC 0.72 0.06 0.36 0.25 0.48 0.35 0.02 0.13 
108 cg20803910 chr17 6659375 XAF1 0.72 0.04 0.28 0.02 0.02 0.77 0.00 0.00 
109 cg04211581 chr6 152011656 ESR1 0.72 0.08 0.10 0.37 0.23 0.27 0.09 0.08 
110 cg03171003 chr2 111875934 ANAPC1 0.71 0.03 0.06 0.38 0.31 0.75 0.00 0.05 
111 cg19282042 chr5 73872818 ARHGEF28 0.71 0.05 0.36 0.00 0.00 0.39 0.10 0.08 
112 cg25951430 chr11 57192432 SLC43A3 0.71 0.04 0.15 0.35 0.16 0.63 0.03 0.08 
113 cg06367135 chr1 3077835 PRDM16 0.71 0.13 0.06 0.48 0.11 0.66 0.19 0.17 
114 cg12345460 chr9 131664788 LRRC8A 0.71 0.04 0.33 0.48 0.21 0.79 0.00 0.11 
115 cg21583284 chr8 134517821 ST3GAL1 0.71 0.04 0.25 0.29 0.34 0.56 0.00 0.12 
116 cg12441203 chr8 41121898 SFRP1 0.71 0.04 0.14 0.48 0.26 0.48 0.02 0.00 
117 cg18614381 chr19 31844182   0.71 0.11 0.21 0.25 0.27 0.37 0.10 0.29 
118 cg02852025 chr7 50348174 IKZF1 0.70 0.03 0.12 0.17 0.28 0.39 0.07 0.07 
119 cg08144172 chr1 41849203 HIVEP3 0.70 0.12 0.19 0.14 0.00 0.85 0.03 0.05 
120 
cg07706375 chr19 13947646 
MIR23A; MIR24-2; 
MIR27A 
0.70 0.08 0.04 0.34 0.36 0.75 0.12 0.00 
121 cg18848965 chr7 8402432   0.70 0.08 0.09 0.13 0.15 0.24 0.03 0.00 
122 cg24570841 chr1 36043401 TFAP2E 0.69 0.03 0.05 0.04 0.22 0.50 0.00 0.03 
123 cg22932808 chr7 41909842   0.69 0.14 0.12 0.34 0.44 0.22 0.17 0.15 
124 cg02367708 chr2 136873789 CXCR4 0.69 0.07 0.11 0.25 0.12 0.10 0.00 0.10 
125 cg21642108 chr8 25056560 DOCK5 0.69 0.05 0.40 0.15 0.29 0.64 0.06 0.08 
126 cg13727629 chr1 2232469 SKI 0.69 0.05 0.05 0.47 0.16 0.71 0.00 0.00 
127 cg18285788 chr7 157475692 PTPRN2 0.69 0.07 0.12 0.16 0.09 0.66 0.08 0.41 
128 cg21603744 chr8 110020783   0.69 0.09 0.33 0.39 0.42 0.54 0.10 0.27 
129 cg12265878 chr7 41995442   0.68 0.07 0.08 0.40 0.08 0.37 0.04 0.11 
130 cg10611580 chr17 75319942 SEPT9 0.68 0.09 0.02 0.36 0.31 0.82 0.00 0.05 





132 cg01274170 chr19 19562378 GATAD2A 0.68 0.04 0.38 0.43 0.20 0.27 0.08 0.17 
133 cg23974730 chr6 71022072   0.68 0.04 0.13 0.21 0.32 0.37 0.07 0.14 
134 cg21393051 chr1 209585310   0.68 0.05 0.30 0.19 0.37 0.33 0.00 0.04 
135 cg20047483 chr1 32732649 LCK 0.67 0.08 0.19 0.32 0.27 0.58 0.02 0.11 
136 cg08273995 chr4 7526521 SORCS2 0.67 0.08 0.00 0.48 0.17 0.00 0.27 0.00 
137 cg18107094 chr8 110020924   0.67 0.12 0.36 0.23 0.46 0.58 0.09 0.19 
138 cg19978318 chr2 215430983 VWC2L 0.67 0.20 0.30 0.42 0.47 0.40 0.31 0.27 
139 cg01592063 chr2 229338518   0.66 0.07 0.38 0.40 0.38 0.41 0.06 0.00 
140 cg05226008 chr8 13372132 DLC1 0.66 0.13 0.01 0.49 0.34 0.35 0.18 0.11 
141 cg23889684 chr22 36556813 APOL3 0.66 0.04 0.10 0.03 0.00 0.46 0.03 0.00 
142 cg27391934 chr1 1369948 VWA1 0.66 0.09 0.11 0.41 0.11 1.00 0.10 0.18 
143 
cg15533448 chr15 66331737 MIR4311; MEGF11 0.66 0.25 0.00 0.18 0.23 0.75 0.16 0.15 
144 cg11964154 chr1 225616987 LBR 0.66 0.09 0.36 0.21 0.40 0.30 0.03 0.13 
145 cg17753212 chr17 6659562 XAF1 0.66 0.02 0.30 0.05 0.09 0.52 0.00 0.00 
146 cg15272173 chr7 157585857 PTPRN2 0.65 0.35 0.29 0.20 0.27 0.68 0.23 0.43 
147 cg20503768 chr18 45958576   0.65 0.09 0.24 0.30 0.34 0.52 0.09 0.33 
148 cg04474049 chr7 116164533 CAV1 0.65 0.28 0.03 0.33 0.07 0.37 0.24 0.30 
149 cg01141339 chr5 72530198   0.65 0.13 0.00 0.05 0.08 0.73 0.00 0.03 
150 cg05135593 chr5 49726092 EMB 0.65 0.04 0.28 0.24 0.25 0.30 0.00 0.00 
151 cg11132443 chr3 130569560 ATP2C1 0.65 0.04 0.02 0.24 0.05 0.38 0.03 0.03 
152 cg25831439 chr2 161508799   0.64 0.03 0.44 0.39 0.30 0.46 0.00 0.14 
153 cg18708013 chr6 149803206 ZC3H12D 0.64 0.07 0.06 0.47 0.29 0.45 0.09 0.03 
154 cg07137934 chr5 180230911 MGAT1 0.64 0.08 0.38 0.20 0.24 0.61 0.00 0.00 
155 cg12183993 chr19 36352005 KIRREL2 0.64 0.11 0.08 0.02 0.09 0.72 0.09 0.06 
156 cg14972362 chr3 153346517   0.64 0.06 0.09 0.25 0.22 0.24 0.11 0.00 
157 cg16220180 chr4 2789378   0.64 0.06 0.32 0.17 0.22 0.68 0.05 0.05 
158 cg20713639 chr11 65185684   0.64 0.02 0.04 0.10 0.00 0.64 0.11 0.00 





160 cg06697540 chr10 125532925 CPXM2 0.64 0.05 0.47 0.25 0.33 0.34 0.09 0.07 
161 cg18241962 chr17 75385432 SEPT9 0.63 0.02 0.36 0.08 0.23 0.24 0.00 0.07 
162 cg24725729 chr12 13741741 GRIN2B 0.63 0.06 0.11 0.43 0.18 0.40 0.06 0.15 
163 cg06613765 chr17 8771055 PIK3R6 0.63 0.03 0.41 0.35 0.08 0.35 0.04 0.05 
164 cg03819134 chr5 957584   0.62 0.02 0.22 0.18 0.33 0.55 0.00 0.03 
165 cg19147390 chr19 4911058 UHRF1 0.62 0.12 0.33 0.48 0.10 0.50 0.00 0.08 
166 cg10655396 chr19 1077244 HMHA1 0.62 0.07 0.47 0.13 0.31 0.74 0.00 0.00 
167 cg09418290 chr1 247579319 NLRP3 0.62 0.02 0.37 0.48 0.38 0.55 0.00 0.13 
168 cg08905567 chr14 76777176   0.62 0.05 0.06 0.23 0.10 0.12 0.00 0.00 
169 cg20495843 chr6 106973166 AIM1 0.61 0.03 0.39 0.15 0.26 0.32 0.00 0.05 
170 cg17175926 chr4 110280376   0.61 0.02 0.11 0.45 0.20 0.44 0.03 0.00 
171 cg12645202 chr11 32442615 WT1 0.61 0.04 0.09 0.23 0.06 0.52 0.03 0.02 
172 cg11953749 chr10 119590608   0.61 0.09 0.28 0.39 0.04 0.66 0.00 0.04 
173 cg04951822 chr12 113345598 OAS1 0.61 0.20 0.09 0.00 0.18 0.50 0.17 0.10 
174 cg24461557 chr6 43892169 LINC01512 0.61 0.03 0.03 0.38 0.40 0.65 0.00 0.22 
175 cg24208921 chr3 107843436 LINC01215 0.60 0.03 0.32 0.38 0.05 0.32 0.03 0.00 
176 cg14415629 chr11 33033607   0.60 0.05 0.27 0.23 0.47 0.45 0.00 0.24 
177 cg12679308 chr7 101500014 CUX1 0.59 0.05 0.05 0.01 0.02 0.48 0.00 0.00 
178 cg22074858 chr1 89488430 GBP3 0.59 0.04 0.26 0.20 0.15 0.35 0.03 0.03 
179 cg05408831 chr5 179220797 LTC4S 0.59 0.02 0.00 0.43 0.29 0.60 0.07 0.00 
180 cg16101156 chr2 6034874   0.59 0.11 0.33 0.37 0.44 0.38 0.07 0.23 
181 
cg06603374 chr12 54807242 ITGA5; LOC102724050 0.58 0.05 0.00 0.14 0.38 0.71 0.00 0.00 
182 cg07385423 chr1 161697574 FCRLB 0.58 0.03 0.20 0.43 0.38 0.38 0.00 0.07 
183 cg20836437 chr10 116561232   0.58 0.03 0.49 0.44 0.25 0.37 0.00 0.08 
184 cg16549694 chr1 42204925 HIVEP3 0.58 0.05 0.14 0.20 0.07 0.45 0.00 0.00 
185 cg09119967 chr20 9494838 C20orf103 0.58 0.13 0.20 0.00 0.23 0.24 0.04 0.10 
186 cg23859630 chr6 32160455 GPSM3 0.58 0.05 0.33 0.27 0.00 0.42 0.17 0.00 





188 cg17095460 chr11 119468660   0.58 0.06 0.40 0.34 0.40 0.29 0.00 0.27 
189 cg04841176 chr5 94363209 MCTP1 0.57 0.03 0.09 0.32 0.21 0.33 0.03 0.04 
190 cg13492139 chr9 111063281   0.57 0.05 0.43 0.36 0.19 0.37 0.04 0.04 
191 cg03317202 chr15 85873141   0.57 0.03 0.11 0.36 0.18 0.27 0.00 0.13 
192 cg15898874 chr15 96515411   0.57 0.11 0.45 0.47 0.11 0.38 0.00 0.16 
193 cg19641327 chr5 15834770 FBXL7 0.57 0.18 0.18 0.24 0.29 0.21 0.20 0.27 
194 cg17276853 chr17 32964596 TMEM132E 0.56 0.01 0.18 0.46 0.16 0.41 0.00 0.15 
195 cg27089606 chr19 40166804   0.56 0.04 0.45 0.36 0.37 0.49 0.03 0.20 
196 cg02285920 chr19 17958956 JAK3 0.56 0.04 0.24 0.29 0.25 0.45 0.00 0.00 
197 cg03983213 chr7 157475737 PTPRN2 0.56 0.02 0.05 0.18 0.16 0.67 0.13 0.28 
198 cg03362174 chr2 26893188   0.56 0.08 0.20 0.06 0.00 0.71 0.14 0.00 
199 cg20704394 chr7 104992726 SRPK2 0.55 0.03 0.05 0.44 0.00 0.29 0.00 0.00 
200 cg11318133 chr12 113416268 OAS2 0.55 0.05 0.00 0.00 0.03 0.26 0.04 0.00 
201 cg05493841 chr12 70083096 BEST3 0.55 0.07 0.02 0.36 0.18 0.39 0.03 0.02 
202 cg13938774 chr9 117148097 AKNA 0.55 0.04 0.05 0.07 0.40 0.52 0.05 0.10 
203 cg01254505 chr19 17516470 BST2 0.55 0.04 0.14 0.11 0.11 0.50 0.00 0.00 
204 cg18454299 chr15 44959064 PATL2 0.55 0.03 0.37 0.45 0.40 0.19 0.16 0.15 
205 cg21988119 chr19 17958937 JAK3 0.55 0.03 0.48 0.35 0.37 0.65 0.00 0.00 
206 cg11683232 chr12 65063404 RASSF3 0.55 0.03 0.00 0.07 0.03 0.37 0.03 0.00 
207 cg20918937 chr17 3443626 TRPV3 0.55 0.07 0.25 0.41 0.27 0.11 0.11 0.11 
208 cg14003853 chr15 86250370 AKAP13 0.55 0.03 0.04 0.47 0.02 0.27 0.02 0.02 
209 cg21689664 chr18 7525014   0.54 0.05 0.41 0.08 0.22 0.23 0.03 0.04 
210 cg22507304 chr14 77709189 TMEM63C 0.54 0.06 0.40 0.36 0.23 0.30 0.00 0.15 
211 cg23140245 chr8 121255387 COL14A1 0.54 0.02 0.00 0.44 0.17 0.49 0.00 0.12 
212 cg05479471 chr14 106733112   0.54 0.06 0.31 0.16 0.31 0.15 0.00 0.18 
213 cg15122111 chr3 130569453 ATP2C1 0.54 0.03 0.02 0.27 0.02 0.16 0.00 0.00 
214 cg15177359 chr17 73840750 UNC13D 0.53 0.06 0.23 0.44 0.06 0.53 0.18 0.00 
215 cg27613992 chr20 4350779   0.53 0.09 0.37 0.43 0.20 0.31 0.04 0.14 





217 cg04385966 chr3 183273741 KLHL6 0.53 0.03 0.06 0.15 0.17 0.30 0.08 0.11 
218 cg26940178 chr1 76082888   0.53 0.04 0.21 0.23 0.03 0.50 0.03 0.04 
219 cg02744457 chr11 95374866   0.52 0.03 0.01 0.00 0.25 0.39 0.21 0.06 
220 cg11657018 chr5 111115809 C5orf13 0.52 0.08 0.02 0.38 0.05 0.44 0.02 0.02 
221 cg06596806 chr16 66550178 TK2 0.52 0.05 0.35 0.15 0.14 0.38 0.05 0.07 
222 cg24680129 chr12 13318625   0.52 0.06 0.12 0.20 0.18 0.58 0.03 0.18 
223 cg03368155 chr6 10206281   0.51 0.03 0.11 0.17 0.29 0.31 0.05 0.12 
224 cg11883221 chr19 54352786   0.51 0.07 0.00 0.30 0.13 0.23 0.00 0.02 
225 cg22999025 chr17 19977025   0.50 0.05 0.05 0.29 0.18 0.45 0.03 0.05 
226 cg19769780 chr1 226863138 ITPKB-IT1; ITPKB 0.50 0.03 0.39 0.24 0.08 0.26 0.03 0.00 
227 cg06483857 chr5 88692528   0.50 0.03 0.02 0.20 0.06 0.27 0.02 0.03 








Table A.4: The differentially hypermethylated CpG sites in the islet genome. 
  CpG ID chromosome position Gene Name islet PBMC aorta liver lung pancreas thymus spleen 
1 cg10469980 chr16 85660101 KIAA0182 0.25 0.83 0.94 0.83 0.76 0.06 1 0.88 
2 cg17546376 chr3 42172097 TRAK1 0.23 0.93 0.93 0.65 0.81 0.15 0.96 0.89 
3 cg27580905 chr2 39335085 SOS1 0.46 0.88 0.65 0.81 0.81 0.37 0.94 0.86 
4 cg03628365 chr6 47432121   0.21 0.85 0.84 0.6 0.71 0.17 0.93 0.93 
5 cg11802553 chr14 65203330 PLEKHG3 0.27 0.9 0.6 0.61 0.86 0.12 0.95 0.77 
6 cg00866541 chr16 85395661   0.36 0.89 0.89 0.56 0.67 0.3 0.95 0.88 
7 cg02261780 chr19 3097728 GNA11 0.43 0.98 0.7 0.79 0.63 0.18 1 0.85 
8 cg09934926 chr4 111115815 ELOVL6 0.2 0.92 0.93 0.53 0.83 0.24 0.98 0.96 
9 cg18603224 chr5 33945764 SLC45A2 0.21 0.81 0.72 0.64 0.62 0.12 0.74 0.74 
10 cg23520688 chr14 103294740 TRAF3 0.26 0.92 0.86 0.84 0.7 0.23 0.97 0.92 
11 cg03395247 chr20 42991330 HNF4A 0.42 0.84 0.79 0.94 0.67 0.29 0.95 0.65 
12 cg06849167 chr11 61449886 DAGLA 0.22 0.94 0.79 0.83 0.79 0.09 1 0.86 
13 cg24214659 chr12 117534674 TESC 0.2 0.95 0.64 0.52 0.7 0.11 0.92 0.82 
14 cg25576801 chr10 49932245 WDFY4 0.45 0.85 0.92 0.87 0.62 0.37 0.97 0.69 
15 cg07971156 chr10 114779609 TCF7L2 0.18 0.9 0.95 0.65 0.59 0.1 0.9 0.88 
16 cg06000659 chr3 168235595 EGFEM1P 0.16 0.72 0.91 0.52 0.93 0.15 0.97 0.88 
17 cg06830529 chr9 124960107 MORN5 0.32 0.79 0.67 0.69 0.67 0.22 0.96 0.92 
18 cg15426815 chr12 7071712 MIR-200C 0.31 0.86 0.92 0.97 0.63 0.13 0.88 0.7 
19 cg16887521 chr10 76784798 KAT6B 0.19 0.88 0.61 0.81 0.54 0.08 0.96 0.83 
20 cg00333703 chr7 123384406 WASL 0.31 0.9 0.92 0.63 0.83 0.33 0.98 0.89 
21 cg00053338 chr5 24714819   0.45 0.88 0.87 0.66 0.76 0.22 0.9 0.78 
22 cg11432036 chr2 226335995 NYAP2 0.23 0.87 0.81 0.76 0.69 0.15 0.98 0.91 
23 cg23008238 chr5 2112459   0.13 0.93 0.8 0.94 0.93 0.18 0.97 0.98 





25 cg04340203 chr19 891986 MED16 0.2 0.86 0.93 0.85 0.63 0 1 0.7 
26 cg18318843 chr8 42354362 SLC20A2 0.23 0.91 0.56 0.63 0.76 0.35 0.85 0.88 
27 cg00698688 chr19 49055432 SULT2B1 0.16 0.86 0.83 0.63 0.54 0 0.67 0.89 
28 cg08549388 chr11 73780601 C2CD3 0.24 0.93 0.89 1 0.71 0.1 0.96 0.94 
29 cg10097015 chr2 55336607   0.2 0.88 0.92 1 0.8 0.07 0.98 0.9 
30 cg18630178 chr14 93154484 RIN3 0.34 0.98 0.57 0.82 0.86 0.15 0.94 0.92 
31 cg09299592 chr22 40765943 SGSM3 0.38 0.8 0.65 0.74 0.56 0.36 0.86 0.83 
32 cg14058329 chr7 27183946 HOXA5 0.37 0.95 0.76 0.68 0.51 0.32 0.96 1 
33 cg16117653 chr19 4891192 ARRDC5 0.44 0.93 0.73 0.63 0.8 0.3 0.96 1 
34 cg09010597 chr17 78945313   0.28 0.83 0.84 0.57 0.86 0.09 0.89 0.69 
35 cg02933228 chr11 64611087 CDC42BPG 0.41 0.84 0.97 0.88 0.57 0.16 0.83 0.65 
36 cg21819409 chr8 120981915 DEPTOR 0.22 0.92 0.71 0.6 0.71 0.09 0.96 0.86 
37 cg04564944 chr2 45558218   0.21 0.86 0.84 0.67 0.64 0.18 0.98 0.98 
38 cg09023515 chr3 185120477 MAP3K13 0.31 0.89 0.92 0.88 0.88 0.16 0.96 0.91 
39 cg18048027 chr2 130502532   0.38 0.92 0.57 0.57 0.7 0.27 0.97 0.86 
40 cg06464468 chr11 65414413 SIPA1 0.41 0.9 0.72 0.94 0.87 0.5 0.92 0.94 
41 cg17540105 chr6 151634287 AKAP12 0.18 0.88 0.86 0.74 0.8 0.13 0.88 0.6 
42 cg01300791 chr16 30448949   0.33 0.88 0.69 0.62 0.64 0.17 0.97 0.86 
43 cg04772968 chr19 12404112 ZNF44 0.44 0.93 0.7 0.51 0.72 0.24 0.97 0.86 
44 cg22280402 chr7 143596849 FAM115A 0.3 0.84 0.73 0.57 0.79 0.24 0.98 0.89 
45 cg27473972 chr6 140864365   0.22 0.84 0.85 0.62 0.8 0.22 1 0.83 
46 cg03377039 chr2 214150956 SPAG16 0.2 0.86 0.79 0.94 0.96 0.16 0.93 0.91 
47 cg01998947 chr7 45500384   0.27 0.91 0.88 0.64 0.85 0.21 0.96 0.86 
48 cg09583041 chr15 60245804   0.1 0.94 0.6 0.53 0.51 0.02 1 0.8 
49 cg21475076 chr1 1100493   0.17 0.96 0.88 0.83 0.89 0.2 1 0.96 
50 cg14527983 chr20 44562104 PCIF1 0.45 0.95 0.96 1 0.98 0.21 1 0.89 
51 cg14285795 chr17 71179222   0.33 0.9 0.69 0.89 0.82 0.21 0.97 0.76 
52 cg03540794 chr5 2112109   0.32 0.97 0.86 0.93 0.96 0.19 0.88 0.87 





54 cg20331074 chr6 154936706   0.19 0.89 0.77 0.69 0.67 0.13 0.94 0.79 
55 cg22165171 chr7 139763574 PARP12 0.45 0.91 0.62 0.67 0.63 0.21 0.96 0.79 
56 cg05327192 chr11 75133593 KLHL35 0.22 0.9 0.85 0.51 0.71 0.26 1 0.98 
57 cg06562682 chr19 35607199 FXYD3 0.27 0.77 0.83 0.75 0.64 0.2 0.94 0.92 
58 cg22846423 chr3 177089912   0.25 0.92 0.93 0.86 0.56 0.16 1 0.91 
59 cg10112854 chr16 80839183 CDYL2 0.49 0.83 0.57 0.66 0.67 0.53 1 0.81 
60 cg16852463 chr1 15523893 TMEM51 0.28 0.85 0.82 0.63 0.81 0.15 1 0.95 
61 cg12092005 chr14 99532847   0.37 0.88 0.88 0.83 0.79 0.32 1 0.83 
62 cg08801866 chr21 46323808 ITGB2 0.42 0.93 0.61 0.91 0.74 0.58 0.92 0.96 
63 cg18631905 chr8 76723432   0.09 0.83 0.58 0.54 0.58 0 0.76 0.7 
64 cg02327604 chr7 808834 HEATR2 0.37 0.78 0.57 0.83 0.69 0.37 0.86 0.7 
65 cg19147912 chr17 17596386 RAI1 0.46 0.88 0.78 0.66 0.59 0.32 0.76 0.74 
66 cg16205506 chr3 172266828   0.2 0.92 0.87 0.7 0.58 0.11 0.97 0.96 
67 cg23893406 chr1 81918997   0.36 0.91 0.88 0.62 0.75 0.25 0.95 0.94 
68 cg10374063 chr13 93496028 GPC5 0.12 0.91 0.73 0.86 0.68 0.14 0.93 0.74 
69 cg06445944 chr5 67586928 PIK3R1 0.15 0.9 0.85 0.51 0.64 0.09 0.98 0.89 
70 cg23822445 chr12 107699855   0.26 0.9 0.85 0.72 0.89 0.3 1 0.91 
71 cg11929042 chr20 19222240 SLC24A3 0.43 0.92 0.82 0.72 0.55 0.25 1 0.75 
72 cg09879666 chr3 157218259 VEPH1 0.32 0.78 0.88 0.61 0.52 0.13 0.88 0.66 
73 cg27104398 chr22 43343739 PACSIN2 0.3 0.92 0.92 0.67 0.79 0.09 0.93 0.8 
74 cg13917433 chr3 52722445 GNL3; SNORD19 0.16 0.93 0.88 0.52 0.83 0.24 0.88 0.89 
75 cg01485975 chr5 156486186 HAVCR1 0.19 0.88 0.7 0.61 0.71 0.11 0.9 0.91 
76 cg01090766 chr2 232660830 COPS7B 0.18 0.93 0.53 0.87 0.83 0.17 0.93 0.87 
77 cg19521573 chr8 74226253 RDH10 0.18 0.9 0.83 0.8 0.62 0.09 0.89 0.82 
78 cg19738924 chr18 24126072 KCTD1 0.38 0.89 0.67 0.9 0.9 0.16 0.96 0.83 
79 cg14435796 chr5 55529207 ANKRD55 0.24 0.92 0.58 0.63 0.7 0.18 0.93 0.79 
80 cg02275413 chr12 101253527 ANO4 0.18 0.87 0.66 0.56 0.6 0.21 0.96 0.78 
81 cg09959931 chr4 671550 MYL5 0.38 0.85 0.81 0.8 0.88 0.13 1 0.78 





83 cg19176928 chr2 139378922   0.27 0.9 0.91 0.64 0.64 0.24 0.98 0.74 
84 cg24345224 chr4 39593037 UGDH-AS1; SMIM14 0.5 0.93 0.53 0.65 0.73 0.21 0.92 0.94 
85 cg05245094 chr16 85669572 KIAA0182 0.46 0.82 0.97 0.68 0.91 0.42 0.94 0.88 
86 cg05780620 chr2 216139649   0.33 0.82 0.84 0.52 0.52 0.17 0.88 0.73 
87 cg14698646 chr17 46684750 HOXB7 0.5 0.91 0.77 0.52 0.73 0.11 1 0.9 
88 cg13362636 chr2 82289309   0.33 0.86 0.81 0.82 0.87 0.19 0.82 0.83 
89 cg07815009 chr8 95220797 CDH17 0.4 0.97 0.87 0.56 0.78 0.24 0.92 0.92 
90 cg01621034 chr6 26190175 HIST1H4D 0.39 0.93 0.85 0.91 0.85 0.2 0.98 1 
91 cg18621357 chr12 65204725   0.49 0.89 0.81 0.86 0.91 0.44 1 0.98 
92 cg03207666 chr7 27183950 HOXA5 0.47 0.89 0.81 0.74 0.53 0.43 0.95 1 
93 cg11489916 chr18 48320337   0.19 0.94 0.95 0.95 0.95 0.19 0.98 1 
94 cg21151735 chr12 64172919 TMEM5 0.5 0.92 0.58 0.68 0.84 0.29 0.92 0.81 
95 cg05859179 chr20 11963914   0.3 0.93 0.81 0.54 0.95 0.28 0.98 0.97 
96 cg06179152 chr16 1069368   0.16 0.93 0.59 0.71 0.52 0.08 1 0.59 
97 cg00823303 chr7 129753942 KLHDC10 0.2 0.9 0.83 0.54 0.75 0.14 0.99 0.72 
98 cg08885197 chr1 10747107 CASZ1 0.21 0.86 0.74 0.63 0.53 0.42 1 0.94 
99 cg09097152 chr6 25411727 LRRC16A 0.36 0.88 0.97 1 0.8 0.27 0.97 0.88 
100 cg06532789 chr5 159008967   0.16 0.83 0.51 0.6 0.61 0.1 0.94 0.84 
101 cg11055649 chr6 31868764 ZBTB12; C2 0.36 0.97 0.9 0.64 0.76 0.31 0.94 0.96 
102 cg21270847 chr1 164604806 PBX1 0.35 0.97 0.93 0.91 0.96 0.63 0.89 0.95 
103 cg04584649 chr18 10525075 NAPG 0.21 0.75 0.64 0.73 0.67 0.14 0.96 0.67 
104 cg05923197 chr14 54418804 BMP4 0.45 0.97 0.81 0.75 0.51 0.23 0.77 0.76 
105 cg22663604 chr1 156030671 RAB25 0.25 0.93 0.53 0.83 0.63 0.27 0.87 0.85 
106 cg00128386 chr16 85665539 KIAA0182 0.46 0.95 0.9 0.82 0.87 0.19 1 0.97 
107 cg06518884 chr3 185822021 ETV5 0.44 0.88 0.97 0.96 0.71 0.38 0.98 0.91 
108 cg16584696 chr10 134875826   0.39 0.87 0.93 0.89 0.89 0.41 0.87 0.93 
109 cg02482497 chr1 153610672 C1orf77 0.09 0.91 0.87 0.88 0.74 0.08 1 0.81 
110 cg17744883 chr5 2279386   0.25 0.84 0.56 1 0.71 0.23 0.85 0.91 





112 cg25271413 chr7 115274698   0.25 0.85 0.59 0.67 0.75 0.17 0.91 0.74 
113 cg19449588 chr16 11841810   0.34 0.89 0.83 0.55 0.78 0.17 1 0.98 
114 cg17624315 chr2 202289200 TRAK2 0.23 0.88 0.66 0.53 0.55 0.08 0.98 0.74 
115 cg12753366 chr10 696321 DIP2C; C10orf108 0.33 0.98 0.65 0.9 0.78 0.31 0.96 0.97 
116 cg15026620 chr11 114081012 ZBTB16 0.3 0.93 0.67 0.75 0.75 0.33 0.9 0.87 
117 cg14945501 chr21 29765810   0.22 0.76 0.69 0.85 0.57 0.21 0.98 0.77 
118 cg15655180 chr20 36831960   0.3 0.87 0.65 0.69 0.78 0.14 0.91 0.88 
119 cg10321146 chr19 6822469 VAV1 0.35 0.9 0.6 0.69 0.56 0.18 0.92 0.93 
120 cg23206888 chr2 242833114   0.41 0.96 1 0.98 0.95 0.5 1 0.89 
121 cg09479341 chr17 40119957 CNP 0.31 0.87 0.68 0.78 0.68 0.08 0.89 0.67 
122 cg24145118 chr10 2777041   0.04 0.97 0.83 0.69 0.7 0.06 0.86 0.79 
123 cg00611395 chr16 86696049   0.17 0.81 0.53 0.65 0.57 0.06 0.8 0.71 
124 cg16279954 chr13 45444906   0.27 0.9 0.95 0.89 0.76 0.07 0.92 0.64 
125 cg27420224 chr20 43029777 HNF4A 0.32 0.97 0.8 0.55 0.83 0.36 1 0.85 
126 cg18794321 chr7 39446233 POU6F2-AS1; POU6F2 0.22 0.84 0.8 0.52 0.7 0.14 0.89 0.9 
127 cg07954572 chr12 117484521 TESC 0.38 0.73 0.73 0.67 0.76 0.24 0.92 0.85 
128 cg05177409 chr7 24620338 MPP6 0.25 0.85 0.85 1 0.55 0.27 0.99 0.84 
129 cg00722323 chr19 31883537   0.36 0.83 0.59 0.7 0.67 0.31 0.87 0.83 
130 cg05422457 chr16 73266282   0.22 0.89 0.95 0.52 0.94 0.22 0.97 0.98 
131 cg08488569 chr4 1749241   0.5 0.92 0.88 0.54 0.61 0.44 1 0.86 
132 cg19455171 chr14 100943011 WDR25; WDR25 0.34 0.87 0.78 0.94 0.84 0.36 0.96 0.83 
133 cg15707050 chr11 77706483 INTS4 0.26 0.87 0.59 0.63 0.84 0.06 1 0.85 
134 cg26206456 chr8 992484   0.27 0.87 0.66 0.68 0.62 0.13 0.76 0.79 
135 cg00920423 chr15 58505242   0.22 0.92 0.67 0.59 0.76 0.11 0.98 0.79 
136 cg06062600 chr10 73977495 ANAPC16 0.29 0.92 0.73 0.57 0.6 0.15 0.93 0.73 
137 cg04853831 chr3 63178269   0.21 0.87 0.66 0.58 0.88 0.27 0.87 0.88 
138 cg04331189 chr2 160142303 WDSUB1 0.27 0.9 0.81 0.73 0.78 0.11 0.93 0.87 
139 cg25076325 chr11 118135407 MPZL2 0.48 0.93 0.73 0.64 0.65 0.56 0.9 0.96 





141 cg22162694 chr13 24323408 MIPEP 0.26 0.92 0.62 0.62 0.55 0.03 0.97 0.9 
142 cg05460314 chr1 56880573   0.2 0.92 0.89 0.52 0.79 0.15 0.95 0.92 
143 cg03610849 chr11 129080113   0.16 0.88 0.83 0.67 0.68 0.16 0.91 0.82 
144 cg15869931 chr6 141347930   0.24 0.69 0.95 0.78 0.55 0.11 0.92 0.74 
145 cg13704328 chr20 10845549   0.31 0.82 0.63 0.86 0.55 0.06 1 0.93 
146 cg05444103 chr3 80745928   0.24 0.86 0.83 0.8 0.68 0.14 0.93 0.78 
147 cg26456435 chr16 31053788   0.45 0.84 0.7 0.94 1 0.69 0.97 0.79 
148 cg19835136 chr19 17650995 FAM129C 0.43 0.85 0.53 0.68 0.71 0.65 0.8 0.94 
149 cg00386007 chr10 50143337 WDFY4 0.39 0.9 0.63 0.75 0.68 0.24 1 0.8 
150 cg01951142 chr1 33787084 A3GALT2 0.33 0.89 0.8 0.54 0.7 0.17 0.88 0.78 
151 cg05283521 chr7 157259343   0.14 0.94 0.94 0.96 0.93 0.42 0.89 0.96 
152 cg04086239 chr16 24067174 PRKCB 0.46 0.9 0.59 0.67 0.85 0.46 1 0.97 
153 cg09609106 chr1 204062352 SOX13 0.18 0.74 1 0.52 0.92 0.15 1 0.94 
154 cg06169135 chr2 231825892   0.48 0.75 0.83 0.75 0.76 0.43 0.71 0.8 
155 cg13007502 chr2 208795771 PLEKHM3 0.33 0.97 0.98 0.83 0.77 0.2 0.96 0.98 
156 cg07665877 chr4 189456103 LINC01060 0.28 0.93 0.87 1 0.68 0.07 0.97 0.97 
157 cg08937768 chr4 3342519 RGS12 0.5 0.88 0.91 0.67 0.68 0.65 0.87 0.97 
158 cg11647944 chr12 5603148 NTF3 0.27 0.91 0.75 0.72 0.63 0.14 1 0.94 
159 cg20647386 chr8 120981885 DEPTOR 0.09 0.93 0.66 0.53 0.7 0.07 0.98 0.85 
160 cg05391892 chr2 208795620 PLEKHM3 0.2 0.97 0.67 0.72 0.85 0.17 0.96 0.89 
161 cg27100471 chr11 794834 SLC25A22 0.35 0.98 0.9 0.54 0.53 0.13 0.91 0.89 
162 cg25610697 chr9 676996 KANK1 0.3 0.93 0.53 0.63 0.67 0.11 0.98 0.98 
163 cg08663896 chr17 40064311 ACLY 0.26 0.8 0.75 0.78 1 0.26 0.96 0.88 
164 cg23613317 chr5 154092109 LARP1 0.19 0.92 0.93 0.88 0.59 0.05 0.97 0.82 
165 cg10143991 chr6 2962408 SERPINB6 0.24 0.78 0.93 0.79 0.64 0.12 0.97 0.85 
166 cg14744743 chr18 13871595   0.45 0.72 0.58 0.56 0.66 0.33 0.84 0.72 
167 cg18967533 chr19 51472725 KLK6 0.46 0.75 0.73 0.69 0.88 0.52 0.82 0.88 
168 cg01914045 chr21 31588584 CLDN8 0.22 0.78 0.85 0.54 0.55 0.23 0.78 0.79 





170 cg19698648 chr7 150759376 SLC4A2 0.3 0.89 0.59 0.64 0.69 0.13 0.95 0.9 
171 cg00366037 chr10 76781121 MYST4 0.21 0.89 0.8 0.81 0.68 0.14 0.97 0.92 
172 cg15431338 chr15 25568711   0.25 0.88 0.76 0.66 0.68 0.23 0.98 0.86 
173 cg09480190 chr16 85671771 KIAA0182 0.43 0.97 0.76 0.88 0.67 0.53 1 0.98 
174 cg03235759 chr1 121264025 EMBP1 0.18 0.91 0.79 0.58 0.57 0.11 1 0.72 
175 cg08329684 chr16 4932620 PPL 0.3 0.91 0.74 0.67 0.67 0.33 1 0.95 
176 cg02442572 chr7 1303351   0.26 0.93 0.96 0.88 0.87 0.34 1 0.94 
177 cg25390025 chr17 64225568 APOH 0.13 0.81 0.94 0.55 0.77 0.24 0.98 1 
178 cg13553204 chr1 26504548 CNKSR1 0.17 0.8 0.9 0.83 0.66 0.1 1 0.81 
179 cg03962019 chr1 41807865   0.29 0.77 0.82 0.81 0.67 0.39 1 0.8 
180 cg19755928 chr3 128723491 CCDC48 0.31 0.92 0.91 1 0.51 0.33 0.96 0.74 
181 cg04493700 chr10 126827067 CTBP2 0.21 0.92 0.87 0.57 0.61 0.16 0.97 0.8 
182 cg17616537 chr17 46628663 HOXB3 0.37 0.87 0.94 0.83 0.72 0.1 0.95 0.91 
183 cg26806260 chr15 62356512   0.25 0.92 0.75 0.83 0.61 0.15 0.93 0.89 
184 cg19794481 chr12 7073240 MIR-141 0.24 0.94 0.93 0.92 0.59 0.17 0.95 0.92 
185 cg12031809 chr5 132074036 KIF3A 0.33 0.77 0.77 0.81 0.54 0.11 0.87 0.81 
186 cg01835489 chr12 53299310 KRT8 0.29 0.92 0.91 0.53 0.71 0.17 0.97 0.92 
187 cg00298399 chr1 17697934 PADI6 0.47 0.86 0.69 0.59 0.57 0.39 0.87 0.84 
188 cg13354219 chr3 143437525 SLC9A9 0.47 0.93 0.85 0.77 0.69 0.26 0.97 0.93 
189 cg24154336 chr11 64659044 MIR192; MIR194-2 0.44 0.95 0.94 0.51 0.85 0.24 1 0.93 
190 cg22843428 chr17 48620231 EPN3 0.39 0.87 0.73 0.72 0.75 0.24 0.95 0.89 
191 cg03461013 chr2 38374414 CYP1B1-AS1 0.43 0.73 0.57 0.84 0.7 0.33 0.94 0.88 
192 cg16992440 chr12 53777383 SP1 0.35 0.74 0.62 0.66 0.55 0.08 0.86 0.68 
193 cg01218903 chr17 74911481 MGAT5B 0.42 0.97 0.98 0.89 0.75 0.47 1 0.92 
194 cg17785018 chr19 17644601 FAM129C 0.42 0.79 0.59 0.58 0.65 0.07 1 0.71 
195 cg15404473 chr8 30421394 RBPMS 0.37 0.91 0.75 0.94 0.89 0.33 1 1 
196 cg23982489 chr12 55979609   0.21 0.89 0.82 0.69 0.79 0.27 0.95 0.93 
197 cg24296440 chr4 99946235 METAP1 0.33 0.91 0.76 0.87 0.79 0.3 1 0.9 





199 cg00131213 chr19 39105043 MAP4K1 0.3 0.82 0.68 0.57 0.71 0.1 0.9 0.92 
200 cg09627060 chr10 134875916   0.28 0.84 0.93 0.75 0.84 0.21 0.91 0.91 
201 cg24702147 chr12 7071814 MIR-141; MIR-200C 0.12 0.96 0.52 0.8 0.56 0.12 0.78 0.76 
202 cg03255783 chr1 6487540 ESPN 0.49 0.78 0.74 0.7 0.73 0.38 0.9 0.77 
203 cg04568522 chr9 97273915   0.17 0.84 0.9 0.72 0.65 0.19 0.91 0.75 
204 cg14151930 chr7 83652513 SEMA3A 0.18 0.92 0.74 0.81 0.65 0.13 0.89 0.83 
205 cg01651311 chr11 117704570 FXYD6-FXYD2 0.2 0.94 0.69 0.54 0.68 0.09 0.9 0.77 
206 cg09978753 chr10 14709476 FAM107B 0.47 0.91 0.88 0.9 0.91 0.45 0.98 0.92 
207 cg08287262 chr4 146652027 C4orf51 0.25 0.91 0.86 0.51 0.72 0.18 0.97 0.9 
208 cg11371119 chr6 167321666   0.31 0.92 0.76 0.72 0.74 0.2 1 0.8 
209 cg15203905 chr1 2845514   0.32 0.82 0.93 0.69 0.65 0.28 0.89 0.85 
210 cg23142048 chr14 103691563   0.36 0.71 0.67 0.85 0.69 0.18 0.91 0.73 
211 cg18792131 chr1 1099166   0.17 0.97 0.94 0.91 0.68 0.19 0.94 0.97 
212 cg18037117 chr4 186732207 SORBS2 0.1 0.9 0.78 0.54 0.68 0.05 0.8 0.83 
213 cg21304163 chr19 35607221 FXYD3 0.27 0.88 0.97 0.88 0.78 0.12 1 0.96 
214 cg22412649 chr13 24736569 SPATA13; MIR-2276 0.33 0.88 0.92 0.71 0.81 0.25 1 0.87 
215 cg22942897 chr1 3680345 CCDC27 0.39 0.84 0.85 0.86 0.88 0.21 0.97 0.95 
216 cg22115892 chr4 177198411   0.25 0.96 0.97 0.89 0.92 0.1 0.98 0.95 
217 cg00207921 chr1 1098992   0.19 0.79 0.86 0.86 0.62 0.18 0.9 0.84 
218 cg09088720 chr5 154091976 LARP1 0.11 0.78 0.76 0.75 0.52 0.12 0.9 0.8 
219 cg07716832 chr2 46077837 PRKCE 0.2 0.88 0.87 0.71 0.71 0.25 0.89 0.92 
220 cg19928703 chr13 30143971 SLC7A1 0.25 0.87 0.53 0.53 0.67 0.11 0.94 0.88 
221 cg06202269 chr7 152272077   0.46 0.86 0.89 0.98 0.94 0.32 0.95 0.88 
222 cg06733198 chr10 10504299 LOC101928322 0.4 0.91 0.96 0.54 0.8 0.22 0.89 0.96 
223 cg13958794 chr19 7483010 ARHGEF18 0.37 0.83 0.51 0.84 0.66 0.39 0.98 0.9 
224 cg10916196 chr12 43966266   0.31 0.91 0.64 0.79 0.53 0.15 0.81 0.78 
225 cg00340024 chr1 92907439   0.39 0.9 0.83 0.85 0.8 0.2 1 0.94 
226 cg07335712 chr5 81682829   0.23 0.93 0.71 0.6 0.67 0.13 0.98 0.94 





228 cg14819525 chr20 11113825   0.41 0.94 0.84 1 0.82 0.36 1 0.93 
229 cg22154447 chr13 78550069 EDNRB 0.42 0.78 0.81 0.56 0.68 0.29 0.88 0.82 
230 cg03554522 chr4 170556187 CLCN3 0.28 0.9 0.93 1 0.77 0.17 0.98 0.98 
231 cg02217206 chr8 94509022 LINC00535 0.27 0.92 0.91 0.76 0.73 0.23 0.91 0.79 
232 cg06912665 chr5 154092290 LARP1 0.21 0.89 0.75 0.68 0.64 0.07 0.95 0.81 
233 cg14053169 chr1 92907586   0.3 0.86 0.8 0.74 0.88 0.2 1 0.98 
234 cg03895045 chr14 39703160 MIA2 0.16 0.92 0.71 1 0.7 0.16 0.93 0.93 
235 cg17112518 chr14 69223221   0.21 0.87 0.91 0.6 0.72 0.25 0.91 0.89 
236 cg09381559 chr1 201567256   0.15 0.75 0.85 0.68 0.51 0.07 0.87 0.74 
237 cg20385489 chr5 95069104 RHOBTB3 0.23 0.92 0.95 0.69 0.85 0.12 0.95 0.9 
238 cg14840561 chr12 121418741 HNF1A 0.13 0.96 1 0.56 0.79 0.11 0.81 1 
239 cg04151661 chr14 99603265   0.4 0.94 1 0.86 0.96 0.27 1 0.83 
240 cg21924314 chr1 99636927   0.2 0.91 0.75 0.73 0.78 0.15 0.95 0.85 
241 cg06876892 chr16 833231 MSLNL 0.25 0.92 0.64 0.6 0.55 0.19 0.92 0.69 
242 cg05275001 chr11 64497598 RASGRP2 0.35 0.91 0.91 0.87 0.76 0.11 0.94 0.65 
243 cg22342893 chr3 10150224 FANCD2OS 0.49 0.88 0.56 0.92 0.83 0.37 0.91 0.81 
244 cg25335876 chr2 16894580   0.21 0.75 0.75 0.86 0.8 0.2 0.87 0.69 
245 cg24635930 chr5 38148572   0.23 0.92 0.67 0.76 0.71 0.16 0.9 0.91 
246 cg11023565 chr6 47428069   0.28 0.93 0.95 0.56 0.71 0.18 0.94 0.96 
247 cg03519907 chr5 154092426 LARP1 0.19 0.87 0.95 0.83 0.68 0.08 0.89 0.82 
248 cg10427062 chr5 60728124 ZSWIM6 0.16 0.9 0.8 0.59 0.59 0.18 0.96 0.76 
249 cg17470674 chr5 1702470   0.24 0.96 0.86 0.9 0.86 0.11 0.92 0.81 
250 cg23659134 chr10 106035168 GSTO2 0.27 0.75 0.65 0.64 0.65 0.16 0.79 0.86 
251 cg25567444 chr1 223018067 DISP1 0.25 0.92 0.86 0.88 0.87 0.29 0.98 0.96 
252 cg10911997 chr11 34653201 EHF 0.33 0.85 0.94 0.53 0.81 0.23 0.97 0.93 
253 cg23167506 chr7 1303302   0.17 0.78 0.58 0.78 0.63 0.27 0.96 0.91 
254 cg26516974 chr6 52475065   0.28 0.75 0.74 0.57 0.52 0.08 0.89 0.71 
255 cg05973305 chr5 87168997   0.27 0.85 0.57 0.78 0.81 0.19 0.93 0.85 





257 cg02624246 chr12 7073264 MIR-141 0.23 0.85 0.89 0.91 0.58 0.15 1 0.89 
258 cg00985983 chr22 30728510 SF3A1 0.37 0.81 0.54 0.73 0.62 0.21 0.98 0.69 
259 cg14943002 chr11 47256035 DDB2 0.18 0.93 0.91 0.56 0.63 0.18 0.97 0.98 
260 cg11797316 chr8 74226661 RDH10; RDH10-AS1 0.2 0.9 0.92 0.87 0.69 0.17 0.93 0.96 
261 cg08155365 chr1 228319085   0.37 0.92 0.61 0.79 0.64 0.15 0.94 0.91 
262 cg08297393 chr2 100937505 LONRF2 0.16 0.88 0.93 0.94 0.69 0.19 0.83 0.8 
263 cg13779682 chr1 11131308 EXOSC10 0.47 0.83 0.89 0.82 0.91 0.28 0.95 0.97 
264 cg16347969 chr2 38673971   0.45 0.85 0.89 0.78 0.91 0.37 0.85 0.81 
265 cg09834343 chr15 32942910 SCG5 0.13 0.92 0.89 0.51 0.82 0.17 0.93 0.73 
266 cg21668964 chr3 182360510   0.47 0.88 0.8 1 0.62 0.43 1 0.89 
267 cg04951677 chr6 137316259   0.14 0.9 0.66 0.67 0.62 0.09 0.98 0.78 
268 cg25726425 chr2 234637574 
UGT1A10; UGT1A6; 
UGT1A8;  
UGT1A4; UGT1A3; UGT1A9; 
 UGT1A7; UGT1A5 
0.23 0.91 0.87 0.54 0.76 0.26 0.86 0.97 
269 cg21899374 chr8 144915517   0.19 0.91 0.91 0.53 0.72 0.2 0.98 0.89 
270 cg13595161 chr10 126713388 CTBP2 0.24 0.84 0.53 0.61 0.71 0.16 0.96 0.94 
271 cg09217922 chr12 7096338 LPCAT3 0.33 0.87 0.89 0.75 0.8 0.33 0.96 0.96 
272 cg04670206 chr7 6699522   0.3 0.75 0.51 0.56 0.7 0.22 0.85 0.61 
273 cg00617776 chr3 36878751 TRANK1 0.45 0.85 0.59 0.83 0.79 0.37 0.88 0.74 
274 cg11515851 chr16 81271013 BCO1 0.5 0.89 0.92 0.58 0.92 0.49 0.94 0.97 
275 cg22874988 chr3 111451090 PHLDB2 0.2 0.83 0.96 0.54 0.95 0.12 1 0.97 
276 cg07375022 chr13 113243073 TUBGCP3 0.35 0.93 0.9 0.71 0.83 0.25 0.97 0.93 
277 cg00674569 chr2 189340785 GULP1 0.24 0.78 0.62 0.59 0.72 0.13 0.83 0.65 
278 cg14266423 chr13 106632013   0.18 0.89 0.98 0.65 0.69 0.08 1 0.92 
279 cg01181301 chr22 22098620   0.13 0.91 0.52 0.73 0.65 0.17 1 0.83 
280 cg08650811 chr13 77572745 CLN5 0.22 0.88 0.89 0.75 0.59 0.12 0.96 0.75 
281 cg03275396 chr3 111451616 PLCXD2 0.23 0.94 0.94 0.73 0.86 0.11 0.98 0.92 
282 cg15489932 chr16 73266628   0.19 0.88 0.78 0.71 0.7 0.12 1 0.82 





284 cg24361808 chr22 46477834   0.37 0.87 0.51 0.75 0.51 0.4 0.95 0.83 
285 cg01274257 chr22 31746540   0.21 0.85 0.56 0.53 0.54 0.08 0.94 0.88 
286 cg23270631 chr12 124371406 DNAH10 0.16 0.91 0.71 0.69 0.6 0.04 0.88 0.77 
287 cg02813126 chr10 115241025   0.24 0.94 0.69 0.55 0.78 0.15 0.97 0.95 
288 cg26281550 chr5 171991589   0.24 0.9 0.95 0.6 0.81 0.16 0.97 0.93 
289 cg13556554 chr15 52855978 ARPP19 0.19 0.92 0.94 0.52 0.86 0.16 0.97 0.9 
290 cg06372503 chr3 54401037 CACNA2D3 0.21 0.9 0.93 0.77 0.81 0.24 0.88 0.83 
291 cg11613427 chr3 52932208 TMEM110 0.41 0.92 0.83 0.96 0.85 0.28 0.95 0.91 
292 cg26115667 chr14 103294656 TRAF3 0.13 0.56 0.65 0.63 0.53 0.14 0.81 0.57 
293 cg02639667 chr5 154092321 LARP1 0.26 0.98 0.91 0.93 0.57 0.08 0.89 0.8 
294 cg01999399 chr3 195537508 MUC4 0.49 0.8 0.91 0.61 0.89 0.33 1 0.9 
295 cg08656596 chr22 32641159 SLC5A4 0.16 0.91 0.86 0.75 0.69 0.03 1 0.97 
296 cg12912809 chr4 128887467 MFSD8; C4orf29 0.15 0.83 0.63 0.57 0.58 0.1 0.91 0.79 
297 cg27219362 chr7 157259285   0.12 0.89 0.54 0.83 0.6 0.1 0.79 0.8 
298 cg06398482 chr13 77411461   0.4 0.83 0.9 0.78 0.87 0.56 0.97 0.81 
299 cg06942239 chr20 4057157   0.36 0.87 0.74 1 0.69 0.09 1 0.93 
300 cg13358134 chr9 96025413 WNK2 0.21 0.87 0.97 0.85 0.62 0.12 0.86 0.86 
301 cg18039298 chr14 100942739 WDR25 0.34 0.95 0.89 0.93 0.96 0.36 0.98 1 
302 cg02063944 chr13 45429070   0.2 0.79 0.92 0.52 0.65 0.11 0.89 0.94 
303 cg12849046 chr5 72063769   0.27 0.92 0.51 0.6 0.52 0.06 0.91 0.71 
304 cg11562836 chr10 134222581 PWWP2B 0.3 0.79 1 0.88 0.64 0.07 1 0.83 
305 cg24698925 chr15 57873089   0.29 0.9 0.97 0.86 0.75 0.12 1 0.98 
306 cg00708814 chr11 30751744   0.35 0.77 0.51 0.85 0.66 0.14 0.95 0.76 
307 cg00965566 chr10 17331997   0.46 0.95 0.91 0.76 0.91 0.2 0.98 0.96 
308 cg02676406 chr14 51863257   0.16 0.92 0.68 0.84 0.88 0.26 0.97 0.91 
309 cg10687709 chr4 11013085   0.39 0.9 0.96 0.55 0.8 0.27 0.96 0.98 
310 cg00769408 chr1 209827637   0.35 0.87 0.95 0.53 0.79 0.23 0.93 0.98 
311 cg00270764 chr16 28511362 IL27 0.41 0.75 0.73 0.73 0.71 0.44 0.95 0.69 





313 cg18695263 chr3 196387505 LRRC33 0.3 0.92 0.79 0.88 0.85 0.12 0.97 0.88 
314 cg14094347 chr9 139131620 QSOX2 0.11 0.72 0.82 0.86 0.68 0.13 0.88 0.73 
315 cg10191560 chr11 115793792   0.39 0.82 0.9 0.8 0.93 0.2 0.96 0.93 
316 cg11856351 chr11 22646355 FANCF 0.31 0.88 0.64 0.53 0.79 0.15 0.89 0.93 
317 cg14528964 chr2 178938591 PDE11A 0.15 0.82 0.55 0.54 0.58 0.09 0.82 0.67 
318 cg01303385 chr3 111451470 PHLDB2 0.22 0.89 0.79 1 0.82 0.04 0.91 0.96 
319 cg09985163 chr19 7187927 INSR 0.4 0.93 0.68 0.74 0.73 0.23 0.9 0.76 
320 cg00909094 chr3 12586368   0.18 0.89 0.84 0.73 0.98 0.09 0.94 0.97 
321 cg21234836 chr11 13018935   0.22 0.93 0.78 0.67 0.82 0.12 0.95 0.87 
322 cg17185473 chr5 64907370 TRIM23 0.2 0.86 0.81 0.61 0.65 0.13 0.92 0.92 
323 cg20785060 chr8 64606039   0.16 0.88 0.62 0.65 0.8 0.11 0.86 0.69 
324 cg26940755 chr1 32694147 EIF3I 0.46 0.94 0.7 0.59 0.86 0.24 0.94 0.78 
325 cg11417701 chr6 401311 IRF4 0.42 0.88 0.96 0.76 0.91 0.2 0.94 0.9 
326 cg14983771 chr14 61201189 MNAT1 0.19 0.92 0.51 0.88 0.87 0.05 0.83 0.93 
327 cg06089322 chr14 65203351 PLEKHG3 0.34 0.9 0.79 0.83 0.83 0.11 1 0.91 
328 cg20810117 chr8 22255186 SLC39A14 0.38 0.88 0.62 0.54 0.86 0.33 0.94 0.86 
329 cg23682432 chr12 113246173 RPH3A 0.33 0.94 0.93 0.81 0.85 0.26 1 0.93 
330 cg22603770 chr18 11005527 PIEZO2 0.44 0.75 0.95 0.72 0.86 0.24 0.98 0.94 
331 cg17006098 chr17 29822786 RAB11FIP4 0.27 0.79 0.85 0.73 0.72 0.27 0.79 0.7 
332 cg01779847 chr7 150599373   0.28 0.77 0.81 0.82 0.71 0.11 0.94 0.69 
333 cg25611750 chr14 101755656   0.34 0.86 0.81 0.58 0.88 0.17 0.97 0.98 
334 cg16331818 chr12 6033190 ANO2 0.22 0.89 0.65 0.8 0.57 0.11 0.9 0.86 
335 cg19023320 chr3 13033587 IQSEC1 0.39 0.83 0.94 0.86 0.87 0.33 1 0.85 
336 cg14123409 chr17 2831903 RAP1GAP2 0.44 0.86 0.92 0.79 0.69 0.77 1 0.97 
337 cg24346519 chr9 131268003 GLE1; MIR1268A 0.43 0.79 0.57 0.81 0.73 0.25 0.92 0.76 
338 cg27304415 chr3 77064282   0.16 0.9 0.8 0.63 0.65 0.13 0.89 0.67 
339 cg23919160 chr9 79484243 PRUNE2 0.21 0.88 0.93 0.76 0.65 0.1 0.97 0.82 
340 cg25451497 chr2 178990729 RBM45 0.44 0.91 0.69 0.82 0.55 0.3 0.93 0.9 





342 cg07015239 chr1 235400645 ARID4B 0.23 0.94 0.9 0.54 0.7 0.16 0.98 0.95 
343 cg12691464 chr10 32231950   0.26 0.91 0.99 0.57 0.66 0.11 0.98 0.95 
344 cg03166324 chr1 161059535 PVRL4 0.3 0.73 0.83 0.83 0.59 0.05 0.83 0.91 
345 cg04084026 chr16 57832309 KIFC3 0.32 0.92 0.93 0.58 0.69 0.36 1 0.88 
346 cg23425669 chr8 117000211 LINC00536 0.19 0.84 0.79 0.69 0.82 0.21 0.95 0.9 
347 cg08977118 chr10 80288744   0.32 0.93 0.9 0.59 0.88 0.19 1 0.95 
348 cg11738790 chr6 24355819 KAAG1; DCDC2 0.17 0.87 0.71 0.76 0.59 0.23 0.95 0.74 
349 cg21235987 chr9 133853434   0.33 0.89 0.61 0.54 0.52 0.14 0.96 0.74 
350 cg04929665 chr17 26652175 TMEM97 0.23 0.95 0.84 0.8 0.68 0.21 0.94 0.91 
351 cg11807356 chr11 71736227 NUMA1 0.46 0.8 0.65 0.81 0.68 0.19 0.92 0.76 
352 cg26936966 chr8 136612125 KHDRBS3 0.2 0.77 0.62 0.92 0.74 0.07 0.64 0.67 
353 cg00606396 chr5 19531574 CDH18 0.29 0.91 0.96 0.89 0.57 0.35 0.98 0.91 
354 cg26190835 chr2 202937899   0.16 0.79 0.6 0.58 0.64 0.13 0.91 0.69 
355 cg05498681 chr20 35973318 SRC 0.34 0.9 0.92 0.52 0.69 0.22 0.97 0.88 
356 cg06103218 chr4 2073751 POLN 0.27 0.87 0.59 0.52 0.56 0.04 0.96 0.65 
357 cg24680492 chr12 3904727   0.34 0.94 0.71 0.53 0.72 0.13 1 0.94 
358 cg11131672 chr1 170588581   0.09 0.88 0.89 0.62 0.66 0.1 0.94 0.79 
359 cg22115148 chr3 177216338 LINC00578 0.31 0.92 0.51 0.91 0.73 0.33 0.92 0.93 
360 cg01434302 chr8 3267208 CSMD1 0.14 0.86 0.52 0.63 0.62 0.22 0.96 0.78 
361 cg02233275 chr1 28961119 TAF12 0.34 0.8 0.77 0.57 0.67 0.18 0.94 0.8 
362 cg02693498 chr13 24758821 SPATA13 0.14 0.93 0.99 0.65 1 0.09 1 0.93 
363 cg00759354 chr8 143758944 PSCA 0.47 0.85 0.69 0.62 0.52 0.3 0.93 0.88 
364 cg21655740 chr8 52945868   0.18 0.89 0.51 0.51 0.61 0.21 0.93 0.87 
365 cg22379697 chr20 40104506 CHD6 0.2 0.91 0.57 1 0.54 0.02 0.93 0.76 
366 cg24491939 chr18 29186408   0.23 0.94 0.87 0.67 0.87 0.14 0.98 0.89 
367 cg01552748 chr13 112225526   0.22 0.94 0.67 0.56 0.54 0.04 1 0.82 
368 cg07138944 chr7 75929652   0.28 0.89 0.83 0.72 0.72 0.24 0.91 0.92 
369 cg05595429 chr1 222759637 TAF1A 0.34 0.89 0.66 0.97 0.79 0.32 0.93 0.86 





371 cg16919295 chr2 23421947   0.29 0.85 0.81 0.54 0.51 0.43 0.93 0.91 
372 cg01823510 chr2 242776354   0.34 0.86 0.75 0.78 0.67 0 0.83 0.69 
373 cg13793676 chr6 7480452   0.14 0.76 0.61 0.79 0.56 0.05 0.93 0.62 
374 cg05802545 chr1 107921855 NTNG1 0.4 0.76 0.55 0.58 0.59 0.21 0.8 0.65 
375 cg24691398 chr9 36637730 MELK 0.47 0.94 0.62 0.91 0.56 0.26 1 0.94 
376 cg05415871 chr8 1008188   0.4 0.97 0.64 0.67 0.65 0.28 0.91 0.89 
377 cg08713760 chr12 40948140 MUC19 0.49 0.82 0.71 0.73 0.88 0.47 0.94 0.81 
378 cg26147915 chr3 47426793 PTPN23 0.4 0.94 0.74 0.69 0.64 0.2 0.93 0.92 
379 cg02960500 chr11 131469924 NTM 0.45 0.85 0.56 0.64 0.76 0.2 0.88 0.9 
380 cg22455699 chr4 79946748 LINC01088 0.37 0.89 0.67 0.86 0.77 0.3 0.98 0.96 
381 cg08271443 chr16 4845348 LOC440335 0.17 0.76 0.9 1 0.76 0.23 1 0.74 
382 cg26289155 chr17 73546144 LLGL2 0.42 0.84 0.97 0.92 0.86 0.08 0.89 0.93 
383 cg10463011 chr5 168978822   0.41 0.9 0.83 0.52 0.72 0.28 1 0.91 
384 cg22802766 chr12 14361288   0.45 0.81 0.87 0.7 0.52 0.21 0.91 0.84 
385 cg10692636 chr17 76470423 DNAH17 0.38 0.9 0.74 0.6 0.89 0.22 0.89 0.87 
386 cg24530480 chr8 1008155   0.43 0.91 0.53 0.76 0.79 0.21 0.9 0.82 
387 cg18700339 chr11 128634547 FLI1 0.49 0.85 0.82 0.95 0.68 0.47 1 0.98 
388 cg16427033 chr10 109023583   0.44 0.97 0.63 0.59 0.71 0.26 0.87 0.86 
389 cg04658707 chr21 47453889   0.45 0.94 0.97 0.97 0.62 0.35 0.94 0.96 
390 cg22958715 chr14 23855309 MYH6 0.35 0.94 0.92 0.82 0.94 0.19 1 0.95 
391 cg21190017 chr11 134124575 THYN1; ACAD8 0.46 0.8 0.62 0.68 0.74 0.22 0.91 0.94 
392 cg07494102 chr11 34662394 EHF 0.4 0.94 0.84 0.93 0.67 0.21 0.94 0.92 
393 cg07173284 chr16 24320466 CACNG3 0.42 0.89 0.67 0.58 0.67 0.21 1 0.91 
394 cg13997361 chr17 8703224 MFSD6L 0.46 0.89 0.91 0.6 0.64 0.43 0.91 0.65 
395 cg01315205 chr5 171534880 STK10 0.49 0.77 0.51 0.83 0.57 0.26 0.91 0.6 
396 cg19866944 chr1 174966309   0.36 0.91 0.93 0.89 0.9 0.19 0.96 0.92 
397 cg06610395 chr12 125350471   0.49 0.78 0.91 0.94 0.51 0.54 0.97 0.87 
398 cg22912485 chr8 57896881 IMPAD1 0.43 0.92 0.74 0.8 0.91 0.23 0.98 0.9 





400 cg03661901 chr12 133093451 FBRSL1 0.45 0.91 0.95 0.89 0.9 0.37 1 0.94 
401 cg16659470 chr8 94744382 RBM12B 0.37 0.88 0.92 0.57 0.65 0.25 1 0.95 
402 cg25415853 chr12 5950373 ANO2 0.48 0.93 0.96 0.95 0.93 0.33 0.93 0.91 
403 cg07484053 chr13 113243279 TUBGCP3 0.31 0.92 0.66 0.76 0.88 0.19 0.96 0.87 
404 cg21545428 chr10 2808784   0.33 0.77 0.61 0.58 0.71 0.03 0.92 0.71 
405 cg01003257 chr12 105056211 CHST11 0.28 0.91 0.78 0.75 0.88 0.12 0.95 0.88 
406 cg02423000 chr5 601568   0.38 0.84 0.88 0.72 0.93 0.13 0.92 0.87 
407 cg25741597 chr3 147722622   0.46 0.88 0.69 0.74 0.71 0.28 0.98 0.86 
408 cg00853742 chr20 39990972 EMILIN3 0.39 0.83 0.87 0.87 0.92 0.22 1 0.89 
409 cg05382021 chr14 23640996 SLC7A8 0.47 0.86 0.92 0.85 0.62 0.48 1 0.95 
410 cg11194863 chr13 98945688 FARP1 0.28 0.82 0.9 0.83 0.7 0.2 0.97 0.92 
411 cg07331478 chr2 221961668   0.44 0.9 0.77 0.82 0.81 0.2 0.94 0.85 
412 cg13812733 chr19 55721821 PTPRH 0.45 0.89 0.96 0.94 0.8 0.34 0.95 0.91 
413 cg08524891 chr7 120365958 KCND2 0.34 0.9 0.66 0.8 0.9 0.23 0.94 1 
414 cg10340409 chr19 9944858 PIN1 0.48 0.88 0.76 0.64 0.76 0.27 1 0.72 
415 cg13049624 chr3 1050278   0.41 0.86 0.73 0.65 0.66 0.15 0.92 0.74 
416 cg22500255 chr1 28384743 EYA3 0.26 0.82 0.66 0.81 0.62 0.22 0.9 0.82 
417 cg18463993 chr17 26653167 TMEM97 0.2 0.91 0.72 0.64 0.64 0.15 1 0.83 
418 cg26748715 chr3 195587468   0.49 0.89 0.95 0.54 0.8 0.38 0.9 0.86 
419 cg04782106 chrX 73075985   0.46 0.8 0.54 0.81 0.71 0.32 0.95 0.61 
420 cg04456720 chr17 54250143 ANKFN1 0.32 0.72 0.59 0.59 0.58 0.36 0.89 0.65 
421 cg10095968 chr21 45847903 TRPM2 0.49 0.92 0.88 0.96 0.9 0.33 0.92 0.87 
422 cg05966608 chr11 117162779 BACE1-AS; BACE1 0.44 0.87 0.62 0.88 0.69 0.27 0.96 0.92 
423 cg03685774 chr1 159870326 CCDC19 0.36 0.93 0.71 0.84 0.68 0.2 0.95 0.9 
424 cg11168687 chr4 185726782 ACSL1 0.21 0.87 0.89 0.57 0.62 0.3 0.93 0.57 








Table A.5: Summery of methylation percentage data derived from targeted next generation 
sequencing of MIR-200c/MIR-141 mutual promoter as well as post MIR-141 (Chr12: 6,963,000-
6,964,001). 




48h high Glucose Exposed  
EndoC-βH1 cell line 
Pancreatic Islet PBMCs Lung PNT2 LNcaP PC3 
-595 0.0 0.0 2.0 52.8 21.7 0.5 0.8 84.1 
-586 0.0 0.0 6.5 74.8 46.1 2.1 0.0 95.0 
-524 0.0 0.0 4.1 95.5 60.4 0.0 1.5 95.1 
-510 0.0 0.0 4.4 97.6 72.2 1.4 0.0 90.8 
-488 0.0 0.0 4.3 100.0 67.3 0.0 0.0 97.5 
-477 0.0 1.1 6.7 93.0 64.8 0.0 0.0 96.6 
-470 0.0 0.0 4.4 93.0 70.4 0.0 0.0 97.5 
-449 0.0 0.0 4.4 100.0 72.2 0.0 0.0 100.0 
-437 0.0 0.0 4.4 95.1 68.5 0.0 0.0 97.1 
-425 0.0 2.2 6.7 95.5 75.0 1.4 0.0 98.2 
-397 0.0 2.2 4.5 97.6 66.0 0.0 0.0 97.4 
-359 0.0 0.0 2.5 64.3 17.6 0.0 0.0 75.0 
-280 0.0  3.6 97.2 57.6 1.8 0.0 97.4 
-270 0.0  3.7 94.4 58.1 1.8 0.0 97.3 
-268 0.0  2.0 94.4 61.3 2.0 0.0 92.1 
-263 0.0  0.0 96.0 55.2 1.9 0.0 89.5 
-250 0.0  6.1 100.0 67.9 0.0 0.0 94.4 
-223 0.0  7.4 94.4 41.2 0.0 0.0 100.0 
-220 0.0  7.7 90.9 54.3 1.9 0.0 97.2 
-215 0.0  5.7 85.3 26.5 1.8 0.0 91.9 
-212 0.0  7.4 94.3 47.1 1.8 0.0 97.4 
-208 0.0  7.4 84.8 48.5 1.8 0.0 100.0 
-198 0.0  9.4 77.8 51.4 3.7 0.0 86.8 
-166 0.0  5.6 66.7 52.8 0.0 0.0 82.9 
-157 0.0  7.5 91.4 58.3 1.8 0.0 100.0 
-135 0.0  7.3 88.6 61.8 1.9 0.0 100.0 





+53 0.0 0.0 9.0 88.8 69.5 3.9 1.5 90.2 
+97 0.0 0.0 4.1 44.6 21.4 1.6 0.0 62.6 
+148 0.0 0.0 4.3 72.6 24.6 2.5 0.0 94.9 
+155 0.0 2.7 5.8 50.9 22.8 2.9 0.0 82.1 
+166 0.0 0.0 4.8 50.1 20.8 2.3 0.0 75.0 
+261 1.3 0.5 9.9 89.3 63.5 2.9 0.6 96.2 
+295 0.1 0.8 2.6 49.8 23.2 0.1 0.8 93.9 
+318 0.0 0.2 4.5 81.2 51.5 0.3 0.2 95.0 
+379 1.3 4.5 9.8 93.2 67.4 2.5 1.1 90.8 
+381 1.1 2.3 6.9 93.8 66.2 2.5 1.4 96.5 
+386 0.3 1.0 5.3 88.1 56.6 2.4 0.6 95.5 
+399 0.3 1.0 6.6 89.0 55.3 2.7 0.6 92.1 
+403 0.5 0.5 7.2 89.2 59.0 1.9 0.7 92.9 
+483 2.1  5.7 95.8 64.5 0.0 0.0 97.0 
+497 1.3  5.1 88.8 64.4 0.4 1.2 92.2 
















0.5 M EDTA, pH 8.0 (500 mL) 
93.06g EDTA  
Dissolved in 500 mL distilled water to form a white solution. 
Add 12g Sodium Hydroxide, NaOH, (~95 pellets) 
Adjust pH to 8.0 
If pH is above 8.0 add drops of HCl, if below add NaOH. 
Autoclave. 
 
60% Sucrose /1 mM Creosol Red (50 mL) 
30g sucrose 
Dissolved in 50 mL autoclaved de-ionised water 
500 L 100 mM Creosol red 
Vortex to mix, then aliquot 1 mL into 1.5 mL Eppendorf tubes. 
Store at -20C. 
 
100 mM Creosol Red (50 mL) 
0.4g Creosol red  
Disolved in 10 mL double distilled water 
Vortex to mix. 
 
5M NaCl (200 mL) 
58.44g Sodium Chloride 
Dissolved in 200 mL distilled water 
Autoclave. 
10% SDS (50 mL)      
5g Sodium Dodecyl Sulphate 







3 M Sodium acetate (CH3COONa) solution, pH 5.2 (100 mL) 
24.61g CH3COONa (Molecular weight = 82.0343). 
Add 80 mL double distilled water. Mix until sodium acetate is completely dissolved. 
Adjust the pH to 5.2 with glacial acetic acid 
Adjust the volume to 100 mL, Mix 













Agarose, molecular biology grade  MB1200 MelFord https://www.melford.co.uk/search.html?keywords=MB1200  
Ampicillin Antibiotic A5354 Sigma https://www.sigmaaldrich.com/catalog/product/sigma/a5354?lang=en&region=GB  





C1000 Touch™ Thermal Cycler  184-1100 Bio-Rad 
https://www.bio-rad.com/en-uk/product/c1000-touch-thermal-
cycler?ID=LGTW9415  








cell-free DNA collection tubes  07785666001 Roche 
https://sequencing.roche.com/en/products-solutions/by-category/sample-
collection/cell-free-dna-collection-tube/ordering.html  
Cell-Free DNA Urine Preserve  230216 Streck https://www.streck.com/collection/cell-free-dna-urine-preserve/  
CMRL-1066 growth medium  C0422 Sigma-Aldrich https://www.sigmaaldrich.com/catalog/product/sigma/c0422?lang=en&region=GB  
ddPCR Supermix for Probes  186-3027 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1863027-ddpcr-supermix-for-
probes?ID=1863027  
ddPCR™ Droplet Reader Oil  186-3004 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1863004-ddpcr-droplet-reader-






DNA ladder (50 bp) N3236 BioLabs 
https://international.neb.com/products/n3236-50-bp-dna-
ladder#Product%20Information  



























Ethylenediaminetetraacetic acid ED-100G Sigma-Aldrich https://www.sigmaaldrich.com/catalog/product/sial/ed?lang=en&region=GB  
EZ DNA Methylation Kit  D5001 Zymo Research https://www.zymoresearch.eu/ez-dna-methylation-kit#format=4&reactions=42  
EZ DNA Methylation-Lightning™ Kit  D5030 Zymo Research 
https://www.zymoresearch.eu/ez-dna-methylation-lightning-
kit#format=4&reactions=42  





Gaskets 186-3009 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1863009-dg8-gaskets-for-qx200-qx100-
droplet-generator?ID=1863009  





HotStar Taq DNA Polymerase 203203 Qiagen  
https://www.qiagen.com/gb/shop/pcr/end-point-pcr-enzymes-and-kits/regular-
pcr/hotstartaq-dna-polymerase/#orderinginformation  
Hypermethylated and Hypomethylated human DNA 
set  
D5014 Zymo Research 
https://www.zymoresearch.eu/human-methylated-non-methylated-dna-
set#methylation_type=271  














MinElute Gel Extraction Kit  28604 Qiagen 
https://www.qiagen.com/kr/shop/sample-technologies/dna/dna-clean-
up/minelute-gel-extraction-kit/#orderinginformation  
miRNeasy Serum/Plasma Kit  217184 Qiagen 
https://www.qiagen.com/kr/shop/sample-technologies/rna/mirna/mirneasy-
serumplasma-kit/#orderinginformation  




Nuclease-Free Water 129114 Qiagen 
https://www.qiagen.com/kr/shop/lab-basics/buffers-and-reagents/nuclease-free-
water/#orderinginformation  
PCR Plate Heat Seal, foil, pierceable 181-4040 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1814040-pcr-plate-heat-seal-foil-
pierceable?ID=1814040  
pGEM-T Easy vector system I  A1360 Promega 
https://www.promega.co.uk/Products/PCR/PCR-Cloning/pGEM-T-Easy-Vector-
Systems/?fq=A1360&catNum=A1360  
PX1™ PCR Plate Sealer  181-4000 Bio-Rad https://www.bio-rad.com/en-uk/sku/1814000-px1-pcr-plate-sealer?ID=1814000  







QiaAmp DNA Blood Mini Kit  51106 Qiagen 
https://www.qiagen.com/kr/shop/sample-technologies/dna/genomic-dna/qiaamp-
dna-blood-mini-kit/#orderinginformation  
QIAprep Spin miniprep kit 27104 Qiagen 
https://www.qiagen.com/kr/shop/sample-technologies/dna/plasmid-dna/qiaprep-
spin-miniprep-kit/#orderinginformation  
QuantiFluor® dsDNA system  E2670 Promega 
https://www.promega.co.uk/Products/DNA-Purification-Quantitation/DNA-and-
RNA-Quantitation/QuantiFluor-dsDNA-System/?fq=E2670&catNum=E2670  
QuantiFluor® RNA System  E3310 Promega 
https://www.promega.co.uk/Products/DNA-Purification-Quantitation/DNA-and-
RNA-Quantitation/QuantiFluor-RNA-System/?fq=E3310&catNum=E3310  
QuantiFluor® ssDNA system  E3190 Promega 
https://www.promega.co.uk/Products/DNA-Purification-Quantitation/DNA-and-
RNA-Quantitation/QuantiFluor-ssDNA-System/?fq=E3190&catNum=E3190  
Quantus™ Fluorometer  E6150 Promega 
https://www.promega.co.uk/Products/Fluorometers-Luminometers-Multimode-
Readers/Fluorometers/Quantus-Fluorometer/?fq=E6150&catNum=E6150  
QX200 Droplet Generation Oil for Probes  186-3005 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1863005-droplet-generation-oil-for-
probes?ID=1863005  
QX200™ ddPCR™ EvaGreen Supermix  186-4033 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1864033-qx200-ddpcr-evagreen-
supermix?ID=1864033  
QX200™ Droplet Generation Oil for EvaGreen 1864005 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1864005-qx200-droplet-generation-oil-for-
evagreen?ID=1864005  
QX200™ Droplet Generator  186-4002 Bio-Rad 
https://www.bio-rad.com/en-uk/sku/1864002-qx200-droplet-
generator?ID=1864002  
QX200™ Droplet reader  186-4003 Bio-Rad https://www.bio-rad.com/en-uk/sku/1864003-qx200-droplet-reader?ID=1864003  
REPLI-g Mini Kit 150023 Qiagen 
https://www.qiagen.com/gb/shop/sample-technologies/dna/genomic-dna/repli-g-
mini-kit/#orderinginformation  









Universal cDNA Synthesis Kit II  203301 Exiqon 
https://www.qiagen.com/gb/shop/pcr/primer-sets/mircury-lna-rt-
kit/#orderinginformation  
QIAGEN Proteinase K (10 mL) 19133 Qiagen 
https://www.qiagen.com/gb/shop/lab-basics/enzymes/qiagen-proteinase-
k/#orderinginformation  
 
